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In vitro-derived cardiomyocytes are ideal for use in cell replacement therapy as 
they constitute a renewable source of wide range of heart cell types that can be 
produced in large numbers for replacement. However, the transition from bench to 
bed necessitates a deeper understanding of the regulatory networks of early 
cardiomyocyte differentiation as it takes place in the early development of embryo. 
Studies have demonstrated that STAT3 is essential for initial stages of 
cardiomyogenesis. Despite the important role of STAT3 in cardiomyogenesis, few 
studies have explored that the role of STAT3 in early cardiomyocyte differentiation 
because conventional STAT3 KO is embryonic lethal at the time of formation of 
cardiomyocyte. In this study, we have established an in vitro inducible STAT3 
knock out and pSTAT3 overexpressed ES cells system in which STAT3 expression 
can be temporally and specifically deleted or overexpressed by doxycyclin 
stimulation to allow the study of STAT3 function during early cardiomyocyte 
differentiation. We show STAT3 expression to be temporal and downregulates in 
the early phrase of cardiac differentiation but upregulates towards late phrase. We 
also show an important stage specific role of STAT3 in regulating cardiomyocyte 
differentiation from ESCs. In addition, STAT3 is found to bind on the promoter 
region of GATA6 in ESCs. Lastly, we propose a potential regulatory role of STAT3 
on promoting cardiomyocyte differentiation through direct transcriptional 





Cardiovascular disease has become a leading global cause of illness and mortality 
worldwide. Previously, we have reported that increased apoptosis, inflammation 
and cardiac fibrosis were observed in aged and also under endotoxin-stress (LPS) 
STAT3 deficient mice compared to those in wild-type. However, the molecular 
mechanisms by which STAT3 promotes cardiomyocyte survival and cardiac 
function remained unclear. Here, we study the possible underlying pathological 
mechanism regulated by STAT3. Real-time PCR results show that acute LPS 
treatment which activated STAT3 downregulates Txnip transcript in H9c2 
myoblast and wild-type heart in a time-dependent manner. Moreover, western blot 
assay demonstrates that high expression of Txnip is found in the aged heart of 
STAT3 deficient mice, indicating that Txnip expression might be regulated by 
STAT3. Earlier reports of published STAT3 ChIP-sequencing results in non-
cardiac cells revealed that Txnip promoter is bound by STAT3. Our present ChIP 
assays validate the published STAT3 ChIP results in which after LPS treatment, 
STAT3 binds on Txnip promoter to regulate its gene expression. Furthermore, 
increased generation of ROS and induction of inflammasome are observed in 
STAT3 deficient mice as a result of elevated Txnip level which subsequently lead 
to heart failure. Taken together, our results first address a novel regulatory role of 
STAT3 in the heart and highlighted the importance of this STAT3-Txnip signaling 
cascade which seems to have in the physiology and pathogenesis of heart failure 
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Chapter 1 Introduction 
1.1 Signal Transducer and Activator of Transcription (STAT) 
1.1.1 STAT proteins 
Our lab has studied STAT (Signal Transducer and Activator of Transcription) 
proteins, especially STAT3 in different systems for a long time. The STAT proteins 
are well conserved through evolution (Zhang et al., unpublished data), and are 
originally described in the interferon-induced regulatory pathways (Darnell, Kerr, 
& Stark, 1994; Fu, Kessler, Veals, Levy, & Darnell, 1990; Fu, Schindler, Improta, 
Aebersold, & Darnell, 1992; Schindler, Shuai, Prezioso, & Darnell, 1992). Seven 
STAT family members exist in mammals, namely STAT1, STAT2, STAT3, 
STAT4, STAT5a, STAT5b and STAT6 (Darnell, 1997) and they are characterized 
by having common functional domains. These include a conserved amino-terminal 
for tetramerization, a DNA-binding domain, a Src-homology2 (SH2) domain for 
receptor binding and STAT dimerization and a carboxyl-terminal transactivation 
domain which consists of phosphorylation site for maximal transcription activity 
(Booz, Day, & Baker, 2002; Hilfiker-Kleiner, Hilfiker, & Drexler, 2005).  
 
1.1.2 STAT Function and Activation 
STAT family proteins are latent cytoplasmic protein but act as transcription factors 
in the nucleus which play crucial roles in immunity, cell growth, survival 
differentiation and tumorigenesis (Darnell, 1997; Darnell et al., 1994). It can be 
stimulated by wide array of ligands, including cytokines, interleukins, interferons, 
growth factors and hormones (Bromberg, 2001; W. J. Leonard & O'Shea, 1998).  
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Various members of STATs family display certain distinct and nonetheless some 
similar functions. STAT1 has been illustrated to play a role in anti-bacterial, anti-
virus, apoptotic, growth inhibitory, and tumor suppressive responses (Durbin, 
Hackenmiller, Simon, & Levy, 1996; Meraz et al., 1996), while STAT3 generally 
has the opposed function, including anti-apoptosis, cell proliferation, survival, 
oncogenesis and inflammation. STAT4 and STAT6 are involved in the 
development of T helper 1 (Th1) and T helper 2 (Th2) cells in the immune system 
(Kaplan, Schindler, Smiley, & Grusby, 1996; Kaplan, Sun, Hoey, & Grusby, 1996; 
Shimoda et al., 1996; Takeda et al., 1996; Thierfelder et al., 1996), whereas 
STAT5a and STAT5b are involved in hormone signaling (Bromberg, 2001; Lim & 
Cao, 2006). 
 
STAT3 belongs to one of the seven STAT family members, is a well-known 
transcription factor participating in a wide variety of biological processes such as 
embryonic stem cells pluripotency maintenance, embryogenesis, cardioprotection, 
cancer and immunity (Hilfiker-Kleiner et al., 2005; Levy & Darnell, 2002; Takeda 
et al., 1997; Ying, Nichols, Chambers, & Smith, 2003; Yu, Pardoll, & Jove, 2009). 
Notably, STAT3 is stimulated by interleukin-6 family of cytokines, include 
leukemia inhibitory factor (LIF), interleukin-6 (IL-6), oncostatin M (OSM), 
cardiotrophin-1 (CT-1) and ciliary neurotrophic factor (CNTF) (Heinrich, 
Behrmann, Muller-Newen, Schaper, & Graeve, 1998). These molecules signal 
through transmembrane receptor, glycoprotein 130 (gp130) (Heinrich et al., 1998).  
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In a classical STAT activation pathway, following dimerization of gp130 by 
cytokines binding, cytoplasmic protein tyrosine kinases in the JAK family (JAK1, 
JAK2, and TYK2) which are associated with the membrane-proximal portion of 
gp130 are rapidly activated by autophosphorylation. Activated JAK sequentially 
phosphorylates the receptor to which it has bound, which enables STAT docking to 
this complex via binding of SH2 domain of STAT to the phosphotyrosine residue 
of the receptor. This leads to phosphorylation of STAT and triggers its release and 
dimerization. Dimerized phosphorylated STAT proteins rapidly translocate to 
nucleus and bind to certain gene promoters with specific STAT binding sequences 
and thereby involved in regulating the transcriptional activation of target genes. 
Therefore, the JAK-STAT pathway denotes an enormously rapid signaling system 
from the cell surface to the nucleus and elucidates at least part of the basis for the 
specificity of signals that are induced by different cytokines (W. J. Leonard & 
O'Shea, 1998; Levy & Darnell, 2002). (Figure 1.1) 




Figure 1.1 JAK-STAT signal transduction pathway. 
Cytokine-receptor interaction leads to sequential tyrosine phosphorylation. Once 
the ligands bind to homodimeric or heterodimeric receptors, Janus kinases (JAK) 
will undergo transphosphorylation and activated JAK phosphorylates the tyrosine 
residue of the cytoplasmic domain of the receptors. Phosphorylated sites by JAK 
kinases serve as docking site for STAT protein.  STAT protein will then bind to the 
phosphorylated site of receptors via SH2 domain.  Phosphorylated STAT protein 
will then homodimerize or heterodimerize before translocation into nucleus and 
bind to targeted sequence and regulate gene expression. 
Figure and caption adapted from (Levy & Darnell, 2002). 
 
Chapter 1 Introduction 
5 
 
1.2 STAT3 in embryonic stem cells pluripotency maintenance 
1.2.1 Embryonic stem cells (ESCs) 
Embryonic stem cells (ESCs) originate from the inner cell mass of blastocyst, 
which is an early stage of preimplantation embryo (A. G. Smith, 2001; Thomson et 
al., 1998). ESCs have high pluripotency to differentiate to all somatic cell types of 
the adult body and germ cell lineage and they can be cultured indefinitely in vitro 
through self-renewing division (M. J. Evans & Kaufman, 1981; Martin, 1981). 
Moreover, ESCs will contribute to all tissues formation, including the germ cells in 
the resulting chimeric mice when reintroduced into blastocyst (Bradley, Evans, 
Kaufman, & Robertson, 1984). 
 
1.2.2 Self-renewal of ES cells requires STAT3 
Self-renewing state of mouse ES cells is maintained in the presence of extrinsic 
factors such as cytokine leukemia inhibitory factor (LIF) (A. G. Smith et al., 1988; 
Williams et al., 1988). LIF belongs to the interleukin-6 family of cytokines engages 
a heterodimeric receptor complex consisting of LIF receptor and gp130, resulting 
in the activation of JAK and subsequently STAT3 phosphorylation (Boulton, Stahl, 
& Yancopoulos, 1994). STAT3 activation is essential to maintain ES cells self-
renewal (Matsuda et al., 1999; Niwa, Burdon, Chambers, & Smith, 1998; Raz, Lee, 
Cannizzaro, d'Eustachio, & Levy, 1999), while interruption of STAT3 leads to ES 
cells differentiation (Ernst, Novak, Nicholson, Layton, & Dunn, 1999; Niwa et al., 
1998).  
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Several investigations have put forth evidence indicating that in the absence of LIF, 
constitutively active of STAT3 is sufficient to inhibit mouse ES cells differentiation 
(Matsuda et al., 1999). By using a conditionally active form of STAT3, namely, a 
fusion protein between STAT3 and estrogen receptor (ER) ligand binding domain, 
in which STAT3 is activated in response to the synthetic ligand 4-
hydroxytamoxifen (4HT),  activation of STAT3 is adequate to sustain the self-
renewal of ES cells (Matsuda et al., 1999). In contrast, expression of STAT3 
dominant-negative mutant using an inducible promoter in ES cells abolishes the 
self-renewal of ES cells as maintained by LIF and promotes differentiation (Niwa 
et al., 1998; Raz et al., 1999). 
 
However, it is unclear how downstream targets of LIF/JAK/STAT3 signaling play 
a preeminent role in the control of  ES cells pluripotency maintenance by interacting 
with the master regulator of pluripotency factors for ES cells; namely, Oct4, Nanog, 
and Sox2 (Boyer et al., 2005; Loh et al., 2006). Until recently, STAT3 has been 
reported that it directly regulates Oct4 and Nanog transcription to maintain 
pluripotency of ES cells and iPSCs. Knockdown of STAT3 expression in ES cells 
leads to substantial reduction of Oct4. Furthermore, STAT3 binds directly to the 
distal enhancer of Oct4 and Nanog and positively regulates Oct4 and Nanog to 
maintain pluripotency of ES cells (Do et al., 2013). 
 
Although LIF-signaling is sufficient to maintain pluripotency of ES cells in serum 
conditions, LIF alone, however, is inadequate to maintain ES cells in serum-free 
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conditions, as the presence of fetal calf serum is required for the maintenance. 
Additional factors present in serum are crucial for the pluripotency maintenance. 
Recently, it was shown that bone morphogenetic proteins (BMPs) appear to be key 
serum-derived factors that act in combination with LIF to sustain mouse ES cells 
self-renewal and pluripotency in serum-free condition (Ying et al., 2003). BMP4 
binds to its receptor and triggers the phosphorylation of Smad1 which drives 
expression of inhibitor of differentiation (Id) genes. As forced expression of Id 
genes in ES cells can renew in the absence of BMP4, induction of Id expression is 
therefore critical contribution of the BMP/Smad pathway (Ying et al., 2003). 
Activated STAT3 and Smad1 form a complex in ES cells following stimulation by 
LIF plus BMP which inhibit differentiation into mesoderm and endoderm lineages. 
Thus, LIF/STAT3 and BMP/Smad signaling act in conjunction on distinct target 
genes and/or commence on common target genes in the maintenance of a stem cell 
pluripotency phenotype.  
 
1.3 STAT3 is involved in early embryo development and cardiomyogenesis 
1.3.1 STAT3 in early embryogenesis 
STAT3 plays a crucial function in early mammalian embryogenesis and 
determination of various cell lineages differentiation. Expression of STAT3 is 
highly detected in mouse oocytes and becomes phosphorylated and translocates 
into the nucleus in the four-cell and later stage embryo, indicating that activated 
STAT3 is present in preimplantation embryos (Do et al., 2013). During mouse 
embryogenesis, high-level expression of STAT3 mRNA initiates at around E7.5 in 
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the embryo itself. In addition, STAT3 mRNA was identified in a number of tissues 
including the yolk sac endoderm, myometrium, cephalic mesenchyme, and blood 
islands by E9.5 (Duncan, Zhong, Wen, & Darnell, 1997). Detection of STAT3 
activity during early postimplantation development in the mouse suggests that 
STAT3 is crucial during early embryogenesis. In addition, the subsequent 
differentiation into various cell lineages including the development of many 
specific organs such as liver development, myeloid cells differentiation, skin 
remodeling, angiogenesis and astrogenesis by neutral stem cells require STAT3 
activation (Chakraborty & Tweardy, 1998; Matsui, Kinoshita, Hirano, Yokota, & 
Miyajima, 2002; Rajan & McKay, 1998; Sano et al., 1999; Valdembri, Serini, 
Vacca, Ribatti, & Bussolino, 2002) . 
 
Among the STATs, STAT3 is the only member in which STAT3 null mice were 
found to be embryonic lethal at E6.5 to E7, suggesting that STAT3 is crucial for 
early embryo development (Takeda et al., 1997). Subsequently, studies of tissue-
specific functions of STAT3 have been carried out using Cre-loxP recombination 
system driven by discrete promoter in specific tissue. Tissue-specific gene targeting 
demonstrated that STAT3 functions in would healing in keratinocytes, mammary 
involution, regeneration of liver, survival of neuron cell, development of Th17 and 
T cell proliferation and cytoprotection of respiratory epithelium during adenoviral 
infection (Alonzi et al., 2001; Chapman et al., 1999; Matsuzaki et al., 2006; Murase, 
Kim, Lin, Hoffman, & McKay, 2012; Sano et al., 1999; Takeda et al., 1998; X. O. 
Yang et al., 2007). 
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1.3.2 Early heart development 
The heart is the first definitive organ to form and function during mammalian 
embryonic development (Fishman & Chien, 1997; Olson & Srivastava, 1996). The 
heart is made up of muscle and non-muscle lineages: atrial/ventricular cardiac 
myocytes, conduction system cells, smooth muscle/endothelial cells of the 
coronary arteries and veins, endocardial cells, valvular components and connective 
cells. Development of heart requires the concurrent differentiation of these 
cardiovascular cell types that must be organized into a complex organ. There are 
three major sources of heart cell precursors: cardiogenic mesoderm, cardiac neural 
crest and the proepicardial organ. Cardiogenic mesoderm forms myocardium, 
neural crest contributes to vascular smooth muscle of aortic arch and cardiac 
autonomous nervous system while the proepicardium forms the endothelial, smooth 
muscle and connective tissues (Kirby, Gale, & Stewart, 1983; Laugwitz, Moretti, 
Caron, Nakano, & Chien, 2008).  
 
During gastrulation, cardiac myocytes progenitors migrate to the anterior and 
anterior/lateral ends of the embryo to form heart fields (Rawles, 1943; Solloway & 
Harvey, 2003). The primary heart field (PHF) is derived from the anterior lateral 
mesoderm and forms the cardiac crescent (Rosenquist, 1970).  In later stages of 
embryonic development, the cardiac crescent proceeds to fuse and forms a 
primitive linear heart tube at approximately E7.5 to E8, which eventually forms the 
left ventricles (Arai, Yamamoto, & Toyama, 1997; Chien, Domian, & Parker, 2008). 
Distinctive beating of cardiac cells within the developing heart begins at 
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approximately E7.5 to E8.5 during tube formation (Ji et al., 2003). Shortly 
thereafter, contractile linear heart undergoes rightward looping to create 
asymmetrical, curved tube (Brand, 2003; R. G. Kelly & Buckingham, 2002; Yutzey 
& Kirby, 2002). Chamber maturation and septation occur to give rise to a functional 
four-chambered heart as the embryo continues to develop (Brand, 2003). Adjacent 
areas added to the heart at the time of cardiac looping is termed as the secondary 
heart field (R. G. Kelly, Brown, & Buckingham, 2001; Mjaatvedt et al., 2001; 
Waldo et al., 2001). The secondary heart field (SHF) is derived from the pharyngeal 
and splanchnic mesoderm and forms the right ventricle, the outflow tract, the atria 
and posterior regions of left ventricle (R. G. Kelly et al., 2001; Mjaatvedt et al., 
2001; Waldo et al., 2001). (Figure 1.2) 
 
 
Figure 1.2 Heart development. 
The main transitions that occur in early mammalian heart development. Days of 
embryonic development (E) is staged based on mouse development. Dark shading 
represents myocardial tissue. 
Figure and caption adapted from (Harvey et al., 2002). 
 
1.3.3 STAT3 in early cardiomyogenesis 
STAT3 conventional all-tissue knockout mice have previously been found early 
embryonic lethal at E6.5 to E7, as a result of embryos rapidly degenerated between 
E6.5 and E7.5 with no obvious mesoderm formation (Takeda et al., 1997). In fact, 
STAT3 ablation resulted in embryonically lethal less than 1 day before the embryo 
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would have develop beating cardiomyocyte at E7.5 to E8.5 (Foshay, Rodriguez, 
Hoel, Narayan, & Gallicano, 2005; Hao et al., 2005; Kotenko et al., 1996; Takeda 
et al., 1997). Earliest evidence revealed that STAT3 was confined to areas within 
the embryo, including the presumptive heart field, and was active when 
cardiomyocyte would be occurring at E7.5 to E8.5 (Duncan et al., 1997). Hence, 
STAT3 is essential for initial stages of cardiomyogenesis.  
 
The initial regulatory mechanisms which control differentiation of progenitor cells 
into beating cardiomyocyte is under investigation due to the difficulty of procuring 
cardiac-committed mesoderm to explore specified signal transduction mechanisms 
in mammalian development and as well as difficult to analyze the few 
cardiomyocytes available from early heart tubes. Until recently, a cardiac in vitro 
model system was developed using ES cells. Among the specialized cell types that 
can form in culture during ES cells differentiation, in vitro-derived cardiomyocytes 
are distinguished by rhythmically contracting structures containing cells that are 
highly reminiscent of normal heart cells (Boheler et al., 2002; Passier, Denning, & 
Mummery, 2006).  They express cardiac-specific genes including α-myosin heavy 
chain (α-MHC), cardiac troponin C and the atrial natriuretic peptide (ANP) similar 
to adult cardiomyocytes (Wobus, Rohwedel, Maltsev, & Hescheler, 1995). 
Moreover, the electrophysiology characteristics and ion channel expression of these 
beating cells have been documented and verified as closely mimicking embryonic 
and post-natal cardiomyocyte electrophysiology (Hescheler et al., 1999; Maltsev, 
Wobus, Rohwedel, Bader, & Hescheler, 1994; Wobus, Wallukat, & Hescheler, 
Chapter 1 Introduction 
12 
 
1991). Because this in vitro differentiation of ES cells to cardiomyocyte closely 
mimics the sequential stages of developing embryonic cardiomyocyte, it is used 
widely to study early initial stages of cardiac differentiation.  
 
It was illustrated that JAK2 signals through STAT3 to direct cardiomyogenesis in 
mouse ES cells. Firstly, expression of STAT3 and its activity is higher in cells of 
beating areas compared with cells on nonbeating areas. While inhibition of STAT3 
by dominant negative of STAT3 resulted in significantly fewer beating areas within 
embryoid body compared with controls. In addition, STAT3 inhibition of ES cells 
leads to downregulation of key specific cardiac genes (Foshay et al., 2005). 
Evidently, STAT3 plays a fundamental role in early cardiomyogenesis, in which 
STAT3 is required during initial remodeling of cardiac progenitor cells to drive the 
differentiation of cardiomyocytes from ES cells. 
 
1.4 GATA transcription factors and cardiac development 
1.4.1 The GATA family of transcription factors 
Members of the GATA family are zinc finger-containing transcription factors that 
play critical roles in cell growth and development, regulation of differentiation 
including in cell-fate specification and control of cell proliferation and movement. 
Six different family members of GATA transcription factors (GATA-1-6) are 
characterized from vertebrate (Laverriere et al., 1994; Yamamoto et al., 1990). 
They all contain two similar but distinct repeats of a highly conserved zinc fingers 
required for sequence-specific binding, usually (A/T)GATA(A/G) and for protein-
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protein interactions (T. Evans, Reitman, & Felsenfeld, 1988; Omichinski, Clore, et 
al., 1993; Omichinski, Trainor, et al., 1993). 
 
The first subgroup is composed of GATA-1, -2, and -3 which are expressed in 
hematopoietic lineages (M. Leonard, Brice, Engel, & Papayannopoulou, 1993) and 
are essential for normal hematopoiesis (Pandolfi et al., 1995; Pevny et al., 1991; 
Simon, 1995; Tsai et al., 1994; Zheng & Flavell, 1997). The second subgroup is 
consisted of GATA-4, -5 and -6, which are expressed in cardiac tissues (Gove et 
al., 1997) and endoderm-derived tissues (Arceci, King, Simon, Orkin, & Wilson, 
1993; Laverriere et al., 1994; Morrisey, Ip, Lu, & Parmacek, 1996; Morrisey, Ip, 
Tang, Lu, & Parmacek, 1997). 
 
Within the heart, GATA4 appears to be one of the earliest transcription factors 
expressed in developing murine cardiac cells and its mRNA is presents throughout 
the developing myocardium and endocardium and also detected at high level in the 
postnatal heart (Grepin et al., 1994; Heikinheimo, Scandrett, & Wilson, 1994). 
GATA6 is expressed in the cardiac-committed mesoderm at the late primitive 
streak stage and also in the developing and postnatal myocardium (Jiang & Evans, 
1996; Morrisey et al., 1996). In contrast, GATA5 is restricted to the endocardium 
(Kelley, Blumberg, Zon, & Evans, 1993). 
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1.4.2 Roles of GATA-4, -5, -6 in heart development 
Over the past decade, emerging evidence has accumulated of different nuclear 
transcription factors in regulation of cardiac gene expression involved in normal 
heart development and growth. Three members of the GATA family of DNA-
binding transcription factors, GATA-4, -5 and -6 factors are amongst the first to be 
expressed in the developing heart. 
 
The first evidence which supports that GATA4 is essential for cardiac 
differentiation derived from in vitro studies of pluripotent P19 embryonal 
carcinoma cells whereby depletion of GATA4 by an antisense strategy prevents 
terminal cardiac differentiation and triggers massive apoptosis of the precardiac 
cells, while overexpression of GATA4 increases differentiation of cardiomyocytes 
(Grepin, Nemer, & Nemer, 1997; Grepin, Robitaille, Antakly, & Nemer, 1995). 
Hence, GATA4 is well illustrated that it mediates differentiation of cardiomyocyte, 
cardiomyocyte proliferation and survival. Studies using mouse ES cells with gene-
targeted disruption of GATA4 is potentially differentiate into cardiomyocyte in 
vitro, though with reduced efficiency, and are defective in the formation of proper 
visceral endoderm and definitive endoderm of the foregut (Narita, Bielinska, & 
Wilson, 1997a, 1997b; Soudais et al., 1995). Subsequently, transgenic mice with 
gene inactivation of GATA4 is embryo lethal between day 8 and 9 postcoitum due 
to failure in the formation of heart tube and ventral morphogenesis resulting in 
cardiac bifida, which suggests that GATA4 is crucial for normal heart development 
(Kuo et al., 1997; Molkentin, Lin, Duncan, & Olson, 1997). However, 
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cardiomyocyte differentiation is observed in the GATA4 deficient mice and cardiac 
atrial natriuretic peptide (ANP) and α-myosin heavy chain (α-MHC) genes are 
expressed normally, indicating that the function of GATA4 in the developing heart 
may be compensated by other proteins or signals and observed upregulation of 
GATA6 in GATA4 deficient mice is potentially compensate for the absence of 
GATA4 (Kuo et al., 1997; Molkentin et al., 1997). 
 
GATA6 deficient mice die shortly precede heart induction, at E5.5-7.5 before a 
potential role in cardiac differentiation can be assessed as a result of abnormal 
visceral endoderm function and defects in extraembryonic tissue (Koutsourakis, 
Langeveld, Patient, Beddington, & Grosveld, 1999; Morrisey et al., 1998). Hence, 
it appears that of the mammalian GATA factors, GATA6 is required at the earliest 
stage of heart development. Nonetheless, GATA6 deficient ES cells are potentially 
contribute to the heart in chimeric embryos in vivo and to differentiate into 
myocardium in vitro which is accompanied by attenuated expression of GATA4 
mRNA, indicating that GATA6 may regulate the expression of GATA4 during 
differentiation (Morrisey et al., 1998). The lack of phenotype in embryoid bodies 
derived from GATA6 null ES cells could be explained by an important link between 
GATA6 and BMP4 signaling. The role of GATA6 in BMP4 signaling pathway has 
been suggested by the phenotypes similarity between inhibition of BMP and 
GATA6 depletion. It was reported that GATA6 regulates BMP4 expression, 
through the functional GATA sites in its promoter (Nemer & Nemer, 2003; Peterkin, 
Gibson, & Patient, 2003). The availability of BMP4 from surrounding wild-type 
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cells or serum explains the ability of GATA6 deficient ES cells to contribute to 
heart tissues in chimeric embryo and embryoid bodies.  
 
Taken together, GATA4 appears indispensable for proper endodermal 
differentiation and ventral morphogenesis and during late heart development such 
as heart septation and valve formation. Moreover, GATA4 is unable to compensate 
for the loss of GATA6 in the drive towards terminal differentiation (Peterkin et al., 
2003), suggesting that GATA4 might not necessarily be responsible for cardiac 
myocytes differentiation. Collectively, GATA-4 and -6 are important for mesoderm 
and endoderm development required for differentiation and proliferation of 
cardiomyocytes, as well as heart tube formation and morphogenesis. 
 
On the other hand, GATA5 null mice cause no obvious cardiac defects, while 
GATA5 mutant in zebrafish has reduced cardiac myocytes and develops a similar 
phenotype, which is cardiac bifida observed in GATA4 null mice (Molkentin, 2000; 
Reiter et al., 1999). However, GATA5 null mice may express a truncated form of 
GATA5, which would still be transcriptionally active and a functionally active 
protein was still produced, and therefore a role for GATA5 involved in 
cardiogenesis cannot yet be excluded (Nemer, Qureshi, Malo, & Nemer, 1999). 
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1.4.3 Regulation of cardiac gene expression by GATA family 
The temporal and tissues specific expression of cardiac-specific genes during 
cardiogenesis is tightly regulated by the combinatorial interactions between 
members of cell-restricted as well as ubiquitous transcription factor families. 
GATA families are receiving increasing attention because they play essential role 
for embryonic and postnatal heart development. GATA-4, -5 and -6 have been 
demonstrated that they have preferential affinity for a subset of GATA elements to 
activate numerous cardiac-specific genes, as shown for α-MHC, cardiac troponin-
C, ANF, BNP and cardiac troponin-I genes regulation (Di Lisi et al., 1998; Grepin 
et al., 1994; Ip et al., 1994; Murphy, Thompson, Peng, & Jones, 1997; Thuerauf, 
Hanford, & Glembotski, 1994). These genes contain GATA binding sites at their 
promoters which are required for cardiac-specific expression. 
 
Moreover, studies in postnatal cardiomyocytes revealed that there is a cooperative 
interaction of GATA factors among themselves. GATA4 and GATA6 co-localized 
in postnatal cardiomyocytes and could therefore functionally interact with each 
other, at a single GATA element, resulting in synergistic activation of ANF and 
BNP promoters (Charron, Paradis, Bronchain, Nemer, & Nemer, 1999), suggesting 
that GATA4 and GATA6, both factors sometimes acting in concert to regulate 
expression of a subset of distinct cardiac genes.  
 
In addition to interactions within GATA families, many of the combinatorial 
interactions between GATA families and several other cardiac transcription factors 
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have been well-defined. The best characterized partner for GATA4 is the 
homeodomain member of the NK family, Nkx2.5. Together, they synergistically 
activate cardiac-specific genes such as ANF (Durocher, Charron, Warren, Schwartz, 
& Nemer, 1997; Y. Lee et al., 1998; Sepulveda et al., 1998).  Also, Nkx2.5 is  
crucial for normal heart development as Nkx2.5 gene-targeted disruption in mice 
results in embryonic lethality due to poor ventricular differentiation and 
abnormalities in heart tube looping (Lyons et al., 1995). Two separate cardiac-
specific enhancers that contain essential GATA-binding sites were reported to 
control mouse Nkx2.5 gene expression (Lien et al., 1999; Searcy, Vincent, 
Liberatore, & Yutzey, 1998) . Interestingly, GATA6 contains an Nkx2.5 binding 
element (NKE), which is crucial for cardiac-specific expression of the promoter 
during cardiogenesis, indicating a reinforcing regulatory network of GATA factors 
and Nkx2.5 in developing heart (Molkentin et al., 2000).  
 
1.5 Cardioprotection role of STAT3 in heart failure 
1.5.1 Proinflammatory cytokines and inflammation on heart failure 
Heart failure (CHF) is one of the global leading causes of mortality and morbidity, 
remaining as an enormous burden in human health despite the vast amount of 
research. Heart diseases such as myocardial infarction (MI), hypertension, valvular 
heart disease, coronary artery disease and dilated cardiomyopathy, eventually lead 
to heart failure (McMurray & Pfeffer, 2005). 
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Proinflammatory cytokine and inflammation have been recently emerged as a 
major factor in the development and progression of many types of heart failure. 
Cytokines potently stimulate host immune responses through triggering an 
inflammatory response by inducing the up-regulation and release of 
proinflammatory cytokines such as interleukin 1(IL-1), interleukin 6 (IL-6), and 
Tumor Necrosis Factor-α (TNF-α) (Ulevitch & Tobias, 1995; R. B. Yang et al., 
1998). Studies have shown that adult patients with congenital heart disease had 
signiﬁcantly elevated levels of circulating IL-6 and TNF-α compared with healthy 
control subjects. In particular, there are a number of studies have implicated that 
prolonged expression of proinflammatory cytokines, such as TNF-α may lead to 
deleterious effects on the heart, contributing to cardiomyopathy and left ventricular 
dysfunction and remodeling (Bryant et al., 1998; Hamid et al., 2009; Haudek, Taffet, 
Schneider, & Mann, 2007; Suffredini et al., 1995). Also, significantly elevated 
levels of circulating cytokines and cytokine receptors, such as IL-6, TNF-α, soluble 
TNF receptor 1 (sTNFR1), and soluble TNF receptor 2 (sTNFR2) are found in the 
patients with advanced congenital heart failure (Deswal et al., 2001; Rauchhaus et 
al., 2000). Taken together, all these observations raise the possibility of a causal 
relationship of inflammatory cytokine and inflammation in the development and 
progression of heart failure. 
 
1.5.2 The STAT3 signaling pathway and heart function 
All 7 STATs are expressed in the heart and cultured cardiac myocytes (Levy & 
Darnell, 2002). In the heart, Interleukin-6 cytokine family such as LIF, 
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cardiotrophin 1 (CT-1), oncostatin M and IL-6 particularly, which is a major 
cytokine generated during inflammation, transduce their signals via homo- or 
heterodimers of gp130 predominantly to STAT3 (Fischer & Hilfiker-Kleiner, 2007).  
 
Experimental evidence suggests IL-6-JAK-STAT signaling cascade to be 
participated in cardioprotection, particularly activation of JAK2-STAT3 signaling 
in response to hypertrophic stimuli and ischemia (Hilfiker-Kleiner et al., 2004). 
Induction of cardiac hypertrophy by LIF and gp130 is mediated primarily by 
STAT3. Silencing of STAT3 blocks LIF-induced hypertrophy, while 
overexpression of JAK inhibitor SOCS3 abolishes gp130 signaling (Barry, 
Davidson, & Townsend, 2008; Uozumi et al., 2001). 
 
STAT3 activation following ischemia injury upregulates bcl-2 and downregulates 
bax, thus reduces cell necrosis through attenuating myocardial infarct size and 
cardiomyocyte apoptosis (Hattori et al., 2001; Negoro et al., 2000). Mice 
expressing cardiac-specific, constitutively active STAT3 develop myocardial 
hypertrophy at early age and are protected from doxorubicin-induced 
cardiomyopathy (Butler, Huffman, Koch, Hahn, & Gwathmey, 2006). In addition, 
overexpression of STAT3 in the heart protects from myocardial infarction, 
increases capillary density and enhances expression of downstream proangiogenic 
factors, such as vascular endothelial growth factor (VEGF) and VE-cadherin (Booz 
et al., 2002; Oshima et al., 2005; Osugi et al., 2002).   
1.5.3 Role of STAT3 in myocardial infarction and ischemia-reperfusion injury 
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Conversely, several studies had highlighted the role of STAT3 as a cardioprotective 
transcription factor using cardiomyocyte-specific STAT3 knockout (STAT3-CKO) 
mice. The Cre-loxP system is used to ablate STAT3 directed by the α-myosin heavy 
chain promoter which drives transgene expression specifically to cardiomyocytes.  
 
Since gp130-STAT3 signaling pathway is required for cardiac protection and 
myocardial ischemia increases the levels of gp130 and IL-6 (Chandrasekar, 
Mitchell, Colston, & Freeman, 1999), the involvement of JAK-STAT signaling has 
been investigated in acute myocardial infarction to determine its 
pathophysiological roles in ischemic heart disease. These STAT3-CKO mice have 
defects in myocardial capillary angiogenesis, evident from the decreased left 
ventricular capillary density and enhanced interstitial fibrosis suggesting that 
STAT3 controls expression of downstream genes in cardiomyocytes that might be 
involved in regulation of myocardial capillarization or fibrosis. Furthermore, long-
term follow-up in STAT3-CKO mice by 12 months of age, these mice showed 
symptoms of heart failure including dilated heart with massive interstitial fibrosis, 
increased rate of apoptosis, impaired contractile function and a decreased systolic 
function overtime (Hilfiker-Kleiner et al., 2004).  
 
Also, STAT3-CKO mice were more susceptible to ischemia-reperfusion induced 
cardiac injury. Ischemia-reperfusion injury is a pathological condition 
characterized by an initial restriction of blood supply to an organ followed by the 
subsequent restoration of blood flow and reoxygenation which surprisingly is often 
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associated with an exacerbation of tissue injury and a profound inflammatory 
response (reperfusion injury) (Eltzschig & Eckle, 2011). Results demonstrated that 
these STAT3-CKO mice experienced larger infarct sizes after 1 hour ischemia and 
24 hours reperfusion as compared to wild-type controls, indicating that STAT3-
CKO mice were more susceptible to ischemia-reperfusion induced cardiac injury 
and thus STAT3 mediated cardioprotection is adequate to prevent further injury 
induced by the inflammatory response following the ischemia-reperfusion injury 
(Hilfiker-Kleiner et al., 2004). 
 
1.5.4 STAT3 in cardioprotection by ischemia preconditioning and 
postconditioning  
 
Ischemia preconditioning (IP) describes the administration of small ischemic 
insults before a subsequent prolonged episode of ischemia-reperfusion, which 
renders the heart more adaptable or tolerant to an ischemia event and reduces the 
irreversible tissue injury. In contrast, ischemia postconditioning (PC) refers to  
reduced infarct size by applying multiple short cycles of ischemia-reperfusion 
following a sustained ischemia insult (Boengler et al., 2008).  
 
Using cardiomyocyte STAT3 KO mice in which STAT3 was ablated under control 
of the MLC2v promoter which drives activation of the Cre-recombinase, the 
important role of STAT3 in mediating the cardioprotection by IP has been revealed. 
STAT3-CKO and wild-type hearts were subjected to 3 conditions, control 
conditions, ischemia (30 min of ischemia and 45 min of reperfusion) and ischemia 
preconditioning just before ischemia (4 cycles of 5 min ischemia and 5 min 
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reperfusion prior to the ischemia, 30 min of ischemia and 45 min of reperfusion).  
In STAT3-CKO mice, reduced infarct size by IP was abolished. This finding was 
further confirmed in cardiomyocytes isolated from both STAT3-CKO and wild-
type mice. IP in STAT3-CKO cardiomyocytes showed no increase in cell viability 
as compared to IP in wild-type cardiomyocytes. In addition, pharmacological 
preconditioning which utilized there agents (adenosine, diazoxide and TNF-α) 
known to afford protection failed to rescue/ reduce cell death in STAT3-CKO 
cardiomyocytes (R. M. Smith et al., 2004). Since the protection conferred by 
ischemia and pharmacological preconditioning was abolished in STAT3-CKO 
mice and STAT3-CKO cardiomyocytes, this finding strongly indicates that STAT3 
signaling is critical for the preconditioning cell survival program.  
 
More recently, tamoxifen-inducible cardiomyocyte-restricted STAT3 deletion was 
used to determine the role of STAT3 in the upregulation of cardioprotective 
proteins by ischemia preconditioning. The mice received vehicle or tamoxifen and 
were subjected to ischemia preconditioning and the hearts were harvested. 
Tamoxifen treated mice (STAT3-CKO) showed abrogation of STAT3 tyrosine and 
serine phosphorylation induced by ischemia preconditioning and STAT1/3 DNA 
binding activity which examined using EMSA. Furthermore, ischemia 
preconditioning upregulated cardioprotective protein cyclooxygenase-2 (COX-2) 
and heme oxygenase-1 (HO-1) in vehicle-treated mice whereas this upregulation 
was almost completely undetected in tamoxifen-treated mice, demonstrating that 
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STAT3 is essential for the upregulation of a battery of proteins which are 
responsible for preconditioning cell survival program (Bolli et al., 2011). 
 
In the case of ischemic postconditioning (PC), studies focus on whether or not 
STAT3 contributes to cardioprotection by ischemic postconditioning and also to 
analyze whether or not ischemic postconditioning is effective in aged mice hearts. 
Young (3 months) and aged (>13 months) mice underwent ischemia-reperfusion 
without or with ischemia postconditioning [3 cycles of 10 sec ischemia and 10 sec 
reperfusion (3x10) or 5 cycles of 5 sec ischemia and 5 sec reperfusion (5x5)]. In 
young mice, ischemia postconditioning by both 3x10 and 5x5 significantly reduced 
infarct size and this cardioprotective effect was associated with an increase in 
STAT3 phosphorylation. In contrast, postconditioning by 5x5 only was effective in 
reduction of infarct size in aged mice. Also, total STAT3 and phosphorylated 
STAT3 were reduced in aged mice as compared to young mice which might 
account for the age-related loss of postconditioning. Moreover, the cardioprotection 
by postconditioning (3x10) was lost in cardiomyocyte-specific STAT3 KO mice, 
indicating that STAT3 is indispensable not only for ischemia preconditioning but 
also for postconditioning (Boengler et al., 2008). 
 
1.5.5 Role of STAT3 in bacterial infection 
Using STAT3-CKO mice, It was demonstrated that these mice were more 
susceptible to doxorubicin-induced cardiac injury and development of heart failure 
(decreased in cardiac systolic function), suggesting that STAT3 has a 
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cardioprotective function against doxorubicin-induced injury. Also, STAT3-CKO 
mice treated with lipopolysaccharide (LPS) has revealed a significant increase in 
apoptosis than their wild-type counterparts (Jacoby et al., 2003). LPS, a major 
constituent of the outer membrane of gram-negative bacteria, potently stimulates 
host immune responses through triggering an inflammatory response by inducing 
the up-regulation and release of proinflammatory cytokines (Ulevitch & Tobias, 
1995; R. B. Yang et al., 1998). In addition, cardiomyocyte cultured from STAT3-
CKO mice secreted significantly more TNF-α in response to LPS than those in 
wild-type. This may be the cause for dramatic increase in cardiac fibrosis in aged 
mice (9 months) despite having no overt signs of heart failure in young cardiac-
specific STAT3 null mice (6 months). Overall, these results suggested that 
cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to 
inflammation and that STAT3 pathway is critical in regulation of inflammatory 
responses of cardiomyocytes, which may contribute to the development of cardiac 
fibrosis. 
 
1.5.6 Role of STAT3 in viral myocarditis 
Viral myocarditis is caused by viral infection by common viral pathogens for 
instance enteroviruses and adenoviruses that might be directly pathogenic to the 
myocardium with the resulting cytokine-driven inflammatory response, leading to 
subsequent destruction of cardiac myocytes. Studies demonstrated that 
coxsackievirus B3 (CVB3) infection is associated with the activation of JAK-STAT 
signaling in the heart with an induction of STAT inhibitor suppressor of cytokine 
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signaling (SOCS) mRNA. SOCS which is a negative feedback of JAK-STAT 
signaling, when induced, it inhibits tyrosine phosphorylation of the cytokine 
receptor mediated by JAK, and subsequently leads to inhibition of STAT signaling. 
In transgenic mice engineered to overexpressed SOCS in the heart, these mice 
suffered from increased viral infection and this increased susceptibility to viral 
infection was via inhibition of gp130 signaling. Additionally, cardia-specific 
knockout of gp130 showed increased susceptibility to viral infection, suggesting 
that the important role of gp130 signaling via activation of STAT3 in protection 
from virally induced cardiac damage (Yajima et al., 2006). 
 
1.5.7 STAT3 regulates myocardial apoptosis 
STAT3 plays a role in decreasing cardiomyocytes apoptotic cell death. The anti-
apoptotic function of STAT3 was demonstrated using acute myocardial infarction 
(AMI) model in rats. Pretreatment with AG-490 which inhibited STAT3 
phosphorylation resulted in significant increase in caspase-3 activity and Bax 
protein (pro-apoptotic) as well as the number of apoptotic nuclei in AMI hearts 
(Negoro et al., 2000). Furthermore, mice with cardiomyocyte-restricted STAT3 
deletion displayed higher rate of apoptosis (higher number of apoptotic nuclei) 
induced by ischemia-reperfusion (Hilfiker-Kleiner et al., 2004) and by 
lipopolysaccharide (Jacoby et al., 2003) than their wild-type counterparts. In 
addition, during ischemia preconditioning, it has been showed that STAT3 exerted 
its anti-apoptotic function by upregulation of anti-apoptotic proteins involved both 
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in the mitochondrial (Bcl-XL and Mcl-1) and death receptor (C-FLIPL and C-
FLIPS) pathways (Bolli et al., 2011). 
 
In a nutshell, it is clear that STAT3 has emerged as a central player in 
cardioprotection in the response of the heart to multiple pathophysiological 
(myocardial infarction, ischemia-reperfusion injury, bacteria and virus infections) 
and physiological (aging) forms of stress which cause the development of heart 
failure. However, the molecular mechanisms underlying STAT3-mediated 
cardioprotection in both cardiac inflammation and ischemia have not been 
addressed. Therefore, it is in great potential to uncover the molecular mechanisms 
of STAT3-regulated cardioprotection and its potential downstream candidate 
targets that associated with cardiovascular inflammation and ischemia. 
 
1.6 Thioredoxin-interacting protein (Txnip) 
1.6.1 Txnip protein 
Txnip, as its name suggested, it is an endogenous ubiquitously expressed protein 
which binds and inhibits thioredoxin (Trx), a major cellular thiol-reducing and 
antioxidant system, which comprised of thioredoxin reductase (TrxR) and NADPH, 
and therefore results in oxidative stress induction and modulates intracellular redox 
state. (Nishiyama et al., 1999; Yamanaka et al., 2000). Also, Txnip promotes 
apoptosis by abolishing Trx-mediated inhibition of apoptosis-signal-regulating 
kinase-1 (ASK1), further activating downstream JNK/p38MAPK pathway (Kaimul, 
Nakamura, Masutani, & Yodoi, 2007). In addition, it can act independently of its 
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binding to Trx, and contributes to cell growth inhibition, suppression of glucose 
uptake and metabolic reprogramming (Elgort, O'Shea, Jiang, & Ayer, 2010; 
Patwari et al., 2009) 
 
1.6.2 Txnip Functions 
Roles of Txnip have been studies in several physiology conditions such as glucose 
metabolism, inflammation, apoptosis, and cardiac viability. Txnip contributes to 
cell growth inhibition through arrestin domain-mediated suppression of glucose 
uptake and metabolic reprogramming (Elgort et al., 2010; Patwari et al., 2009). In 
addition, it acts as tumour suppressor in various malignancies, by suppression of 
tumour growth and transcription repressor (Jeon et al., 2005), inhibited metastasis 
and induced apoptosis in cancer cells (Kaimul et al., 2007). Also, Txnip modulates 
inflammatory responses (Z. Wang et al., 2006; Zhou, Tardivel, Thorens, Choi, & 
Tschopp, 2010) and vascular cells signaling and apoptosis (Perrone, Devi, Hosoya, 
Terasaki, & Singh, 2009; Schulze, De Keulenaer, Yoshioka, Kassik, & Lee, 2002; 
World, Yamawaki, & Berk, 2006; Yamawaki, Pan, Lee, & Berk, 2005). 
  
In the heart, studies have reported that enhanced Txnip expression is associated 
with increased cell death in diabetic rat heart, in which high expression of Txnip is 
related to dilated cardiomyopathy (Barth et al., 2006; J. Chen, Cha-Molstad, Szabo, 
& Shalev, 2009; van Lunteren & Moyer, 2007). Moreover, cardiac Txnip mRNA 
expression is increased in the rat heart post 48-hour myocardial infarction 
demonstrated by RT-PCR and Txnip-specific DNA enzyme transfection in H9c2 
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cell illustrated a reduced in apoptosis in response to cellular stress of H2O2 (Xiang 
et al., 2005). Recently, it has been validated that overexpression of Txnip triggers 
inflammasome activation and therefore increased ROS production and caspase-1 
expression (Zhou et al., 2010; Zhou, Yazdi, Menu, & Tschopp, 2011). In addition, 
Txnip-KO hearts protect the myocardium from ischemia-reperfusion injury and 
early phrase of pressure overload (Yoshioka et al., 2012; Yoshioka et al., 2007). 
However, the mechanism by which Txnip mediates myocardial injury is unclear. 
 
1.7 Txnip and NLRP3 inflammasome 
1.7.1 The inflammasome complex 
Inflammasome is a large (700kDa) multiprotein cytoplasmic complex, which is 
sufficient to activate caspase-1 by cleavage of procaspase-1. The inflammasome 
complex typically comprises of a nucleotide-binding domain leucine rich repeat 
(NLR) protein, caspase-1 and the adaptor molecule apoptosis-associated speck-like 
protein containing a CARD (ASC) (Martinon, Burns, & Tschopp, 2002). Four 
inflammasome complexes have been identified to date: NLRP1, NLRP3, NLRC4, 
and AIM2 (Stutz, Golenbock, & Latz, 2009).  
 
1.7.2 NLRP3 inflammasome and activation 
The NLRP3 inflammasome consists of the NLRP3 scaffold, ASC, and procaspase-
1. Upon activation, NLRP3 oligomerization leads to its pyrin (PYD) domain 
interacting with the PYD domain of ASC, whose caspase recruitment domain 
(CARD) interacts and recruits the CARD domain of procaspase-1. Active caspase-
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1, a p10/p20 tetramer formed from the auto-catalytic cleavage of procaspase-1 
would then process pro-IL-1β and pro-IL-18 into mature IL-1β and IL-18, which 
are subsequently secreted. IL-1β secretion is the hallmark of NLRP3 
inflammasome activation and activation of caspase-1(G. Y. Chen & Nunez, 2010). 
 
While most inflammasomes are triggered by certain stimuli, interestingly the 
NLRP3 inflammasome is activated by various stimuli of dissimilar physico-
chemical nature. These include microbial stimuli (Muruve et al., 2008), crystalline 
substances (Dostert et al., 2008), pore forming toxins, extracellular ATP and 
necrotic cell components (Mariathasan et al., 2006). Lately, it was identified that 
the assembly of NLRP3 inflammasome requires the presence of reactive oxygen 
species (ROS), which are generated by all known NLRP3 activators. This induces 
a conformational change in an unidentified protein that subsequently activates the 
inflammasome (Martinon, Mayor, & Tschopp, 2009). Conversely, ROS inhibitors 
block inflammasome activation (Dostert et al., 2008; Zhou et al., 2010). 
 
Until recently, Txnip was identified as one of the NLRP3 binding partners, and 
interaction between Txnip and NLRP3 is essential for activation of the NLRP3 
inflammasome (Zhou et al., 2010). In resting cells, Txnip interacts with Trx and 
hence unavailable to interact with NLRP3. Upon an increase in ROS caused by 
NLRP3 activators, Txnip is dissociated from oxidized Trx and in turn binds NLRP3 
and leads to assembly and activation of NLRP3 inflammasome (Zhou et al., 2010). 
(Figure 1.3) 




Figure 1.3 Mechanisms of NLRP3 inflammasome activation. 
Under normaxic condition, Txnip is bound to Trx and inhibits the reducing activity 
of Trx. During oxidative stress, ROS causes Txnip to dissociate from Trx and 
interacts with NLRP3. NLRP3 recruits ASC which in turn interacts with caspase-1 
leading to its activation. Once activated, caspase-1 promotes the maturation of the 
proIL-1B. 
Figure adapted from (Davis & Ting, 2010). 
 
1.7.3 NLRP3 inflammasome in the heart 
Several groups have independently demonstrated that inflammasome contributes to 
the pathophysiology of myocardial ischemia-reperfusion (I/R) injury. ASC and 
caspase-1 were markedly expressed at the site of myocardial I/R injury. Conversely, 
ASC and caspase-1 deletion experienced reduced inflammatory responses and 
protect the myocardium from ischemia reperfusion injury with reduced infarct sizes 
in mice (Kawaguchi et al., 2011). In addition, NLRP3 was upregulated within the 
myocardium following myocardial I/R injury, particularly in myocardial fibroblast. 
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Hearts from NLRP3 deletion mice featured smaller infarct size and showed 
decreased myocardial apoptosis during I/R injury compared with wild-type mice 
(Sandanger et al., 2013). Another group demonstrated that inflammasome was 
induced in cardiomyocytes and inflammasome activation in the cardiomyocyte 
leads to caspase-1 dependent cell death (Mezzaroma et al., 2011). Therefore, 
targeting the inflammasome formation is a potential strategy for cardioprotection. 
 
1.8 Objectives and significance of study 
1.8.1 Objective I 
In vitro-derived cardiomyocytes are a prime candidate for the donor cells for use in 
regenerative medicine as they constitute a renewable source of wide range of 
cardiovascular cell types including cardiomyocytes. Also, it is an ideal model to 
understand the process of early development of cardiomyocyte differentiation. 
Extensive investigations have put forth evidence indicating that STAT3 is 
important in ES cells pluripotency maintenance, however, STAT3 function during 
ES cells differentiation is poorly understood. Therefore, the transition from bench 
to bed necessitates a deeper understanding of the STAT3 function in the regulatory 
networks of early cardiomyocyte differentiation as it take places in the developing 
embryo.  
 
Here, we want to establish an in vitro inducible STAT3 KO and STAT3 CA ES 
system because conventional knock out of STAT3 results in early embryonic 
lethality at the time of cardiomyocyte formation at E7.5-E8.5 and before a potential 
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functional role in cardiac differentiation can be assessed. Therefore, by using these 
inducible systems, the function of STAT3 during early cardiac differentiation can 
be revealed. This project also aims to identify direct downstream targets of STAT3 
during course of early cardiomyocyte differentiation in order to understand the 
transcriptional regulatory mechanisms that underlie early cardiomyocyte 
differentiation. 
 
1.8.2 Objective II 
Cardiovascular disease remains one of the leading causes of human mortality in the 
developed world. In Singapore alone, approximately 1 out of 3 deaths were 
attributable to cardiovascular disease, accounting for 29.9% of all deaths in 2014. 
Moreover, statistics show a pessimistic trend worldwide in which by 2020 
cardiovascular disease is expected to be the leading cause of death in the world (B. 
B. Kelly, Narula, & Fuster, 2012). 
 
Several lines of evidence suggest that STAT3 has function of cardiac protection. 
However, the underlying molecular mechanism by which STAT3 mediated 
cardioprotection is not fully elucidated. Therefore, it is crucial to elucidate the 
changes in genes related to heart pathogenesis and the underlying regulatory role 
of STAT3 involved in this cardiovascular pathogenesis. In this present study, we 
would like to examine potential cardiac genes regulated by STAT3, either by 
upregulating cardioprotective genes or downregulating harmful genes in which 
together they contribute to the survival of the heart under pathogenesis. Hence, this 
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study might provide new insight for potential clinic therapy for heart failure and to 
explore and develop new biomarkers and therapeutic treatments for the disease by 
developing such STAT3 downstream mediators as novel therapeutic targets. 
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Chapter 2 Materials and Methods 
2.1 Antibodies, chemicals and other reagents 
2.1.1 Antibodies 
Antibodies against STAT3 (C-20), ASC, α-tubulin, actin were purchased from 
Santa Cruz; antibodies against STAT3 phospho-Tyr705, STAT3 and IL-1β were 
purchased from Cell Signaling; antibodies against GATA6 was purchased from 
Abcam; antibodies against Txnip was purchased from MBL and antibodies against 
Troponin T, α-Actinin, Flag tag (Flag M2), NLRP3 were purchased from Sigma. 
2.1.2 Chemicals 
Table 2.1 List of chemicals used in this study 
Name  Source 






2.1.3 Other reagents 
Restriction enzymes and T4 DNA ligase were from New England Biolabs (NEB). 
 
2.2 Plasmids 
For recombinant DNA cloning procedures and plasmid DNA amplification, E.coli 
strain DH5α (Invitrogen) was used as host. Bacteria cells were grown in LB liquid 
or solid medium with ampicillin (100μg/ml) for selection of positive cells. All 
plasmids were verified by sequencing. 
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2.3 Animal Experiments 
2.3.1 Generation of Mice with Cardiac-Specific Deletion of STAT3 
To study the biological function of STAT3 in the heart, mice express alpha-MHC 
(Myosin heavy chain) promoter driven Cre recombinase (Agah et al., 1997) was 
crossed with mice which carry crucial exons of the STAT3 gene flanked by LoxP 
sites (floxP) to generate cardiomyocyte-specific STAT3 knockout mice. Details of 
the procedure for generating the mice were described in our previous article (Jacoby 
et al., 2003). Cardiomyocyte-specific STAT3 KO mice is referred to as STAT3 
CKO whereas its control which has both alleles carrying floxP STAT3 gene but 
without Cre is referred to as STAT3flox/flox. 
2.3.2 LPS Application Procedures 
One dose LPS treatment: Mice of floxP/ floxP (STAT3flox/flox) genotype were 
treated with LPS (0.5mg/kg, i.p), and then sacrificed 2 and 18 hours after treatment. 
H9c2 myoblast was treated with LPS (100uM) and samples were collected after 0.5, 
1, 2, and 18 hours.  
 
2.4 Cell culture 
2.4.1 ES cell culture 
E14 murine embryonic stem cells were maintained in undifferentiated state with 
Glasgow Minimum Essential Medium (Gibco, Invitrogen, Carlsbad, CA, USA), 
supplemented with 15% ES cell-qualified fetal bovine serum (ES-FBS; Gibco), 
1mM sodium pyruvate (Gibco), 0.1mM non-essential amino acids (Gibco), 0.1mM 
2-mercaptoethanol (Sigma-Aldrich, St Louis, MO, USA), 50U/ml penicillin 
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(gibco), 50ug/ml streptomycin (gibco) and 1000U/ml murine leukemia inhibitory 
factor (LIF; Sigma-Aldrich) on gelatin-coated culture dish at 37°C in humidified 
air with 5% CO2. Medium was changed every two days and the cells were 
subcultured when they reached 70-80% confluency. Cells were made to undergo 2 
passages after thawing before commencement of cardiomyocyte induction. 
2.4.2 H9c2 cell culture 
Rat H9c2 cardiac myoblast cell line was cultured in high glucose 1X Dulbecco’s 
modified Eagle’s medium (DMEM) with L-Glutamine and D-glucose (Gibco- 
Invitrogen, CA, USA), supplemented with 10% Fetal Bovine Serum (FBS) (Gibco- 
Invitrogen, CA, USA) and 1% penicillin (10,000U/mL) and streptomycin 
(10,000μg/mL ) (1% Pen-Strep) (Gibco-Invitrogen, CA, USA) in 25cm2 or 75cm2 
tissue culture flasks (NUNCTM, Roskilde, Denmark). The cells were incubated at 
37°C in a humidified atmosphere of 5% CO2
 and 95% air. Cells were passaged by 
trypsinization upon reaching 80% confluency to prevent them from losing their 
myoblastic properties at a subcultivation ratio of 1:2 to 1:4. Cells from passages 
four to 15 were used for experiments.  
 
2.5 Generation of inducible ES cell lines 
2.5.1 pTRE3G-IRES Tet-on System 
The 3rd generation Tet-on System was purchased from Clontech Laboratories (Cat. 
no. 631167). These Tet-On 3G Systems are inducible gene expression systems for 
mammalian cells. The system consists of the Tet-On 3G transactivator, TetR 
(Supplementary figure 1A) and contains a gene of interest (GOI) under the control 
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of a TRE3G promoter (pTRE3G) (Supplementary figure 1B, 1C, 1D) which will 
express high levels of GOI driven by TetR with doxycycline induction. 
 
Full-length of mouse wild-type STAT3 cDNA was cloned from ES cDNA pool by 
PCR, constitutive activated STAT3 (CA-STAT3) or overexpression of pSTAT3 
was obtained from pXJ40-CA (kindly provided by Professor Cao Xinmin), and 
NlsCre was purchased from commercial entities. mSTAT3, CA-mSTAT3 and 
NlsCre were cloned into a TetR response vector controlled by the tetracycline 
responsive element (pTRE-), fused with C-T2ACherry and C-IRESzsGreen 
respectively. 
2.5.2 Generation of Inducible STAT3 KO and overexpressed ES cell lines 
The regulatory vector pEF1a-Tet was transfected into mouse STAT3flox/flox ES cells 
or wild-type ES cell line E14. The G418 resistant cell clones with high luciferase 
expression and low background were transfected with pTRE3GCret2acherry, 
pTRE3GSTAT3-IRESzsGreen, pTRE-STAT3CAIRESzsGreen respectively. 
Selected by puromycin, the transgenic cell clones were obtained. In these clones, 
the mCherry or GFP, indicating STAT3-KO or pSTAT3-overexpression, could be 
turned on or off by adding or removing doxycycline (Dox). In conclusion, we have 
established the ES cell lines in which STAT3 expression can be switched on or off 
and regulated by Dox induction. (Figure 2.1) 
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Figure 2.1 Schematic chart for establishing the Inducible STAT3 KO and 
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2.6 ES cells differentiation 
2.6.1 Preparation of ES cells for Embryoid Bodies (EB) formation 
ES cells were dissociated using 0.1% trypsin-EDTA (Invitrogen) and suspended in 
Glasgow Minimum Essential Medium (Gibco, Invitrogen) supplemented with 15% 
ES cell-qualified fetal bovine serum ,1mM sodium pyruvate (Gibco), 0.1mM non-
essential amino acids, 0.1mM 2-mercaptoethanol, 50U/ml penicillin, 50ug/ml 
streptomycin, and 50ug/ml Ascorbic acid  (EB medium) (T. Takahashi et al., 2003). 
2.6.2 EB formation induced by Hanging Drops method 
ES cells were differentiated to form embryoid bodies using the hanging drops 
method as previously reported (Boheler et al., 2002) (Figure 2.2). Hanging drops 
each of 25ul, containing 1000 embryonic stem cells were seeded on the lid of 10cm2 
cell culture dish and the dish was filled with PBS to prevent desiccation of EBs. A 
total of 50 drops were seeded on each culture dish. To ensure quantifiable 
measurement of RNA and lysate concentration for RT-PCR and Western blot 
analysis respectively, an equal number of hanging drops were seeded on each plate. 
A total of 200 hanging drops were allocated for each differentiation phase. Hanging 
drops were incubated at 370C in humidified air with 5% CO2 for 3 days. EBs were 
then seeded on gelatin-coated plate on the 4th day of differentiation. EB medium 
was changed every two day. The beating cardiomyocytes could be observed as early 
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Figure 2.2 Schematic diagram of the experimental protocol used for induction 
of embryonic stem cells to the cardiac lineage.  
Figure adapted from (Boheler et al., 2002). 
 
2.7 Transfection  
Transfection was done when cells grown to 70%-80% of confluency. Cells were 
transfected by Lipofectamine 2000 and the manufacturer’s protocol (Life 
Technologies) was followed. 5μg of plasmid DNA was diluted in Opti-MEM 
medium for a final volume of 50μl. 2µl of Lipofectamine 2000 was diluted in 48µl 
Opti-MEM medium followed by a 5 min incubation at room temperature. Diluted 
DNA was added to diluted Lipofectamine 2000 at 1:1 ratio and incubated for 20 
min at room temperature. After incubation, the DNA/lipofectamine mixture was 
added to each well and gentle swirl to mix. The transfected cells were incubated at 
37°C with 5% CO2. After about 4 to 6 hours, media was removed and replaced with 
fresh media. Then cells were moved back to 37°C incubator with 5% CO2 until cells 
reached full confluency for harvest and the transfection efficiency was checked by 
viewing in a fluorescent microscopy. 
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2.8 Histological and Immunofluorescent 
Heart tissues were embedded in OCT compound, frozen immediately after excision, 
and sectioned and mounted on Silane coated slides. Slides were washed with PBS 
solution, fixed with 4% paraformaldehyde for 10 min at room temperature and 
permeabilized with 0.2% Triton X-100 in PBS for 10 min. Then slides were blocked 
with 3% BSA in PBS with 0.1% Triton X-100 for 10 min, followed by incubation 
with indicated primary antibodies at 4°C overnight. Then slides were washed three 
times with 0.1% Triton X-100 in PBS, each time for 10 min and incubated with 
fluorescence-labeled secondary antibodies in dark at room temperature for 1 hour. 
Nuclei were visualized by DAPI staining. Coverslips were mounted onto slides by 
VECTASHIELD HardSet Mounting Medium (Vector Laboratories, H-1400). 
Labeled sections were imaged using Nikon A1R-A1 confocal microscopy system.  
 
2.9 RNA Isolation and Quantitative Real-Time PCR (qRT-PCR)  
Total RNA was harvested using TRIzol reagent (Invitrogen) according to the 
manufacturer’s instructions, purified by the RNeasy mini kit (Qiagen), and then 
reverse transcribed using the M-MLV Reverse Transcriptase system (Promega) to 
obtain cDNA. The cDNA products were subjected to semi-quantitative RT–PCR 
with KAPA SYBR® FAST Universal 2X qPCR Master Mix (KK4600) using a 
7300 Real-Time PCR machine (Applied Biosystems). All gene-specific mRNA 
expression values were normalized against the internal housekeeping gene GAPDH. 
The sequences of primers used are in Table 2.2. Triplicate was done for the analysis 
of each samples. 
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Table 2.2 List of primers used in this study 
Gene 
(Mouse) 











































Chapter 2 Materials and Methods 
44 
 
2.10 Illumina Microarray analysis 
Inducible STAT3 CA and wild-type TetR ES cells as control and inducible STAT3 
KO and STAT3 F/F TetR ES cells as control were treated with Dox for 48 hours. 
Biological triplicates of induced ES cells were harvested and total RNA was 
extracted and purified by the RNeasy mini kit with on-column DNase digestion 
(Qiagen) according to the manufacturer’s instructions. The array was done using 
MouseWG-6 v2 Expression BeadChip Kit (Illumina) according to the 
manufacturer’s protocol. RNA quantity, quality and purity were assessed on an 
Agilent Bioanalyzer. The microarray analysis was carried out using R language by 
our bioinformatician.  
 
2.11 Chromatin Immunoprecipitation Assay 
ChIP assay was performed following Yang’s published ChIP protocol (T. I. Lee, 
Johnstone, & Young, 2006). Crosslink was performed by addition of formaldehyde 
at final concentration of 1% for 10 min followed by quenching with Glycine. Cell 
lysates were fragmented by sonication and pre-cleared with protein-G agarose 
beads (Invitrogen), and subsequently precipitated with anti-STAT3 antibody (Santa 
Cruz) or normal rabbit IgG (Santa Cruz) overnight at 4oC with continuous rotation. 
After washing and elution, cross-linking reversal was carried out by incubating the 
eluate at 65oC for 8 hours. DNA was isolated with phenol-chloroform and ethanol 
precipitated with the help of glycogen. The eluted DNA was analyzed by qRT-PCR 
to inspect possible binding sites of STAT3. The promoter region for GATA6 and 
Chapter 2 Materials and Methods 
45 
 
Txnip was analyzed by real-time PCR using the following primers indicated in 
Table 2.2. 
 
2.12 Protein Extraction and Western Blotting 
Cell and tissue were washed twice with ice-cold PBS, and lysed in whole cell 
extract buffer supplemented with protease inhibitor (Roche, Switzerland). The 
supernatant was collected by centrifugation, and protein concentrations were 
measured with BCA assay (Bio-Rad, CA). The absorbance of the proteins in the 
lysates was then measured using GeneQuant 1300 machine with wavelength set at 
595nm. Appropriate amount of lysate samples were mixed with sample buffer, 
separated by SDS-polyacrylamide gel electrophoresis of a gel percentage 
dependent on the size of the target protein and transferred onto a polyvinylidene 
difluoride (PVDF) membrane in cold room. After blocking with 5% nonfat milk in 
washing buffer, the membranes were incubated with the indicated primary 
antibodies at 4°C overnight. Following washes, they were incubated in horse-radish 
peroxidase (HRP) conjugated secondary antibodies. The immunoreactive bands 
were visualized using SuperSignalR Chemiluminescent Substrate (Pierce) on 
audiographic film (Thermo Scientific) that was developed by a film cassete. Equal 
loading the blots was shown by β-Actin level. 
 
2.13 Statistical Analysis 
Data are expressed as mean ± SEM. A p value of <0.05 was considered a 
statistically significant difference. 
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Chapter 3 Results (Part I) 
Results (Part I): The role of STAT3 from embryonic stem cells into cardiac 
lineage differentiation  
 
3.1 Recombinant ES cells allowing Dox inducible expression of a Cre mCherry 
transgene and STAT3 constitutively expressed GFP transgene. 
 
To determine the biological function of STAT3 in ES cells and in vitro 
cardiomyocyte differentiation of ES cells, we used an inducible Tet-on system to 
generate mouse ES cell lines harboring a doxycycline (Dox)-inducible Cre and 
STAT3 constitutively activated (STAT3 CA) transgenes which can be temporally 
and specifically induced upon Dox addition. Cre and STAT3 CA Tet-on positive 
ES clones were selected and propagated. Following 24 hours Dox stimulation, 
mCherry and GFP expression were imaged suggesting that Cre transgene was 
induced and its recombinase activity function to delete STAT3flox/flox  (Figure 3.1A) 
in vitro resulting in a mutant STAT3 protein missing the SH2 domain for STAT3 
function whereas STAT3 was constitutively activated (Figure 3.1B) in ES cells. 
A          B      
                     pTRE-Cre                                             pTRE-STAT3 CA 
 
          White field        White field 
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      pTRE-Cre                                        pTRE-STAT3 CA 
 
              mCherry             GFP 
    
    Merge            Merge 
    
 
Figure 3.1 Inducible STAT3 KO and STAT3 CA ES clones. 
A. In pTRE-CreCh/pEF1aTetR inducible STAT3 KO ESCs, mCherry was 
observed after 24 hours Dox induction, indicating that Cre was expressed and 
function to delete STAT3 in vitro. 
B. In pTRE-STAT3 CA/pEF1aTetR inducible STAT3 CA ESCs, GFP was 
expressed after 24 hours Dox induction, suggesting that STAT3 CA was expressed. 
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3.2 STAT3 genomic DNA deletion by genotyping of ES cells after dox 
induction 
 
Following the previous study described (Jacoby et al., 2003), the primer pair 1 (5′-
ATT GGA ACC TGG GAC CAA GTG G) and 3 (5′-GCT GGC TCA TAG GCA 
AAA ACA C) was used to detect the STAT3 deleted (STAT3D) alleles by PCR 
analysis. The STAT3D was detected as a 480 base pair fragment. Inducible Cre 
(iCre) ESCs following 24 hours Dox induction, along with mice heart tissue 
samples as positive control, which included the hearts from STAT3-deficient mice 
(C/F/D), heterozygous (C/F/+), and STAT3flox/flox mice (F/F) as well as the 
STAT3flox/flox (F/F) ESCs. The STAT3D allele was detected as a 480-bp fragment in 
STAT3-deficient heart (C/F/D) and STAT3 KO ESCs (Figure 3.2 lane 1 and 4). 
With this primer pair, it amplified an approximately 1.5 kb fragment and a 480-bp 
in heterozygous (C/F/+) heart sample (Figure 3.2 lane 2), whereas the STAT3flox/flox 
(F/F) heart and F/F ESCs just gave a 1.5 kb fragment (Figure 3.2 lane 3 and 5). 
                                   
                 
 
Figure 3.2 Generation of inducible STAT3 KO ES cells. 
Ablation of STAT3 genomic DNA in inducible STAT3 KO ES cells was detected 
as a 480 base pair fragment.  
Chapter 3 Results (Part I) 
49 
 
3.3 pSTAT3 and STAT3 protein expressions in inducible STAT3 KO ESCs 
and inducible STAT3 CA ESCs 
 
Western blot analysis confirmed that pSTAT3 and STAT3 protein levels in these 
inducible ES cells were deleted or induced by Dox stimulation. Tyrosine 705 (Y705) 
phosphorylation in STAT3 (pSTAT3) is a prerequisite for increasing STAT3 
transcriptional activation (Decker & Kovarik, 1999) and also our inducible STAT3 
CA ES cells system functions to induce overexpression of pSTAT3. Therefore 
pSTAT3 protein expression was detected in these inducible ES cells using an 
antibody that specifically recognizes STAT3 protein phosphorylated on Y705. 
 
In pTRE-Cre ES cells, pSTAT3 protein level was efficiently ablated and undetected 
after 48 hours Dox induction while STAT3 protein level was decreased, but still 
detectable after 48 hours Dox induction (Figure 3.3A). In pTRE-STAT3 CA ES 
cells, pSTAT3 was rapidly upregulated after 24 hours Dox induction (Figure 3.3B). 
Since STAT3 antibody can detect total STAT3 which included both pSTAT3 and 
STAT3 proteins, therefore STAT3 protein level was upregulated slightly upon Dox 
induction due to the increased expression of pSTAT3 protein level. Our results 
showed that Clone 1 was a better clone for our study due to its higher level of 
pSTAT3 induction as compared to clone 2 upon Dox induction (Figure 3.3B). 
Flagged-STAT3 CA expression was detected using anti-flag antibody. While 
undetectable in basal condition, STAT3 CA was rapidly upregulated after Dox 
stimulation (Figure 3.3C). 
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A      B 
      
                      Clone       1                2             
                      pTRE-Cre                                     pTRE-STAT3 CA 
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Figure 3.3 pSTAT3 and STAT3 protein levels in inducible ES cell lines after 
Dox induction. 
A. In pTRE-CreCh/pEF1aTetR ESCs, after the Dox induction, pSTAT3 was 
reduced and undetected after 48 hours induction, while STAT3 was decreased, but 
still detectable after 48 hours. 
B. In pTRE-STAT3 CA/pEF1aTetR ESCs, pSTAT3 and STAT3 were rapidly 
upregulated after 24 hours Dox induction. 
C. In pTRE-STAT3 CA/pEF1aTetR ESCs, after the Dox induction, flagged-
STAT3 CA expression was detected, which indicated that CA-STAT3 was 
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3.4 Illumina Microarray Analysis of STAT3 Target Genes 
Microarray experiments were conducted in three independent experiments to 
profile fully the genes activated or repressed by STAT3. STAT3 CA ES cells 
(Constitutively Activated STAT3 or pSTAT3 overexpression) and STAT3 F/F Cre 
ES cells (STAT3 KO) were induced with Dox for 2 days and harvested for RNA 
profiling using illumina microarrays, compared with uninduced wild-type TetR or 
F/F TetR ES cells as controls. 
 
Heatmaps were generated by using fold-change more than 4-fold, and we found 48 
genes differentially expressed by more than 4-fold (38 up and 10 down) between 
wild-type TetR and STAT3 CA ES using illumina array platform (Figure 3.4A). By 
using fold-change more than 2-fold, 436 genes were found to be differentially 
expressed (260 up and 176 down) between wild-type TetR and STAT3 CA ES 
using illumina array platform. The top elevated and repressed genes (>4-fold) were 
depicted in Supplementary table 1, arranged according to average fold changes. We 
found that GATA6, was among the top 2 upregulated genes (11-fold) upon pSTAT3 
constitutively overexpressed (Figure 3.4A, indicated by arrow). 
 
To gain an overview of genes modulated when pSTAT3 was overexpressed and 
STAT3 was knockout, enrichment of functional gene ontology (GO) annotations 
among genes that are at least 2-fold differentially expressed were searched (Figure 
3.4B). 15 biologic functions were significantly associated when pSTAT3 was 
overexpressed, which included those related to the phosphoprotein, alternative 
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splicing, cytoplasm, development protein, cell fraction, apoptosis, embryonic 
development ending in birth or egg hatching, epithelium development, vasculature 
development, heart development, epithelial cell differentiation, and methylation, as 
well as regulation of transcription, transcription regulator activity and regulation of 
transcription from RNA polymerase II promoter. GATA6 was involved in 9 
biological functions which were epithelium and heart development, embryonic 
development ending in birth or egg hatching, and epithelial cell differentiation. It 
was also involved in transcription regulation, transcription regulator activity, and 
regulation of transcription from RNA polymerase II promoter, apoptosis and 
phosphoprotein. 
 
Between F/F TetR and STAT3 Cre ES, we found 135 genes differentially expressed 
by more than 4-fold (102 up and 33 down) using illumina array platform (Figure 
3.4C). By using fold-change more than 2-fold, 1244 genes were found to be 
differentially expressed by more than 2-fold (869 up and 375 down) between F/F 
TetR and STAT3 Cre ES using illumina array platform. The top 20 elevated and 
repressed genes were depicted in Supplementary table 2, arranged according to 
average fold changes. 15 biologic functions were significantly associated when 
STAT3 is knockout (Figure 3.4D), which included those related to the alternative 
splicing, cytoplasm, development protein, embryonic development ending in birth 
or egg hatching, vasculature development, blood vessel development, heart 
development, embryonic organ development, differentiation, and negative 
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regulation of differentiation, as well as angiogenesis, vitamin binding, EGF 
calcium-binding, response to oxidative stress and inorganic substances. 
 
Next, a heatmap was generated using the agree list of genes in expression regulated 
by STAT3 CA and in STAT3 Cre (Figure 3.4E). There were 209 genes 
differentially expressed by more than 2-fold (72 upregulated by STAT3 CA while 
downregulated in STAT3 Cre; 137 downregulated by STAT3 CA while 
upregulated in STAT3 Cre) between wild-type TetR and STAT3 CA and F/F TetR 
and Cre ES using illumina array platform. Txnip was one of the genes in which its 
expression was upregulated when STAT3 is KO (4-fold) while downregulated upon 
STAT3 constitutively overexpressed (0.48-fold) (Figure 3.4E, indicated by arrow).  
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Figure 3.4 Illumina Microarray Analysis of STAT3 Target Genes. 
A. Comparison of the expression of genes regulated by STAT3 CA by heatmap. 
B. Gene oncology (GO) analysis of STAT3 CA regulated genes.  
C. Comparison of the expression of genes when STAT3 is knockout by heatmap. 
D. Gene oncology (GO) analysis of genes when STAT3 is knockout.  
E. A heatmap of genes expression which obey STAT3 CA and STAT3 KO agree 
list.  
For heatmaps, red colour indicates upregulation, and green colour indicates 
downregulation, of gene expression relative to corresponding control, with colour 
intensity corresponding to the fold-change amplitude (fold-change scale shown at 
top). 
For GO analysis, the bar charts show the number of genes regulated by STAT3 and 
only top significant categories (p<0.01) were selected to show. The same gene may 
be assigned to more than one category. 
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3.5 Temporal expression profile of STAT3 during normal ESC differentiation 
into cardiomyocyte 
 
STAT3 expression profile in ES cells and during normal ES cells differentiation 
was measured by qRT-PCR and Western blot analysis. STAT3 was highly 
transcribed at undifferentiated ES cells at day 0 (Figure 3.5A). However, its 
expression declined once the commencement of ES cells cardiomyocyte 
differentiation began at day 1 and was decreased further thereafter in the 
differentiation phrases from day 2 to day 4.  STAT3 showed upregulation at late 
phrase of cardiomyocyte differentiation from day 5 onwards, which increased 
progressively from day 5 to day 9 (Figure 3.5A). 
 
Western blot was used to examine quantitative protein expressions of STAT3 and 
pSTAT3. Activation status of STAT3 was revealed by using pSTAT3 and our 
analysis reaffirmed that STAT3 was active and functional during the course of 
cardiomyocyte differentiation. Results from Western blot analysis supported that 
of qRT-PCR. STAT3 and pSTAT3 protein expressions were highly detected at ES 
undifferentiated state, downregulated at day 1 until day 5 and upregulated towards 
late cardiomyocyte differentiation process from day 5 onwards and reached its peak 
on day 8 (Figure 3.5B). These results indicated that STAT3 is a prominent factor 
in cardiomyocyte differentiation. STAT3 showed temporal expression and it was 
downregulated during early phrase of cardiac differentiation process but 
upregulated towards late phrase of differentiation process. 
 
 






              WT ES                       WT EB   
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Figure 3.5 STAT3 mRNA and protein dynamic expressions during cardiac 
differentiation from ESCs. 
A. STAT3 mRNA decreased during ESC into mesoderm stage at day 4 and became 
increased from cardiac progenitor stage at day 5 till cardiomyocyte at day 9. 
B. pSTAT3 protein decreased during ESC into mesoderm stage and became 
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3.6 STAT3 is required for cardiomyocytes differentiation of ESCs 
Next, inducible STAT3 KO system was utilized to identify the role and mechanism 
of STAT3 in cardiomyocytes differentiation of ESCs. The effect of deletion of 
STAT3 on cardiomyocytes differentiation of ESCs was first examined. STAT3 was 
deleted from Day 0 onwards of cardiomyocytes differentiation of ESCs. 
Undifferentiated ESCs and differentiated EBs were collected at day 0, 3, 6, 9, 12, 
and day 15 and qRT-PCR was performed to analyze the expression of mesodermal 
markers and cardiac transcription factors in these STAT3 KO differentiated EBs as 
compared to uninduced EBs. 
 
Time course qRT-PCR suggested that deletion of STAT3 reduced the expression 
of mesodermal markers such as T-Brachyury, Mesp1, Fgf5 and Hand1 significantly 
during differentiation as compared to uninduced EBs (Figure 3.6A). In addition, 
time course qRT-PCR revealed that deletion of STAT3 led to significantly 
reduction in the expression of cardiac transcription factors such as GATA4, Mef2c, 
Nkx2.5 and GATA6 (Figure 3.6B). Together, these results demonstrated that 















Figure 3.6 Time course qRT-PCR of mesodermal markers and cardiac 
transcription factors when STAT3 was deleted from D0 of cardiomyocytes 
differentiation of ESCs. 
Deletion of STAT3 led to significantly reduction in the expression of mesodermal 
markers (A) and cardiac transcription factors (B) when STAT3 was deleted from 
Day 0 onwards of cardiomyocytes differentiation of ESCs, indicating that STAT3 
is required for cardiomyocytes differentiation of ESCs 
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3.7 Effect of deletion of STAT3 on cell growth 
Next, in order to find out whether or not the deletion of STAT3 had any effect on 
the formation of EBs, the morphology of EBs formed when STAT3 was deleted 
from Day 0 onwards of cardiomyocyte differentiation from ESCs was first observed. 
Pictures of Cre inducible embryoid bodies 48 hours following Dox induction 
showed not much different in the size of STAT3 KO EBs as compared to 
unstimulated EBs (Figure 3.7 A, B), suggesting that STAT3 has no effect on the 
cell growth and morphology of EBs formed when STAT3 is deleted.  
A 
- Dox 
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Figure 3.7 Pictures of embryoid bodies 48 hours following Dox stimulation. 
Not much different in EBs size in STAT3 KO EBs as compared to unstimulated 
EBs, indicating that STAT3 has no effect on the cell growth and morphology of 
EBs formed when STAT3 is deleted. 
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3.8 Inducible deletion of STAT3 delays cardiac differentiation from ESCs 
 
To access how STAT3 function is involved in cardiac lineage differentiation, 
STAT3 is deleted at different time point prior to the onset of cardiomyocyte 
precursor throughout the course of cardiomyocyte differentiation from ESCs. 
Cardiac progenitors are specified at approximately day 4 of culture of 
differentiating EBs (Kattman, Huber, & Keller, 2006). Therefore, Dox is added at 
day 0, 3 and 4 to induce deletion of STAT3 and monitor the temporal appearance 
of beating EBs daily, whether or not the deletion of STAT3 will result in a delay of 
cardiac differentiation as demonstrated by decreased beating cardiomyocytes or the 
beating cells occur later than control EBs in which Dox is not added. 
 
In control EBs (Dox was not added), beating cardiomyocyte was first observed at 
day 9. However, when STAT3 was deleted at day 0, no beating cardiomyocyte was 
observed (Figure 3.8B). Therefore, STAT3 might play a crucial role in regulation 
of cardiomyocyte differentiation. In contrast, when STAT3 was deleted at day 3, 
beating cardiomyocyte was first observed at day 13, which was 4 days later then 
the control EB. Interestingly, deletion of STAT3 on day 4 did not affect much on 
cardiac differentiation because beating cardiomyocyte was observed on day 9 
which was the same as control (Figure 3.8B). The beating EBs were maintained 
thereafter, in good accordance with the contractile phenotype of the cells observed 
upon microscopic inspection until day 16 of differentiation. Videos of beating 
cardiomyocyte were recorded at day 9 and day 13.  
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Day 16 of beating cardiomyocytes were harvested and western blot analysis showed 
that both pSTAT3 and STAT3 protein levels were decreased when Dox was added 
at day 0, 3 and 4 (Figure 3.8C). α-Actinin and Troponin T are markers for mature 
cardiomyocytes and were expressed in the control EBs, indicating that the 
precursors generated are of the cardiac lineage (Figure 3.8C). α-Actinin and 
Troponin T were decreased dramatically when STAT3 was deleted at day 0 and 3 
as compared to control (Dox was not added) (Figure 3.8C). These results 
demonstrated that STAT3 deletion may delay cardiac-committed mesoderm 
development and thus beating cells occurred 4 days later than the control EB when 
STAT3 was deleted at Day 3. Interestingly, deletion of STAT3 on day 4 of cardiac 
differentiation did not affect the α-Actinin and Troponin T protein that much as 
compared with deletion of STAT3 at day 0 and 3 (Figure 3.8C) and therefore, 
beating cardiomyocyte was first observed at day 9 which was the same as control. 
In contrast, no sign of beating EBs formed when Dox was administrated 
constitutively from day 0 of cardiac differentiation, suggesting that deletion of 
STAT3 from day 0 onwards inhibited cardiac differentiation probably through 
inhibition on formation of cardiac-committed mesoderm or cardiac progenitor cells. 
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Day of Dox being added Day of beating cardiomyocyte first observed 
Control EBs (no Dox added)  Day 9 
Day 0 No beating cardiomyocyte was observed 
Day 3 Day 13 (4 days later than control) 
Day 4 Day 9 (same as control) 
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Figure 3.8 Inducible deletion of STAT3 delayed cardiac differentiation from 
ESCs. 
A. Deletion of STAT3 at day 0 inhibited cardiac differentiation as no beating 
cardiomyocyte was observed as compared to unstimulated EBs in which beating 
cardiomyocyte was first observed at day 9. In contrast, when STAT3 was deleted 
at day 3, beating cardiomyocyte was first observed at day 13, which was 4 days 
later then our control EB. 
B. Table summarized the day of beating cardiomyocyte first observed when Dox 
was added at different time point, at Day 0, 3 and 4 to induce deletion of STAT3.  
C. pSTAT3 and STAT3 were rapidly downregulated after Dox induction. α-Actinin 
and Troponin T, a specific marker of cardiomyocytes were downregulated 
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3.9 STAT3 is essential for cardiomyocyte differentiation from ESCs through 
positively regulation on GATA6 
 
Microarray analysis revealed that GATA6 is one of the top target genes regulated 
by overexpression of pSTAT3 in ESCs (Figure 3.4A) and our data has 
demonstrated that STAT3 is essential for cardiomyocyte differentiation (Figure 
3.8). Therefore, we next asked whether STAT3 regulates GATA6 expression and 
thus promoting cardiomyocyte differentiation from ESCs. 
 
We first examined the expression of GATA6 by qRT-PCR and western blot. 
Deletion of STAT3 on day 0 onwards and day 3 during cardiac differentiation from 
ESCs led to decreased expression of GATA6 at both mRNA and protein level 
(Figure 3.9A, B), demonstrating GATA6 is positively regulated by STAT3, and is 
important in mediating cardiomyocyte differentiation from ESCs. Therefore, no 
beating cardiomyocyte was observed or beating occurred later when STAT3 was 
deleted on day 0 and day 3 due to decreased level of GATA6 which is important 
for cardiac differentiation. In contrast, deletion of STAT3 on day 4 of cardiac 
differentiation did not affect the GATA6 mRNA and protein levels much (Figure 
3.9A, B). This indicated that STAT3 has stage specific function during 
cardiomyocyte differentiation from ESCs. Deletion of STAT3 during early phrase 
of cardiomyocyte differentiation (Day 0 and Day 3) will affect or delay the 
determination of cardiac lineage from ESCs. However, when STAT3 was deleted 
during later phrase (Day 4), the cardiac lineage has been determined and deletion 
of STAT3 has no effect anymore on cardiomyocyte differentiation as shown by 
unaffected level of GATA6 when STAT3 was deleted on day 4. 
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To determine whether GATA6 is a direct target of STAT3, ChIP was performed in 
E14 ESCs using anti-STAT3 antibody. Immunoprecipitated DNA was analyzed 
using qRT-PCR with primer sets designed to detect ChIP-enriched DNA fragments. 
The expression of GATA6 was about 2.6-fold higher in DNA samples 
immunoprecipated with anti-STAT3 antibody than that of the isotype control IgG 
antibody (Figure 3.9C), indicating STAT3 enrichment in the GATA6 promoter 
region. Transcriptional regulation of GATA6 by STAT3 could be a possible 
mechanism by which STAT3 promotes cardiomyocytes differentiation. This 
STAT3 binding site is located within 2kb upstream of the TSS of GATA6 genes. 
Fold enrichment is the relative abundance of DNA fragments at the indicated region 
over control region as measured by qRT-PCR.  
 
Next, D13 EBs were co-stained with STAT3 and cardiac specific marker, Actn2 to 
examine the expression of STAT3 when Dox was added on D0 of cardiomyocytes 
differentiation of ESCs. Immunofluorescent staining demonstrated that decreased 
expression of STAT3 and cardiac specific marker, Actn2 following STAT3 
deletion on D0 as compared to uninduced EBs (Figure 3.9D). Similarly, D13 EBs 
were co-stained with GATA6 and cardiac specific marker, Actn2 and the 
immunostaining suggested that decreased expression of GATA6 and cardiac 
specific marker, Actn2 following STAT3 deletion on D0 as compared to uninduced 
EBs (Figure 3.9E). Together, these results indicated that STAT3 is essential for 
cardiomyocyte differentiation of ESCs through positive regulation on GATA6. 
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Figure 3.9 STAT3 is essential for cardiomyocyte differentiation from ESCs 
through positively regulation on GATA6. 
A. Deletion of STAT3 from Day 0 onwards and Day 3 during cardiac 
differentiation downregulated GATA6 mRNA levels as compared to control. 
Deletion of STAT3 on Day 4 of cardiac differentiation did not affect the GATA6 
level much.  
B. Consistent with its mRNA levels, GATA6 protein levels decreased significantly 
when STAT3 was deleted on Day 0 and Day 3 during cardiac differentiation. 
Deletion of STAT3 on Day 4 of cardiac differentiation did not affect the protein 
level of GATA6. 
C. STAT3 binds GATA6 promoter in mouse E14 ESCs.  
D. Decreased expression of STAT3 and Actn2 following STAT3 deletion on D0. 
E. Decreased expression of GATA6 and Actn2 following STAT3 deletion on D0.   
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Chapter 4 Results (Part II) 
Results (Part II): Cardioprotection role of STAT3 in adult heart 
 
4.1 Data Extraction of STAT3-ChIP publication 
The protection role of STAT3 in the heart has been clearly illustrated in the 
introduction. Next, we would like to address the underlying cardioprotection 
mechanism played by STAT3, to find out potential downstream target genes of 
STAT3 in which together they contribute to the survival of the heart under 
pathogenesis. Supplementary table 3 revealed the potential list of cardiac genes 
which may involve in the pathophysiology of cardiovascular diseases and might 
also contain STAT3 binding sites in 10kb distance from its TSS. Location of 
STAT3 binding site was extracted from published STAT3 ChIP-sequencing 
datasets (Durant et al., 2010; Ho et al., 2011; Hutchins, Poulain, & Miranda-
Saavedra, 2012). From this list of cardiac genes, we had chosen Txnip, thioredoxin 
interacting protein, also known as thioredoxin binding protein 2 or vitamin D3 
upregulated protein for our subsequent studies. 
 
4.2 Enrichment of STAT3 binding on Txnip promoter 
To determine whether Txnip is a direct target of STAT3 and to validate the 
published STAT3-ChIP datasets (Figure 4.2A), we performed STAT3-ChIP using 
anti-STAT3 antibody to access the binding of STAT3 to the Txnip promoter in 
H9c2 myoblast. Expression of Txnip was about 15-fold higher in DNA samples 
immunoprecipitated with anti-STAT3 antibody than that of the isotype control IgG 
antibody, indicating that elevated binding of STAT3 on Txnip promoter region at 
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18hr after LPS treatment (Figure 4.2B). This implies that Txnip is one of the 
potential target genes regulated by STAT3, and therefore contributes to 
cardioprotection under pathogenesis. SOCS3 gene which is a downstream targeting 
gene regulated by STAT3 (Hilton, 1999) was used as a positive control in this ChIP 
experiment. STAT3 binding site on SOCS3 promoter was examined and results 
showed upregulation of STAT3 binding on SOCS3 promoter at both 2hr (24-fold) 
and 18hr (12-fold) after LPS treatment (Results not shown). Further studies are 
needed to elucidate the detailed mechanism of STAT3 involvement in Txnip 
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Figure 4.2 STAT3 binds Txnip promoter.  
A. The map of partial mouse chromosome 3 harboring Txnip locus. Along the 
Txnip locus, the small black box indicated one STAT3 binding site located 6.6 kb 
upstream. Binding site for STAT3 was identified by extraction of different ChIP-
Sequencing datasets, Promo genome sequence analysis and Sabioscience websites.  
B. STAT3-ChIP assay showed elevated binding of STAT3 on Txnip promoter at 
18hr after LPS treatment. 
 
4.3 Reduced expression of Txnip immediately in the wild-type heart and H9c2 
myoblast after LPS treatment 
 
Initial studies were performed to screen whether Txnip expression is directly 
regulated by STAT3 in cardiomyocytes. STAT3 was activated in both wild-type 
mice and H9c2 myoblast by injection of LPS into mice for 2 hours and 18 hours 
while applying LPS treatment for 30 minutes, 1 hour, 2 hours and 18 hours in H9c2 
myoblast. qRT-PCR result suggested that Txnip mRNA expression was reduced 
after 2 hours LPS treatment in wild-type mice as compared to untreated mice. Txnip 
mRNA expression was also reduced after 18 hours of LPS treatment, in which its 
mRNA expression was lower than those of untreated mice, but slightly higher than 
2 hours LPS treatment (Figure 4.3A). Consistence with its mRNA expression, 
western blot assay demonstrated that reduced Txnip protein expression was 
observed after 2 hours LPS treatment. Protein expression of Txnip was reduced 
after 18 hours of LPS treatment as compared to untreated mice, but still slightly 
higher than those of 2 hours LPS treatment (Figure 4.3B). Also, H9c2 myoblast 
treated with LPS suggested that Txnip protein level decreased in a time-dependent 
manner, decreased after 30 minutes, 1 hour and 2 hours LPS treatment and then 
retained close to control level of Txnip protein at 18 hours (Figure 4.3C). Thus, this 
suggested that STAT3 may play a role in the regulation of Txnip in this LPS-
induced heart inflammation. 
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A                 Wild-type heart               C                         H9c2 myoblast  
 







Figure 4.3 STAT3 activation by LPS treatment decreased Txnip expression in 
wild-type mice and H9c2 myoblast.   
A. Txnip mRNA level was reduced after 2 hours and 18 hours of LPS treatment in 
wild-type heart. 
B. Protein expression of Txnip was reduced after 2 hours and 18 hours of LPS 
treatment in wild-type heart which was consistence with its mRNA expression. 
C. H9c2 myoblast treated with LPS and Txnip protein level decreased in a time-
dependent manner and then retained close to control level at 18 hours. 
 
4.4 Increased Txnip expression in hearts of STAT3 deficient mice 
Knowing that Txnip is a direct target of STAT3 and its expression was reduced 
after STAT3 activation by LPS, these results suggested that Txnip is negatively 
regulated by STAT3. Studies have demonstrated that deletion of Txnip in mice 
protects the myocardium from ischemia-reperfusion (I/R) injury (Yoshioka et al., 
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involved in causing STAT3 CKO heart failure.  Hence, we want to address whether 
deletion of STAT3 will result in an increase of Txnip expression, further validating 
that STAT3 negatively regulated Txnip expression. The whole hearts were 
harvested from wild-type mice, STAT3 heterozygous (C/F/+) and STAT3 CKO 
(C/F/F) mice.  High level of Txnip expression was detected in STAT3 deficient 
heart. Decreased in STAT3 increased the expression of Txnip at both the mRNA 
and protein levels (Figure 4.4A, B). This implied that increased Txnip expression 
may cause the STAT3 CKO heart failure and one of the STAT3 mediated 
cardioprotection pathways may involve downregulation of Txnip. Therefore, 
modulation of Txnip expression can be an effective strategy for treating 
cardiovascular diseases in which ROS accumulation and cardiomyocyte apoptosis 
occur (Jacoby et al., 2003). 
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Figure 4.4 Deletion of STAT3 increased Txnip expression in STAT3 deficient 
heart. 
A. Txnip mRNA expression was increased in STAT3 deficient heart. 
B. In consistence with its mRNA expression, Txnip protein expression was greatly 
upregulated in STAT3 deficient heart. 
C. Immunofluorescent staining showed increased expression of Txnip in the 
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4.5 Expression of the components of the inflammasome in the STAT3 deficient 
heart 
 
Knowing that Txnip was increased in STAT3 deficient heart and inhibition of 
Txnip is suggested as a potential cardioprotective approach, we would like to 
investigate multiple downstream mechanisms by which Txnip can cause heart 
pathogenesis in the absence of STAT3. Also, knowing that Txnip is essential for 
activation of NLRP3 inflammasome in macrophages (Zhou et al., 2010), therefore, 
we next asked whether increased in Txnip expression will result in activation of 
inflammasome in the heart. 
 
We proposed that the involvement of Txnip in activating the NLRP3 inflammasome 
and thereby accounting for the increased inflammation and apoptosis observed in 
STAT3 CKO heart. Expression of the components of the inflammasome was 
quantified by three different investigators. Firstly, NLRP3, ASC and Caspase-1 
mRNA levels were upregulated in STAT3 deficient heart compared with wild-type 
heart (Figure 4.5A). Next, protein expressions of Txnip, NLRP3, and pro IL-1β 
were markedly increased in STAT3 deficient heart compared with wild-type heart 
(Figure 4.5B). Immunofluorescent staining of key structural components of the 
inflammasome, NLRP3 and ASC revealed that increased expression of NLRP3 and 
ASC when STAT3 was deleted in the heart (Figure 4.5C).  Hence, deletion of 
STAT3 in the heart increased Txnip expression, which subsequently resulted in 
induction of inflammasome and elevated oxidative stress which may account for 
the heart pathogenesis observed in STAT3 CKO heart. 
 




        
           






















































































































Figure 4.5 Deletion of STAT3 increased Txnip, which resulted in induction of 
inflammasome in aged STAT3 CKO hearts.  
A. Important structural components of the inflammasome, ASC, NLRP3 and 
Caspase-1 mRNA were upregulated in STAT3 deficient heart.  
B. Western blot demonstrated that upregulation of Txnip, NLRP3 and IL-1β protein 
expressions in the C/F/F heart which were consistent with their mRNA expression.  
C. Immunostaining fluorescent showed increased expression of inflammasome 
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Chapter 5 Discussion 
Establishing of in vitro inducible STAT3 KO and STAT3 CA ES cell lines 
Several investigations have demonstrated that STAT3 signaling is essential for 
early mammalian embryogenesis and determination of various cell lineages 
differentiation. However, analysis of STAT3 function during cardiomyogenesis 
was under investigation primarily due to the limitation of the model systems that 
were used. In mammalian development, it is difficult to procure cardiac-committed 
mesoderm to explore specified signal transduction mechanisms and as well as 
difficult to analyze the few cardiomyocytes available from early heart tubes. 
Additionally, the difficulty in analyzing STAT3 during early cardiomyogenesis was 
exemplified because STAT3 knockout resulted in early embryonically lethal at the 
time of cardiomyocyte formation at E7.5-E8.5 (Duncan et al., 1997; Takeda et al., 
1997). STAT3 knockout is embryonic lethal and it failed to provide a potential 
functional role for STAT3 in cardiac differentiation. Moreover, it is noteworthy 
that cardiomyocyte specific KO of STAT3 generated by conventional Cre/loxP 
technology (Jacoby et al., 2003) did not address the function of STAT3 during early 
cardiomyocyte differentiation because the Cre driven by α-myosin heavy chain (α-
MHC) promoter is weakly expressed before birth, reaching high levels long after 
cardiomyocyte differentiation. Taken together, it was difficult to elucidate very 
early molecular events in mammalian cardiomyogenesis using in vivo mammalian 
systems.  
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Consequently, in this study, we have established an in vitro inducible STAT3 knock 
out and pSTAT3 overexpressed ES cells system in which STAT3 expression can 
be temporally and specifically deleted or overexpressed by doxycyclin stimulation 
to allow the study of STAT3 function during early cardiomyocyte differentiation 
(Figure 3.1). Genotyping of inducible STAT3 KO ES cells following 24 hours Dox 
stimulation showed deletion of STAT3 alleles as detected as a 480bp fragment 
(Figure 3.2). Western blot further confirmed that pSTAT3 and STAT3 protein 
levels were significantly reduced in inducible STAT3 KO ES cells while 
tremendously upregulated in inducible STAT3 CA ES cells following Dox 
stimulation (Figure 3.3). Here, we have established a new tool to study function of 
STAT3 during ES cell differentiation into multicellular aggregates of ES cells, 
called embryoid bodies (EBs) which consist of derivatives of all three germ layers 
and in our project, we focus on cardiac lineage differentiation. 
 
 Illumina Microarray Analysis of STAT3 Target Genes 
 Firstly, SOCS3 gene which is a downstream targeting gene regulated by STAT3 
(Hilton, 1999) was used as a positive control in this microarray experiment. SOCS3 
expression was upregulated upon overexpression of pSTAT3 (>2-fold) while 
downregulated when STAT3 is KO (<0.34-fold). In addition, inhibitor of DNA-
binding 1 (Id1) is a direct target gene transcriptionally induces by STAT3 (Yu et al., 
2014). Its expression was upregulated upon overexpression of pSTAT3 (>2.5-fold) 
while downregulated when STAT3 is KO (<0.43-fold). Studies have demonstrated 
that Id1 is important in development, stem cell self-renewal activity, differentiation, 
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senescence, angiogenesis and migration (Fong, Debs, & Desprez, 2004; Romero-
Lanman, Pavlovic, Amlani, Chin, & Benezra, 2012; Ying et al., 2003). Also, Our 
GO analysis was consistent with the known function of Id1 and demonstrated that 
it is involved in alternative splicing, phosphoprotein, developmental protein as well 
as vasculature development, epithelium development, heart development and 
epithelial cell differentiation, cell morphogenesis involved in differentiation.  
 
Among the genes which contain STAT3 binding site, insulin like growth factor-2 
(Igf2) and SPARC Related Modular Calcium Binding 1 (Smoc1) were among the 
top 10 upregulated genes by pSTAT3 overexpression, while Odd-skipped related 2 
(Osr2) and Stanniocalcin-1 (Stc1) were those of the top 10 downregulated genes 
when pSTAT3 was overexpressed (Supplementary table 1). Igf2 works in 
cooperation with LIF to sustain ES cells self-renewal (A. Takahashi, Takahashi, 
Matsumoto, & Miyata, 1995) while Smoc1 is crucial for development of ocular and 
limb in mice and humans (Okada et al., 2011). Osr2 functions as a transcription 
factor for craniofacial, limbs, and kidney development (Lan, Kingsley, Cho, & 
Jiang, 2001) whereas Stc1 is protein hormone that regulates calcium/phosphate 
homeostasis and is upregulated by IL-6 in response to hypoxia (Westberg et al., 
2007).  
 
In addition, Laminin subunit alpha-1 (Lama1) and JunB proto-oncogene (JunB) 
were among the top 10 downregulated genes when STAT3 is KO which also contain 
STAT3 binding site (Supplementary table 2). Lama1 is expressed early during 
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embryo development at two cell-stage and widely expressed during organogenesis 
(Dziadek & Timpl, 1985; Ekblom, Falk, Salmivirta, Durbeej, & Ekblom, 1998) but 
its expression is highly restricted in adults (Falk, Ferletta, Forsberg, & Ekblom, 
1999). It mediates cell adhesion, migration, and organization of cells into tissues 
during embryonic development by interacting with other extracellular matrix 
components and these interactions are important for epithelial morphogenesis 
(Ekblom et al., 1998). In addition, it promotes angiogenesis by directly regulates 
the expression profile of genes and protein in endothelial cells (Dixelius et al., 2004; 
Malinda et al., 1999). 
 
In addition to those genes that contain STAT3 binding site, our microarray analysis 
also revealed some interesting genes those are important during embryonic 
development and regulation of STAT3 of these genes are yet to be discovered.  
Serine protease inhibitor Kazal type 3 (Spink3), one of the top 10 downregulated 
genes when STAT3 was KO while upregulated when pSTAT3 was overexpressed 
(Supplementary table 1 and 2), has been shown that it is expressed during early 
development and this suggests that it may have important physiological roles in 
differentiation and proliferation of numerous cell types during development (J. 
Wang et al., 2008). Another interesting gene is Leucine rich repeat containing 
protein 51 (LRRC51), one of the top 10 downregulated genes when pSTAT3 was 
overexpressed but upregulated when STAT3 was KO (Supplementary table 1). 
However, the exact function of LRRC51 remains unknown. 
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Moreover, a heatmap was generated using the agree list of genes in expression 
regulated by STAT3 CA and in STAT3 KO ES cells (Figure 3.4E). We found long 
length of agreement in gene list regulated by STAT3 CA and in STAT3 KO. Txnip 
was one of the genes in which its expression was upregulated when STAT3 was 
KO while downregulated upon STAT3 constitutively overexpressed. Nonetheless, 
the exact function of Txnip in ES cells pluripotency and differentiation remains 
unclear. 
 
Collectively, our microarray results were consistent with known changes in gene 
expression of STAT3 targeted genes. Also, it revealed some potentially novel genes 
that might be regulated by STAT3 during embryonic development, heart 
development and differentiation. Therefore, further functional analysis on 
identified genes is needed to facilitate a better understanding of the underlying 
molecular mechanisms by which STAT3 is involved in maintaining the ES cells.  
 
In vitro Cardiomyocytes differentiation derived from ESCs 
A differentiation program is established to generate cardiomyocyte precursors from 
embryonic stem cells (ESCs). The differentiation program adopts the hanging drops 
approach to generate embryoid bodies (EB) of equivalent size and contains the 
same number of ESCs as was previously reported (Boheler et al., 2002). In our 
present differentiation program, in regard to cardiac differentiation, ascorbic acid 
is added which enhances spontaneous differentiation of ESCs into cardiomyocytes. 
Ascorbic acid has been demonstrated to specifically induce cardiac-specific genes 
including GATA4, Nkx2.5, α-MHC, β-MHC, and ANF in mouse ES cells derived 
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cardiomyocytes and they also showed spontaneous and rhythmic contraction (T. 
Takahashi et al., 2003).  This is in agreement with the findings that ascorbic acid 
increased the number of beating areas in human ES cells (Passier et al., 2005). In 
addition, mesenchymal stem cells from adult human bone marrow developed 
features of cardiomyocytes when differentiated in a medium containing ascorbic 
acid (Shim et al., 2004). Consistent with these reports, it has been reported that by 
using a stable form of ascorbic acid, namely, L-ascorbic acid 2-phosphate (A2-P), 
it significantly enhanced cardiac differentiation of mouse ES cells when added 
during the early phrase of cardiac differentiation (Sato et al., 2006).  
 
Since the effects of ascorbic acid are always attributed to its antioxidant properties, 
the effect of alternative antioxidant agents were examined to assess the involvement 
of the antioxidant properties of ascorbic acid in the promotion of cardiac 
differentiation. Treatment with alternative antioxidant agents was unable to mimic 
the effect of ascorbic acid on cardiac differentiation. These results indicate that the 
promoting effect of ascorbic acid on cardiac differentiation is independent of its 
antioxidant properties, or that its antioxidant properties is insufficient to induce 
cardiac differentiation of ESCs (Sato et al., 2006; T. Takahashi et al., 2003). Then, 
Sato’s group demonstrated that ascorbic acid increases collagen synthesis, leading 
to the promotion of cardiac differentiation from ES cells (Sato et al., 2006). This 
finding was supported by another group who reported that ES cell-derived 
cardiomyocytes cultured on extracellular matrix (ECM) secreted from cardiac 
fibroblast matured more rapidly, suggesting that the matrix components are 
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involved in the cardiac differentiation and the growth characteristics of 
cardiomyocytes (Baharvand, Azarnia, Parivar, & Ashtiani, 2005). Collagen and 
other ECM components may constitute the in vitro microenvironment that supports 
cardiac differentiation which is generally exhibited in vivo. In the heart, 
cardiomyocytes are surrounded by a basement membrane consisting of many other 
molecules, the most predominant molecules are interstitial collagen type I and III 
(Eghbali et al., 1989). However, further studies are required to better understanding 
the mechanisms underlying this enhancing effect of ascorbic acid.  
 
Despite the use of ascorbic acid to direct ESCs to the cardiac lineage, ascorbic acid 
does not partake in the signaling of STAT3, at least for now no study reported on 
that of ascorbic acid signals through STAT3. Therefore, this approach increases 
cardiomyocyte precursors yield but eliminates confounding factors that might 
partake in STAT3 signaling pathway.  
 
Temporal activation of STAT3 is required for ESCs derived cardiomyocytes 
Having established a differentiation program that directs ESCs to the cardiac 
lineage, and little is known of the very earliest targets of STAT3 regulation in 
differentiating cardiomyocytes, therefore, we question the expression of activated 
pSTAT3 and STAT3 during this differentiation process to assess whether STAT3 
is directly involved in initial stages of cardiac differentiation. 
 
 In our in vitro model of cardiomyocyte differentiation, STAT3 and pSTAT3 were 
detected throughout differentiation, levels of pSTAT3 and STAT3 that were high 
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in undifferentiated ES cells decreased dramatically as soon as the commencement 
of cardiomyocyte differentiation that was day 1 of the differentiation process. 
pSTAT3 and STAT3 levels were steadily increased again in EBs from day 5 and 
reached its peak on day 8,  which is approximately 1 to 3 days before the average 
onset of beating within EBs (Figure 3.5). This observation fits nicely with the 
known temporal activation of STAT3 compared with the onset of beating in vivo 
(Duncan et al., 1997; Ji et al., 2003), that is correlation of phosphorylation of 
STAT3 with these timelines suggested that STAT3 activation is involved in 
cardiomyocyte differentiation. In our study, we showed that downregulation of 
STAT3 during early cardiac differentiation, followed by upregulation again during 
late cardiac differentiation implies a temporal expression of STAT3 in 
cardiomyocyte differentiation. The correlation of STAT3 phosphorylation with 
these timelines suggests that phosphorylation of STAT3 is corresponds with 
cardiomyocyte derivation and might be involved in cardiomyocyte differentiation. 
Our experimental evidence complemented what has been reported that STAT3 
activity is elevated at the undifferentiated stage (day 0), as demonstrated by its 
phosphorylation, as well as during cardiomyocyte differentiation process (day 5 
onwards). It is interesting to note that STAT3 is required in both undifferentiated 
ESCs to maintain its self-renewal division and in lineage differentiation. STAT3 
functions as a regulator of cardiomyocyte differentiation and proliferation during 
development. 
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STAT3 is considered to be the most important transcription factor in the STATs 
family during mouse embryo development because only the loss of STAT3 results 
in embryonic fatality (Takeda et al., 1997). Among many diverse roles of STAT3, 
its most prominent role is in cell proliferation. In ES cells, STAT3 is an essential 
mediator downstream of LIF in maintaining ES cells self-renewal and pluripotency 
(Matsuda et al., 1999; Niwa et al., 1998). Often, STAT3 function is associated with 
proliferation rather than differentiation. Nonetheless, the results of the present study 
suggest that temporal activation of STAT3 is required for ES cells derived-
cardiomyocyte. In addition to embryonic stem cells, role of STAT3 is also 
implemented in proliferation and differentiation of adult muscle stem cell-derived 
myoblast. Differentiation of muscle stem cell-derived myoblast is mainly 
responsible for postnatal muscle growth and injury-induced muscle regeneration. 
Several groups have independently detected activated STAT3 in LIF-treated 
proliferating myoblasts and regenerating muscles (Kami & Senba, 2002; 
Spangenburg & Booth, 2002). This is further validated by reduction in myoblast 
proliferation in the absence of a functional STAT3 gene despite LIF induction (Sun 
et al., 2007). Wang’s group (K. Wang, Wang, Xiao, Wang, & Wu, 2008) showed 
STAT3 to be functioning downstream of JAK2 and activates expression of myocyte 
enhancer factor 2 (MEF2) genes, which are essential regulators of cardiac 
myogenesis and right ventricular development. Targeted deletion of the MEF2 gene 
results in a small left ventricle and complete loss of the right ventricle (Lin, Schwarz, 
Bucana, & Olson, 1997). The role of STAT3 in proliferation and pluripotency in 
previous publications is consistent with our study that reveals STAT3 to be 
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activated at ES undifferentiated state. Upon removal of LIF and activation of 
cardiac differentiation, STAT3 is downregulated during early cardiac 
differentiation, followed by upregulation again during late cardiac differentiation 
implies a temporal expression of STAT3 in cardiomyocyte differentiation. 
 
Inducible deletion of STAT3 delays cardiac differentiation from ESCs 
Next, the morphology of EBs formed when STAT3 is deleted from Day 0 onwards 
of cardiomyocyte differentiation from ESCs is first observed in order to find out 
whether or not the deletion of STAT3 has any effect on the formation of EBs. 
STAT3 KO EBs 48 hours following Dox induction showed not much different in 
the size as compared to unstimulated EBs, suggesting that STAT3 has no effect on 
the cell growth and morphology of EBs formed (Figure 3.7). 
 
The beauty of the inducible STAT3 KO ES system that we have established is that 
STAT3 can be specifically deleted at different time point during the 
commencement of cardiomyocyte differentiation from ESCs. Here, in order to 
understand function of STAT3 and its temporal activity during cardiomyocyte 
differentiation, 3 time points were chosen to delete STAT3 by Dox stimulation at 
Day 0 onwards, Day 3 and Day 4 of cardiomyocyte differentiation. Knowing that 
cardiac progenitors are specified at approximately day 4 of EBs differentiation and 
cardiac-committed mesoderm has to be formed prior to cardiac progenitors 
(Kattman et al., 2006), therefore, we decided to delete STAT3 before and at Day 4 
in order to determine whether STAT3 is directly involved in initial stages of cardiac 
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differentiation by examine the effect of STAT3 deletion on formation of cardiac-
committed mesoderm and later differentiation into cardiac lineage. 
 
Interestingly, inducible deletion of STAT3 EBs from day 0 onwards and day 3 
resulted in significantly downregulation of cardiac-specific genes, Actinin and 
Troponin T protein expression as revealed by western blot (Figure 3.8C). The 
absence of differentiated cardiac myocytes could result from a failure in formation 
of cardiac-committed mesoderm or cardiac progenitor cells due to deletion of 
STAT3 from day 0 onwards of cardiomyocyte differentiation. In contrast, deletion 
of STAT3 from day 3 resulted in delay formation of beating cardiomyocyte first 
observed on day 13 which was 4 days later than the control EBs, indicating that 
STAT3 impacts development around the time when mesoderm progenitors commit 
to a cardiac fate. While inducible deletion of STAT3 EBs from day 4 resulted in 
lesser downregulation of cardiac-specific genes as compared to those inducible 
STAT3 deletion EB from day 0 onward and day 3 (Figure 3.8C). This result 
indicated that inducible STAT3 deletion on Day 4 after cardiac-committed 
mesoderm has become committed to the cardiac lineage at approximately day 3 did 
not show any difference compared with unstimulated EBs, that is, beating 
cardiomyocyte was first observed at Day 9 (Figure 3.8B). Therefore, alteration of 
STAT3 activity is an important event in the initialization of ES cells differentiation 
and the orientation of cardiac lineage differentiation. 
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It has been reported that STAT3 has an essential role in the promotion of ESCs 
differentiation into cardiomyocyte.  By using specific dose of LIF and BMP2, it 
could efficiently differentiate mESCs into cardiomyocyte via their synergistic 
activation of STAT3 signal transduction pathway, indicated by upregulation of 
cardiac-specific genes and protein expression. Nonetheless, neither of the LIF nor 
BMP2 by themselves were sufficient for cardiomyocyte differentiation. In addition, 
synergistic effect of LIF and BMP2 induced expression of cardiac-specific 
transcripts and STAT3 tyrosine and serine phosphorylation was attenuated by 
STAT3 inhibitors (Rajasingh et al., 2007). In relation, another study demonstrated 
that the dominant negative form of STAT3 ESCs resulted in significantly reduced 
beating areas within EBs and also downregulation of cardiac-specific genes 
(Foshay et al., 2005). One of these genes, Nkx2.5 was not expressed and it has been 
reported that its promoter contains STAT3 binding site (Reecy et al., 1999), 
suggesting that a potential regulatory role of STAT3 on Nkx2.5, and lack of Nkx2.5 
could prevent complete cardiomyocyte differentiation via downstream effect. 
Nkx2.5 is expressed specifically within cardiac progenitor cells of the heart-
forming region precedes cardiogenic differentiation and throughout adult life in the 
mouse (Lints, Parsons, Hartley, Lyons, & Harvey, 1993). 
 
STAT3 is essential for cardiomyocyte differentiation from ESCs through 
positive regulation on GATA6 
 
The formation of beating heart is a multistep process which requires the activation 
of a cascade of transcription factors under tight temporal and spatial control 
defining each development stage of the heart. We have here demonstrated that the 
Chapter 5 Discussion 
95 
 
important role of STAT3 in promoting the cardiomyocyte differentiation through 
regulation of GATA6 transcription factor. Both mRNA and protein level of 
GATA6 expression were  decreased dramatically when STAT3 was deleted on Day 
0 onwards and Day 3 during cardiac differentiation from ESCs (Figure 3.9A, B), 
indicating that GATA6 is positively regulated by STAT3, and is important in 
mediating cardiomyocyte differentiation from ESCs. Therefore, no beating 
cardiomyocyte was observed or beating occurred later when STAT3 was deleted 
on Day 0 and Day 3 due to decreased level of GATA6 which is essential for cardiac 
differentiation. In contrast, deletion of STAT3 on Day 4 of cardiac differentiation 
did not affect the GATA6 mRNA and protein levels much (Figure 3.9A, B). This 
suggested that STAT3 has stage specific function during cardiomyocyte 
differentiation from ESCs. Deletion of STAT3 during early phrase of 
cardiomyocyte differentiation (Day 0 and Day 3) will affect or delay the 
determination of cardiac lineage from ESCs. However, when STAT3 was deleted 
during later phrase (Day 4), the cardiac lineage has been determined and deletion 
of STAT3 has no effect anymore on cardiomyocyte differentiation as shown by 
unaffected level of GATA6 when STAT3 was deleted on day 4.  
 
GATA6 downregulation by STAT3 inducible deletion in differentiating EBs is 
mediated by the direct binding of STAT3 to the promoter region of GATA6 factor 
(Figure 3.9C), indicating that GATA6 is an immediate downstream target of 
STAT3 regulation during early cardiomyocyte differentiation. This is in agreement 
with previous findings that ChIP-Seq data verifies a STAT3 binding site on GATA6 
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promoter (Kidder, Yang, & Palmer, 2008) in ESCs. It has been reported that STAT3 
binds both active and inactive genes in ESCs. Also, STAT3 is associated with genes 
highly expressed in undifferentiated ESCs and differentiated EBs (Kidder et al., 
2008). Thus, regulation of GATA6 by STAT3 provides a pathway in which STAT3 
deletion could result in the loss of or a delay in beating cardiomyocyte formed due 
to decreased GATA6 expression and therefore incomplete differentiation of 
cardiomyocyte. 
 
A number of studies have linked GATA6 to heart formation. Based on studies of 
function of GATA6 using knock down models in zebrafish and xenopus embryos, 
it results in either heartless embryos or embryos in which cardiogenesis is severely 
perturbed. Also, GATA6 is required for the maintenance and differentiation of 
cardiac progenitors in zebrafish and xenopus embryos (Peterkin et al., 2003). Then 
again, another group reported that morpholino knock down of GATA6 in zebrafish 
causes defects in heart development, characterized by a lack of circulation by 3-4 
dpf (days post-fertilization) and formation of a non-looped heart tube (Holtzinger 
& Evans, 2005).  
 
The important of GATA6 during early cardiogenic differentiation is further 
validated by other studies that reveal coexpression of GATA transcription factors 
with the homeoprotein Nkx2.5 in the cardiac-committed mesoderm during the 
earliest stages of its specification and are known to be important determinants of 
cardiac gene expression. In that study, by using P19 CL6 model system of 
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cardiomyocyte differentiation, it has been reported that upregulation of GATA4 
and GATA6 expression occurs before the transcriptional activation of Nkx2.5 in 
these differentiating cardiomyocyte. Furthermore, overexpression of GATA4 and 
GATA6 at the time just prior to that of normal Nkx2.5 induction results in a 
significant upregulation of endogenous Nkx2.5 expression, suggesting that GATA4 
and GATA6 are capable of acting upstream of Nkx2.5 in the transcriptional cascade 
that leads to cardiac differentiation (Brewer et al., 2005). Regulation of Nkx2.5 
expression by a GATA-dependent enhancer has been reported by others as well 
(Lien et al., 1999; Searcy et al., 1998). However, the onset of GATA6 expression 
observed during cardiac differentiation is not addressed yet. Therefore, the 
regulatory mechanisms that activate expression of GATA factors within cardiac 
committed mesoderm are of particular interest because they may represent the 
initial steps in the cardiac differentiation program. In our study, we propose that 
initial transcriptional activation of GATA6 by STAT3 is essential for the onset of 
cardiogenic commitment and have thus established a link between two families of 
genes known to have major roles in early cardiomyocyte differentiation. 
 
From the discussion described earlier, our study revealed that STAT3 expression 
was downregulated during early cardiac differentiation, followed by upregulation 
again during late cardiac differentiation. We here propose that decline in level of 
STAT3 expression during early cardiac differentiation is essential for the 
completion of the cardiomyocyte differentiation programme. Studies in xenopus 
and chick revealed that a reduction in the level of GATA6 expression prior to the 
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terminal differentiation of cardiomyocytes (Gove et al., 1997; Laverriere et al., 
1994). Injection of GATA6 mRNA to maintain level of GATA6 in gastrulating 
embryos results in transient block of differentiation of heart precursors. When the 
injected GATA6 mRNA decays, cardiomyocytes resumed differentiation, giving 
rise to normal, beating hearts but increased in myocardial tissues by holding the 
cells in the precursor state for a longer period would increase the proliferation of 
cardiac progenitor cells (Gove et al., 1997). This suggests that GATA6 might 
regulate proliferation of cardiac progenitor cells. These observations are in 
agreement with our findings that STAT3 expression falls during early cardiac 
differentiation, leading to decreased level of GATA6 since GATA6 is a potential 
cardiac differentiation gene directly regulated by STAT3 positively and decline in 
levels of STAT3 and GATA6 during early differentiation is associated with 
complete differentiation of cardiomyocyte. Then, STAT3 expression is upregulated 
again during late cardiac differentiation, which is approximately 1 to 3 days before 
the average onset of beating within EBs. Therefore, we propose that STAT3 is at 
the upstream of the cardiac differentiation cascade by regulating expression of 
GATA6 which is essential for cardiomyocyte differentiation and temporal 
activation of STAT3 and GATA6 is important for the completion of the 
cardiomyocyte differentiation. 
  
Collectively, our in vitro data obtained from ESCs-derived cardiomyocyte point 
towards role of STAT3 activation is necessitated in both undifferentiated and 
differentiated stages. STAT3 is positioned at a critical juncture upstream of the ES 
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cells differentiation, distinctly regulating the cardiomyocyte differentiation 
pathway by controlling the expression of GATA6 which is essential for cardiac 
differentiation. Moreover, we have provided another new tool to study function of 
STAT3 during ES cells differentiation into cardiac lineage. 
Transcriptional regulation of Txnip expression by STAT3  
Several studies demonstrated that STATs family proteins mediate gene 
transcription through chromatin modification. Chromatin immunoprecipitation 
(ChIP)-sequencing technology revealed that STATs family proteins bind to their 
target gene locus and act as transcription activator on a global scale (Durant et al., 
2010; Good et al., 2009; Hutchins et al., 2012; Li et al., 2012; Wei et al., 2010). On 
the other hand, in T cells, STAT5 is required for binding on the target gene 
promoter to suppress transcription through chromatin modification (Mandal et al., 
2011; X. P. Yang et al., 2011).  
 
There are several criteria for identifying a STAT3 target gene. The first one is the 
presence of an evolutionarily conserved STAT3 binding consensus motif (Ehret et 
al., 2001) for the activating or repressing STAT3 transcription factor in the 
promoter or enhancer regions of a gene of interest. This requirement was met in 
Txnip as shown by both gene promoter analysis and ChIP assay (Figure 4.2). A 
second commonly presented form of evidence is that constitutively active mutant 
form of STAT3 induces or suppresses the expression of the given gene, which in 
our case we used LPS treatment instead to activate STAT3, which could indeed 
suppress Txnip expression (Figure 4.3). Another way of identifying a role for 
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STAT3 in the transcriptional regulation of a particular gene is to show that acute 
genetic deletion of STAT3 gene results in the increase or loss of target gene 
expression. Txnip mRNA and protein levels are increased in STAT3 CKO as 
compared to wild-type heart (Figure 4.4), suggesting that role of STAT3 in 
regulating Txnip.  
 
Regulation of Thioredoxin-interacting protein by STAT3 is crucial for heart 
protection 
 
Research has established the importance of STAT3 in development as global 
STAT3 deletion results in embryonic lethality (Takeda et al., 1997), yet cardiac 
specific knock-out of STAT3 mice survive into adulthood and do not show 
symptoms of dysfunction up to age of 6 months. Nonetheless, with advanced age 
at 9 months, these STAT3-CKO mice exhibited severe fibrosis, and experienced 
higher sensitivity to inflammation and apoptosis (Jacoby et al., 2003). This 
postulates a post-natal role of STAT3 in cardiac protective function. However, the 
molecular mechanism by which STAT3 contributes to heart protection and function 
is not well understood.  
 
In this study, we first reported that the possible pathological mechanism of cardiac 
inflammation and fibrosis in cardiomyocyte-restricted STAT3 knock out mice. 
Firstly, after LPS endotoxin challenge, STAT3 wild-type heart and rat H9c2 
myoblast showed significant decreased in the expression of Txnip (Figure 4.3). 
Endotoxin stress has been proposed that it is a potential trigger for cytokine 
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signaling during heart failure in humans. Endotoxin levels are greatly increased in 
adult patients with congenital heart disease (Sharma et al., 2003). Recent studies 
suggest that the JAK-STAT signaling pathway participates in negative regulation 
of LPS responses. Loss of STAT3 in mouse cardiomyocytes leads to increased 
TNF-α  production after LPS stress in vitro, suggesting that STAT3-mediated 
signaling is required to regulate innate immunity in cardioprotection from 
endotoxin stress (Jacoby et al., 2003). In the present study, after acute LPS 
challenge (2 hours to 18 hours) in vivo and in vitro, Txnip mRNA and protein levels 
were decreased in both STAT3 wild-type heart and rat H9c2 myoblast, suggesting 
that STAT3 negatively regulates LPS responses and at the same time, it also 
negatively regulates Txnip expression after LPS stress. 
 
In addition, we observed that STAT3-CKO heart displayed higher expression of 
Txnip as seen in the increased of both Txnip mRNA and protein levels in 
comparison with its controls (Figure 4.4). Deletion of STAT3 increased Txnip 
expression, which also experienced significantly more induction of inflammasome 
activation, as indicated by the significantly more NLRP3 inflammasome3 
components observed in STAT3-CKO heart (Figure 4.5). Since the STAT3-CKO 
heart develops increased activation of NLRP3 inflammasome and upregulation 
expression of Txnip, we suspect that STAT3 plays a crucial role in the regulation 
of innate immunity of NLRP3 inflammasome activation at the molecular level 
through regulating other intermediate proteins involved in the NLRP3 
inflammasome assembly. Here, we propose the intermediary protein to be Txnip. 
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Hence, increased Txnip expression and induction of NLRP3 inflammasome 
activation are account for the higher sensitivity of inflammation, apoptosis and 
severe fibrosis which eventually lead to heart failure in STAT3-CKO heart. 
This is further validated in systemic deletion of Txnip in mice. Mice with deletion 
of Txnip exhibit impaired mitochondrial function, but provide protection to the 
myocardium from ischemia-reperfusion injury. Protection from myocardial 
ischemia is enhanced as result of a coordinated shift to increased anaerobic 
metabolism, which provides an energy source outside of mitochondria (Yoshioka 
et al., 2012; Yoshioka et al., 2007). In addition, microarray analysis demonstrated 
that higher expression of Txnip was found in the heart of myocardial infarction 
mice as compared to wild-type mice (Lachtermacher et al., 2010).   
 
Fittingly, it was reported that overexpression of Txnip has been shown to increase 
cardiomyocytes sensitivity to oxidative stress-induced apoptosis, suggesting that 
regulation of Txnip may protect against apoptosis from mechanical overload or 
oxidative stress. While the Txnip natural antagonist, thioredoxin (Trx), has function 
of cardioprotection. Elevated Trx levels attenuate myocardial damage induced by 
ischemia-reperfusion injury (Y. Wang, De Keulenaer, & Lee, 2002). Moreover, 
Thioredoxin overexpressed mice promote neovascularization by increasing 
capillary and arteriolar density during ischemia stress and prevent the post-ischemic 
ventricular remodeling. Also, Trx overexpression reduced Txnip expression, while 
increased angiogenic protein VEGF, anti-apoptotic proteins BCL-2 and survivin 
(Adluri et al., 2011). 




Inflammation response has been implicated in myocardial infarction and heart 
failure. Inflammation is an innate immune response that prevents the spread of 
infection and promotes tissue healing after the clearance of pathogens but also 
causes excessive damage and maladaptive ventricular remodeling leading to 
impaired myocardial function and heart failure (Frangogiannis, Smith, & Entman, 
2002). Inflammation is an innate immune response regulated by several families of 
pattern recognition receptors (PRRs). Toll-like receptors (TLRs) is the best studies 
PRR family and it is triggered by pathogen-associated molecular patterns (PAMPs) 
and initiates a signaling cascade leading to enhanced synthesis of inflammatory 
cytokine (Ionita, Arslan, de Kleijn, & Pasterkamp, 2010; Takeuchi & Akira, 2010). 
IL-1β is the first upstream inflammatory cytokines produced, and it is potent to 
induce secretion of other cytokines (Dinarello, 2009) . Release of IL-1β is tightly 
regulated and inflammasomes are important regulators of activation of 
inflammatory caspases and IL-1β (Martinon et al., 2002).  
 
Our present study revealed that deletion of STAT3 in the heart significantly 
increases the mRNA of key components of inflammasome, NLRP3, ASC and 
Caspase-1 and Txnip when compared to wild-type mice (Figure 4.5). Protein 
expression levels of NLRP3, pro-IL-1β and Txnip were increased in STAT3 
deficient heart (Figure 4.4 and 4.5). In view of that, this data suggests that STAT3 
may exert its effects indirectly by negatively regulate other proteins involved in the 
NLRP3 assembly which in this study is Txnip, thereby deletion of STAT3 in the 
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heart accounts for increased inflammation mediated by NLRP3 inflammasome 
activation and apoptosis as observed. This is in agreement with previous findings 
that demonstrated Txnip mediates NLRP3 inflammasome activation (Zhou et al., 
2010). Fittingly, it was reported that intramyocardial NLRP3 siRNA significantly 
decreased the activation of NLRP3 inflammasome and infarct size and restored 
heart function during I/R injury (Liu et al., 2014). However in our study, cleaved 
IL-1β was not observed but could be reexamined to further confirm this. 
Nonetheless, we indeed showed that, an initial signal leads to increased pro-IL-1β 
synthesis as revealed by increased protein level of pro-IL-1β because pro-IL-1β is 
not constitutively expressed and requires transcriptional and translational induction. 
Here, the increased of pro-IL-1β as activated by NLRP3 inflammasome suggesting 
that increased signaling cascade leading to enhanced synthesis of inflammatory 
cytokine that might account for the increased inflammation, apoptosis and fibrosis 
as observed in STAT3 deficient heart. 
 
Here, it is hypothesized that the increased inflammasome activation would 
stimulate a more enhanced inflammatory cytokine signaling and subsequently 
leading to increased apoptosis and fibrosis as observed in aged STAT3 CKO heart. 
Several recent key publications based on studies of myocardial I/R injury showed 
NLRP3, ASC and caspase-1 were upregulated at the site of myocardial I/R injury 
whereas knock out mice model of various inflammasome components revealed 
reduced inflammatory responses, reduced infarct sizes and myocardial fibrosis 
(Kawaguchi et al., 2011; Mezzaroma et al., 2011; Sandanger et al., 2013). 
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Inflammation responses driven by NLRP3 inflammasome has been implicated in 
the pathophysiology of heart failure, particularly in myocardial I/R injury.  
Neutralization of IL-1β reduces I/R injury suggesting that IL-1β is the key mediator 
in the pathophysiology of I/R injury (Hwang et al., 2001; Pomerantz, Reznikov, 
Harken, & Dinarello, 2001).  Moreover, it has been reported that IL-1β and TNF-α 
promote tissue fibrosis in vivo (Neumann, Lane, Allen, Herskowitz, & Rose, 1993; 
Ono, Matsumori, Shioi, Furukawa, & Sasayama, 1998; Yue, Massie, Simpson, & 
Long, 1998).  Levels of  IL-1β are related to the degree of interstitial fibrosis (Ono 
et al., 1998).  In line with these recent reports, our data show that targeting 
inflammasome activation may have a cardioprotective role against heart failure. 
 
 As a whole, we illustrate clear molecular evidence of the role of key transcription 
factor, STAT3, exerts its patho-physiological in heart disease and confers its 
cardioprotection role in adult heart by negatively regulating of the NLRP3 
inflammation activation through mediating Txnip expression. 
 
Even though our data and other studies have been identified involvement of Txnip 
in NLRP3 activation (Zhou et al., 2010), nonetheless, opposing results were found 
by another research group using bone marrow-derived macrophages (BMDM) 
model (Masters et al., 2010). IL-1β secretion and caspase-1 activation were directly 
compared by using Txnip-deficient macrophages and NLRP3-deficient 
macrophages and found that these parameters were lower only in NLRP3-deficient 
macrophages. Hence, this study reported that they did not identify Txnip in 
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regulating inflammasome or IL-1β production by the inflammasome, in BMDM. 
However, this difference may be attributed to the distinct roles of Txnip in 
activation of NLRP3 inflammasome in different systems, and in this case, in 
cardiovascular system and hematopoietic lineage cells especially of the myeloid 
lineage such as macrophages. In addition, another group first revealed that STAT3 
Tyrosine phosphorylation is critical for pro-IL-1β production by using in murine 
bone marrow-derived dendritic cells and this implies that STAT3 is probably 
required for activation of NLRP3 inflammasome assembly (Samavati et al., 2009). 
This is at first sight contradictory to data presented here and to other studies 
indicating a pro-inflammatory role for STAT3. Nonetheless, it appears that pro- 
and anti-inflammatory roles of STAT3 are mostly cell- and stimulation-specific, 
and also multiple post-translational modifications, such as phosphorylation plays a 
major role in this process. Here, we propose that STAT3 confers cardioprotection 
in the adult heart by its anti-inflammatory role in which it negatively regulates 
activation of NLRP3 inflammasome possibly through mediating Txnip expression. 
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Chapter 6 Conclusion, limitation of the study, future work 
6.1 Conclusions 
6.1.1 Conclusion from part I 
ESCs is pluripotency cell that can potentially proliferates indefinitely as well as 
differentiates into almost all the cell types in our body. Hence, it is regarded that 
ES-derived cardiomyocytes are ideal for use in regenerative medicine as they 
represent a renewable source of multiple heart cell types that are participating in 
the process of myocardial regeneration on the repair of major heart injuries. 
However, the transition from bench to bed necessitates a deeper understanding of 
the STAT3 function in the molecular control of early cardiomyocyte differentiation 
as studies have revealed that STAT3 is crucial for early cardiomyocyte 
differentiation. Conventional STAT3 KO is embryonic lethal before the function 
of STAT3 in early cardiomyocyte differentiation can be assessed. Therefore, we 
need a tool which can temporally and specifically delete or overexpress STAT3 
expression in ES cells. In this study, we have established an in vitro inducible 
STAT3 knock out and pSTAT3 overexpressed ES cells system in which STAT3 
expression can be deleted or overexpressed by doxycyclin stimulation to allow the 
study of STAT3 function during early cardiomyocyte differentiation. Conclusively, 
our present study has illustrated an efficient cardiomyocyte differentiation program 
in generating cardiomyocyte from ESCs. STAT3 showed temporal expression 
during cardiomyocyte differentiation from ESCs and plays stage specific function 
in promoting cardiomyocyte differentiation from ESCs. We identified a molecular 
mechanism by which STAT3 and GATA6 may interact functionally and a 
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promoting role of STAT3 in cardiac differentiation may be mediated through 
upregulation of GATA6 expression.  
 
6.1.2 Conclusion from part II 
Finding a cure for cardiovascular disease remains a major unmet medical need. 
Therefore, elucidating the molecular mechanism of heart pathogenesis is of great 
clinical significance for devising new treatments. Studies have revealed that 
STAT3-deficient hearts are more sensitive to endotoxin-induced cell death and 
inflammation, possibly due to elevated production of TNF-α, which eventually 
leads to severe cardiac pathogenesis of myocardial fibrosis with advanced age. 
Therefore, STAT3 plays a crucial role to promote cardiomyocyte survival and 
cardiac function. Hence, it is essential to elucidate the changes in genes related to 
heart pathogenesis and the underlying regulatory role of STAT3 involved in this 
cardiovascular pathogenesis. Given the increased Txnip expression and 
inflammation as demonstrated by increased activation of inflammasome3 we 
observed in STAT3-deficient heart, this supports the notion that some of these 
deteriorate effects might be mediated by Txnip induction in the absence of STAT3. 
Therefore, our findings now reveal for the first time that STAT3 signaling pathway 
might regulate Txnip expression and hence contributes to cardioprotection under 
pathogenesis condition. Hence, this study supports the potential role of Txnip as a 
therapeutic target for cardioprotection, be it through STAT3 signaling pathway or 
by novel compounds designed to specifically inhibit cardiac Txnip expression, and 
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hence providing new insight for potential clinic therapy for heart failure and to 
explore and develop new biomarkers and therapeutic treatments for the disease. 
 
6.2 Limitation of the study and future work 
6.2.1 Limitation of the study and future work for part I 
More studies can be done to find out the phenotype of STAT3 knock out ES cells 
derived cardiomyocyte. Electrophysiology patch clamp studies is useful for further 
characterization of cardiomyocytes. Also, more expression profiles of mesodermal 
and cardiac genes can be examined to better understand the consequence of STAT3 
KO in ES cells derived cardiomyocyte. This will aid in elucidating a more 
prominent role that STAT3 plays in cardiogenesis, particularly during early stages 
of cardiomyocyte differentiation. In our study, STAT3 is downregulated during 
early differentiation process, thus the next question to elucidate is the array of genes 
that are regulated by STAT3 prior designation to a cardiac fate. 
 
Our preliminary data are not conclusive in elucidating STAT3 signaling acts 
through GATA6 to regulate ES cell derived cardiomyocyte. Future works intending 
to pursue STAT3 and GATA6 in cardiomyocyte precursors using suggested cardiac 
differentiation program should first seek to isolate a pure sample of cardiac 
precursors by means of FACS sorting. It is critical to carry out more studies at 
characterizing the precursors. Co-immunoprecipitation analysis using STAT3 and 
GATA6 will be convincing to deduce physical interactions among these 
transcription factors. Epigenetic studies is suggested to verify the mode of action 
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of STAT3 on GATA6 expression. Given that ChIP-Seq data verifies a STAT3 
binding site on GATA6 promoter (Kidder et al., 2008), STAT3 may be involved in 
epigenetic modifications of GATA6 gene transcription. To prove this, H3K27 tri-
methylation and H3K9 acetylation ChIP assay can be carried out using E14 ES cells 
and STAT3 inducible KO ES cells. 
 
6.2.2 Limitation of the study and future work for part II 
Our present study has proved that upregulation of Txnip in STAT3-deficient heart 
experienced higher inflammation as demonstrated by higher activation of 
inflammasome3 in the STAT3-deficient heart and thereby eventually lead to 
fibrosis and heart failure. However, the causal role and molecular events by which 
increased Txnip is responsible for the increased activation of inflammasome3 in 
STAT3-deficient heart have not been fully elucidated.  
 
In future, we would like to examine whether inhibiting Txnip expression in STAT3-
deficient heart can rescue or reverse the phenotype and thus provide 
cardioprotection.  Pharmacological tool such as calcium channel blockers, 
verapamil (J. Chen et al., 2009) which specifically inhibit Txnip expression can be 
used in vivo by feeding the mice, both wild-type and STAT3 CKO mice with or 
without verapamil in their drinking water (1mg/ml) for 3 weeks at different ages 
such as 2 month old, 4 month old and 6 month old mice and the mice will be 
sacrificed at age 3 month old, 6 month old and 9 month old. Real-time RT-PCR and 
western blot can be carried out to reveal a significant decrease in the mRNA and 
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protein expression of Txnip. Next, inflammatory mediators such as TNF-α and IL-
1B, and antioxidant status such as Thioredoxin (Trx), thioredoxin reductase 1 
(TrxR1), and nitrotyrosine formation can be tested. Also, fibronectic markers such 
as Tissue inhibitor of metalloproteinase (Timp1), Fibroblast specific protein 1 
(FSP1) and collagen genes can be examined to test whether or not these markers 
will reduce in reduced Txnip expression in STAT3-deficient heart. Furthermore, 
histological examination can be carried out. Sections can be stained with 
hematoxylin/eosin to view the overall phenotype. Masson’s trichrome can be used 
to detect fibrosis in heart sections while in situ labelling of apoptotic cells can be 
performed on tissue sections. All these results will suggest that whether down-
regulation of cardiac Txnip expression in vivo in STAT3-deficient heart might 
reduce apoptosis, cardiac fibrosis and heart failure. 
 
Next, Txnip knockdown can be done using Txnip siRNA and scramble siRNA as 
control in STAT3-deleted cardiomyocyte in vitro. In addition, double KO of Txnip 
and STAT3 CKO mice could be generated in order to examine whether or not KO 
of Txnip can rescue the increased inflammation and fibrosis in STAT3 CKO heart. 
Immunostaining and similar experiments as discussed above can be performed such 
as to examine the levels of inflammatory mediators, antioxidant status and cardiac 
fibrosis. Apoptosis markers such as cleaved caspase-3 and Tunel assay can be 
performed in reduced Txnip expression in STAT3-deficient cardiomyocyte. This 
might suggest that Txnip may be involved in the pathogenesis of heart failure in 
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which cardiomyocyte apoptosis represents one of the key mechanism and it is a 
potential downstream gene regulated by STAT3.  
 
Knowing that inhibition of Txnip is suggested as a potential cardioprotective 
approach on the basis of knockdown experiment, we would like to investigate 
multiple downstream mechanisms by which Txnip can cause heart pathogenesis in 
the absence of STAT3 in addition to activation of inflammasome3. Enhanced Txnip 
expression might contribute to heart pathogenesis by three possible mechanisms, 
involving induced release of inflammatory mediators such as TNF-α, altered 
antioxidant status, and disrupted Trx-ASK-1 inhibitory complex leading to 
activation of the p38 MAPK/JNK apoptotic pathway (C. L. Chen et al., 2008; Ichijo 
et al., 1997; Nishiyama et al., 1999; Yamawaki et al., 2005).  
 
Inflammatory mediators such as TNF-α, IL-1B, and IL-6 and oxidative markers 
such as 4-HNE and nitrotyrosine formation can be examined in reduced Txnip 
expression in STAT3-deficient heart and cardiomyocyte. In addition, the increased 
expression of antioxidant (MnSOD and HO-1) and anti-apoptosis (Bcl-xL) proteins, 
as well as decreased levels of pro-apoptotic (Bad and Bax) proteins will be 
examined. Also, the association between Txnip and Trx can be examined using 
immunoprecipitation and Trx activity assay can be measured before and after Txnip 
expression being inhibited in vitro and in vivo.  In addition, p38 MAPK/JNK 
apoptotic pathway can be further confirmed by the expression of cleaved caspase-
3 and cleaved PARP. 
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Nonetheless, we cannot exclude the possibility that some of the protective effects 
observed in STAT3 wild-type mice as compared to STAT3-deficient mice are 
independent of elevated Txnip levels and based on the regulation of other potential 
genes by STAT3 involved in apoptosis and inflammation signaling pathway. 
Besides Txnip, we are also interested in looking for other potential cardiac genes 
regulated by STAT3 to unravel this critical signaling network in cardioprotection. 
Microarray experiment is chosen to unravel this network and identify critical 
STAT3 target genes. Total RNA is harvested from wild-type and STAT3 CKO 
heart at age 3 month old, 6 month old and 9 month old and send for microarray 
analysis. Gene expression between wild-type and STAT3 CKO can be compared 















Supplemental Table  
Table S1. Differentially expressed genes more than 4-fold in STAT3 CA ES cells. 
Gene Symbol Fold Change Regulation 
Igf2 11.34 up 
GATA6 11.08 up 
Tcfap2c 9.69 up 
LOC381844 7.24 up 
Slc30a2 7.02 up 
Zscan4c 6.37 up 
Khdc3 2410004A20Rik 6.36 up 
Smoc1 6.27 up 
AF067061 6.25 up 
Ndp52 5.66 up 
Auh 5.56 up 
Lrrc15 5.43 up 
Glipr2 5.37 up 
Nupr1 5.17 up 
Glipr2 5.11 up 
Il28ra 4.86 up 
S100a6 4.82 up 
Stmn2 4.68 up 
Tcstv1 4.58 up 
Pdzk1 4.56 up 
LOC100046049 4.51 up 
Tuba3a 4.50 up 
Xlr4a 4.46 up 
Fgfbp1 4.45 up 
Pdlim4 4.44 up 
Tcstv3 4.39 up 
Ubap1I LOC208080 4.32 up 
Rcsd1 4.26 up 
Gm7969 LOC666185 4.26 up 
Gbp2 4.24 up 
Col4a2 4.23 up 
Spink3 4.22 up 
Plvap 4.21 up 
Amn 4.15 up 
Pdzk1 4.07 up 
Tcfap2a 4.06 up 
Slc29a3 4.04 up 
Plac8 4.01 up 
Snurf 48.51 down 
Snurf 43.99 down 
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Snurf 19.91 down 
Tex13 11.32 down 
Svop 6.68 down 
Osr2 5.48 down 
Lrrc51 4.70 down 
Stc1 4.60 down 
Osr2 4.19 down 






Table S2. Differentially expressed genes more than 4-fold in STAT3 KO ES cells. 
 
Gene Symbol Fold Change Regulation 
Zscan4c 20.77 up 
Gm428 17.77 up 
Ubap1I LOC208080 16.82 up 
LOC381844 15.95 up 
LOC548597 13.81 up 
LOC433722 11.14 up 
Nupr1 11.02 up 
LOC433721 10.30 up 
Gm13119 OTTMUSG00000010537 9.90 up 
Tcstv3 8.96 up 
Gdf15 8.52 up 
Tcstv1 8.37 up 
Ccdc155 8.22 up 
Thy1 8.21 up 
AF067061 8.19 up 
Nptx2 7.54 up 
Masp2 7.33 up 
Gm16513 AU018829 7.05 up 
A730027B03Rik 6.78 up 
Synm 6.49 up 
Spink3 24.61 down 
Fgf17 8.11 down 
Junb 7.94 down 
Bmp4 6.83 down 
Notum 6.48 down 
Gbx2 6.37 down 
Klk7 6.32 down 
Lama1 5.92 down 
Car2 5.71 down 
Cltb 5.67 down 
RIKEN cDNA 9430052C07Rik 5.61 down 
Slc27a2 5.57 down 
LOC670917 5.48 down 
Fgf17 5.01 down 
STAT3 5.00 down 
Tgm1 4.93 down 
Cyp11a1 4.83 down 
Dtx3l 4.80 down 
Irak3 4.80 down 




Table S3. STAT3 binding sites on selected cardiac genes were extracted from 








Adluri, R. S., Thirunavukkarasu, M., Zhan, L., Akita, Y., Samuel, S. M., Otani, H., . . . Maulik, 
N. (2011). Thioredoxin 1 enhances neovascularization and reduces ventricular 
remodeling during chronic myocardial infarction: a study using thioredoxin 1 
transgenic mice. J Mol Cell Cardiol, 50(1), 239-247. doi: 
10.1016/j.yjmcc.2010.11.002 
Agah, R., Frenkel, P. A., French, B. A., Michael, L. H., Overbeek, P. A., & Schneider, M. D. 
(1997). Gene recombination in postmitotic cells. Targeted expression of Cre 
recombinase provokes cardiac-restricted, site-specific rearrangement in adult 
ventricular muscle in vivo. J Clin Invest, 100(1), 169-179. doi: 10.1172/jci119509 
Alonzi, T., Maritano, D., Gorgoni, B., Rizzuto, G., Libert, C., & Poli, V. (2001). Essential role 
of STAT3 in the control of the acute-phase response as revealed by inducible gene 
inactivation [correction of activation] in the liver. Mol Cell Biol, 21(5), 1621-1632. 
doi: 10.1128/mcb.21.5.1621-1632.2001 
Arai, A., Yamamoto, K., & Toyama, J. (1997). Murine cardiac progenitor cells require 
visceral embryonic endoderm and primitive streak for terminal differentiation. 
Dev Dyn, 210(3), 344-353. doi: 10.1002/(sici)1097-0177(199711)210:3<344::aid-
aja13>3.0.co;2-a 
Arceci, R. J., King, A. A., Simon, M. C., Orkin, S. H., & Wilson, D. B. (1993). Mouse GATA-4: 
a retinoic acid-inducible GATA-binding transcription factor expressed in 
endodermally derived tissues and heart. Mol Cell Biol, 13(4), 2235-2246.  
Baharvand, H., Azarnia, M., Parivar, K., & Ashtiani, S. K. (2005). The effect of extracellular 
matrix on embryonic stem cell-derived cardiomyocytes. J Mol Cell Cardiol, 38(3), 
495-503. doi: 10.1016/j.yjmcc.2004.12.011 
Barry, S. P., Davidson, S. M., & Townsend, P. A. (2008). Molecular regulation of cardiac 
hypertrophy. Int J Biochem Cell Biol, 40(10), 2023-2039. doi: 
10.1016/j.biocel.2008.02.020 
Barth, A. S., Kuner, R., Buness, A., Ruschhaupt, M., Merk, S., Zwermann, L., . . . Sultmann, 
H. (2006). Identification of a common gene expression signature in dilated 
cardiomyopathy across independent microarray studies. J Am Coll Cardiol, 48(8), 
1610-1617. doi: 10.1016/j.jacc.2006.07.026 
Boengler, K., Buechert, A., Heinen, Y., Roeskes, C., Hilfiker-Kleiner, D., Heusch, G., & Schulz, 
R. (2008). Cardioprotection by ischemic postconditioning is lost in aged and 
STAT3-deficient mice. Circ Res, 102(1), 131-135. doi: 
10.1161/circresaha.107.164699 
Boheler, K. R., Czyz, J., Tweedie, D., Yang, H. T., Anisimov, S. V., & Wobus, A. M. (2002). 
Differentiation of pluripotent embryonic stem cells into cardiomyocytes. Circ Res, 
91(3), 189-201.  
Bolli, R., Stein, A. B., Guo, Y., Wang, O. L., Rokosh, G., Dawn, B., . . . Xuan, Y. T. (2011). A 
murine model of inducible, cardiac-specific deletion of STAT3: its use to 
determine the role of STAT3 in the upregulation of cardioprotective proteins by 
ischemic preconditioning. J Mol Cell Cardiol, 50(4), 589-597. doi: 
10.1016/j.yjmcc.2011.01.002 
Booz, G. W., Day, J. N., & Baker, K. M. (2002). Interplay between the cardiac renin 
angiotensin system and JAK-STAT signaling: role in cardiac hypertrophy, 
 120 
 
ischemia/reperfusion dysfunction, and heart failure. J Mol Cell Cardiol, 34(11), 
1443-1453.  
Boulton, T. G., Stahl, N., & Yancopoulos, G. D. (1994). Ciliary neurotrophic factor/leukemia 
inhibitory factor/interleukin 6/oncostatin M family of cytokines induces tyrosine 
phosphorylation of a common set of proteins overlapping those induced by other 
cytokines and growth factors. J Biol Chem, 269(15), 11648-11655.  
Boyer, L. A., Lee, T. I., Cole, M. F., Johnstone, S. E., Levine, S. S., Zucker, J. P., . . . Young, R. 
A. (2005). Core transcriptional regulatory circuitry in human embryonic stem cells. 
Cell, 122(6), 947-956. doi: 10.1016/j.cell.2005.08.020 
Bradley, A., Evans, M., Kaufman, M. H., & Robertson, E. (1984). Formation of germ-line 
chimaeras from embryo-derived teratocarcinoma cell lines. Nature, 309(5965), 
255-256.  
Brand, T. (2003). Heart development: molecular insights into cardiac specification and 
early morphogenesis. Dev Biol, 258(1), 1-19.  
Brewer, A. C., Alexandrovich, A., Mjaatvedt, C. H., Shah, A. M., Patient, R. K., & Pizzey, J. 
A. (2005). GATA factors lie upstream of Nkx 2.5 in the transcriptional regulatory 
cascade that effects cardiogenesis. Stem Cells Dev, 14(4), 425-439. doi: 
10.1089/scd.2005.14.425 
Bromberg, J. F. (2001). Activation of STAT proteins and growth control. Bioessays, 23(2), 
161-169. doi: 10.1002/1521-1878(200102)23:2<161::aid-bies1023>3.0.co;2-0 
Bryant, D., Becker, L., Richardson, J., Shelton, J., Franco, F., Peshock, R., . . . Giroir, B. (1998). 
Cardiac failure in transgenic mice with myocardial expression of tumor necrosis 
factor-alpha. Circulation, 97(14), 1375-1381.  
Butler, K. L., Huffman, L. C., Koch, S. E., Hahn, H. S., & Gwathmey, J. K. (2006). STAT-3 
activation is necessary for ischemic preconditioning in hypertrophied 
myocardium. Am J Physiol Heart Circ Physiol, 291(2), H797-803. doi: 
10.1152/ajpheart.01334.2005 
Chakraborty, A., & Tweardy, D. J. (1998). Stat3 and G-CSF-induced myeloid differentiation. 
Leuk Lymphoma, 30(5-6), 433-442. doi: 10.3109/10428199809057555 
Chandrasekar, B., Mitchell, D. H., Colston, J. T., & Freeman, G. L. (1999). Regulation of 
CCAAT/Enhancer binding protein, interleukin-6, interleukin-6 receptor, and 
gp130 expression during myocardial ischemia/reperfusion. Circulation, 99(3), 
427-433.  
Chapman, R. S., Lourenco, P. C., Tonner, E., Flint, D. J., Selbert, S., Takeda, K., . . . Watson, 
C. J. (1999). Suppression of epithelial apoptosis and delayed mammary gland 
involution in mice with a conditional knockout of Stat3. Genes Dev, 13(19), 2604-
2616.  
Charron, F., Paradis, P., Bronchain, O., Nemer, G., & Nemer, M. (1999). Cooperative 
interaction between GATA-4 and GATA-6 regulates myocardial gene expression. 
Mol Cell Biol, 19(6), 4355-4365.  
Chen, C. L., Lin, C. F., Chang, W. T., Huang, W. C., Teng, C. F., & Lin, Y. S. (2008). Ceramide 
induces p38 MAPK and JNK activation through a mechanism involving a 
thioredoxin-interacting protein-mediated pathway. Blood, 111(8), 4365-4374. doi: 
10.1182/blood-2007-08-106336 
Chen, G. Y., & Nunez, G. (2010). Sterile inflammation: sensing and reacting to damage. 
Nat Rev Immunol, 10(12), 826-837. doi: 10.1038/nri2873 
Chen, J., Cha-Molstad, H., Szabo, A., & Shalev, A. (2009). Diabetes induces and calcium 
channel blockers prevent cardiac expression of proapoptotic thioredoxin-
 121 
 
interacting protein. Am J Physiol Endocrinol Metab, 296(5), E1133-1139. doi: 
10.1152/ajpendo.90944.2008 
Chien, K. R., Domian, I. J., & Parker, K. K. (2008). Cardiogenesis and the complex biology 
of regenerative cardiovascular medicine. Science, 322(5907), 1494-1497. doi: 
10.1126/science.1163267 
Darnell, J. E., Jr. (1997). STATs and gene regulation. Science, 277(5332), 1630-1635.  
Darnell, J. E., Jr., Kerr, I. M., & Stark, G. R. (1994). Jak-STAT pathways and transcriptional 
activation in response to IFNs and other extracellular signaling proteins. Science, 
264(5164), 1415-1421.  
Davis, B. K., & Ting, J. P. (2010). NLRP3 has a sweet tooth. Nature immunology, 11(2), 105-
106. doi: 10.1038/ni0210-105 
Decker, T., & Kovarik, P. (1999). Transcription factor activity of STAT proteins: structural 
requirements and regulation by phosphorylation and interacting proteins. Cell 
Mol Life Sci, 55(12), 1535-1546.  
Deswal, A., Petersen, N. J., Feldman, A. M., Young, J. B., White, B. G., & Mann, D. L. (2001). 
Cytokines and cytokine receptors in advanced heart failure: an analysis of the 
cytokine database from the Vesnarinone trial (VEST). Circulation, 103(16), 2055-
2059.  
Di Lisi, R., Millino, C., Calabria, E., Altruda, F., Schiaffino, S., & Ausoni, S. (1998). 
Combinatorial cis-acting elements control tissue-specific activation of the cardiac 
troponin I gene in vitro and in vivo. J Biol Chem, 273(39), 25371-25380.  
Dinarello, C. A. (2009). Immunological and inflammatory functions of the interleukin-1 
family. Annu Rev Immunol, 27, 519-550. doi: 
10.1146/annurev.immunol.021908.132612 
Dixelius, J., Jakobsson, L., Genersch, E., Bohman, S., Ekblom, P., & Claesson-Welsh, L. 
(2004). Laminin-1 promotes angiogenesis in synergy with fibroblast growth factor 
by distinct regulation of the gene and protein expression profile in endothelial 
cells. J Biol Chem, 279(22), 23766-23772. doi: 10.1074/jbc.M311675200 
Do, D. V., Ueda, J., Messerschmidt, D. M., Lorthongpanich, C., Zhou, Y., Feng, B., . . . Fu, X. 
Y. (2013). A genetic and developmental pathway from STAT3 to the OCT4-NANOG 
circuit is essential for maintenance of ICM lineages in vivo. Genes Dev, 27(12), 
1378-1390. doi: 10.1101/gad.221176.113 
Dostert, C., Petrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008). 
Innate immune activation through Nalp3 inflammasome sensing of asbestos and 
silica. Science, 320(5876), 674-677. doi: 10.1126/science.1156995 
Duncan, S. A., Zhong, Z., Wen, Z., & Darnell, J. E., Jr. (1997). STAT signaling is active during 
early mammalian development. Dev Dyn, 208(2), 190-198. doi: 
10.1002/(sici)1097-0177(199702)208:2<190::aid-aja6>3.0.co;2-d 
Durant, L., Watford, W. T., Ramos, H. L., Laurence, A., Vahedi, G., Wei, L., . . . O'Shea, J. J. 
(2010). Diverse targets of the transcription factor STAT3 contribute to T cell 
pathogenicity and homeostasis. Immunity, 32(5), 605-615. doi: 
10.1016/j.immuni.2010.05.003 
Durbin, J. E., Hackenmiller, R., Simon, M. C., & Levy, D. E. (1996). Targeted disruption of 
the mouse Stat1 gene results in compromised innate immunity to viral disease. 
Cell, 84(3), 443-450.  
Durocher, D., Charron, F., Warren, R., Schwartz, R. J., & Nemer, M. (1997). The cardiac 
transcription factors Nkx2-5 and GATA-4 are mutual cofactors. EMBO J, 16(18), 
5687-5696. doi: 10.1093/emboj/16.18.5687 
 122 
 
Dziadek, M., & Timpl, R. (1985). Expression of nidogen and laminin in basement 
membranes during mouse embryogenesis and in teratocarcinoma cells. Dev Biol, 
111(2), 372-382.  
Eghbali, M., Blumenfeld, O. O., Seifter, S., Buttrick, P. M., Leinwand, L. A., Robinson, T. 
F., . . . Giambrone, M. A. (1989). Localization of types I, III and IV collagen mRNAs 
in rat heart cells by in situ hybridization. J Mol Cell Cardiol, 21(1), 103-113.  
Ehret, G. B., Reichenbach, P., Schindler, U., Horvath, C. M., Fritz, S., Nabholz, M., & Bucher, 
P. (2001). DNA binding specificity of different STAT proteins. Comparison of in 
vitro specificity with natural target sites. J Biol Chem, 276(9), 6675-6688. doi: 
10.1074/jbc.M001748200 
Ekblom, M., Falk, M., Salmivirta, K., Durbeej, M., & Ekblom, P. (1998). Laminin isoforms 
and epithelial development. Ann N Y Acad Sci, 857, 194-211.  
Elgort, M. G., O'Shea, J. M., Jiang, Y., & Ayer, D. E. (2010). Transcriptional and Translational 
Downregulation of Thioredoxin Interacting Protein Is Required for Metabolic 
Reprogramming during G(1). Genes Cancer, 1(9), 893-907. doi: 
10.1177/1947601910389604 
Eltzschig, H. K., & Eckle, T. (2011). Ischemia and reperfusion[mdash]from mechanism to 
translation. Nat Med, 17(11), 1391-1401.  
Ernst, M., Novak, U., Nicholson, S. E., Layton, J. E., & Dunn, A. R. (1999). The carboxyl-
terminal domains of gp130-related cytokine receptors are necessary for 
suppressing embryonic stem cell differentiation. Involvement of STAT3. J Biol 
Chem, 274(14), 9729-9737.  
Evans, M. J., & Kaufman, M. H. (1981). Establishment in culture of pluripotential cells from 
mouse embryos. Nature, 292(5819), 154-156.  
Evans, T., Reitman, M., & Felsenfeld, G. (1988). An erythrocyte-specific DNA-binding 
factor recognizes a regulatory sequence common to all chicken globin genes. Proc 
Natl Acad Sci U S A, 85(16), 5976-5980.  
Falk, M., Ferletta, M., Forsberg, E., & Ekblom, P. (1999). Restricted distribution of laminin 
alpha1 chain in normal adult mouse tissues. Matrix Biol, 18(6), 557-568.  
Fischer, P., & Hilfiker-Kleiner, D. (2007). Survival pathways in hypertrophy and heart 
failure: the gp130-STAT3 axis. Basic Res Cardiol, 102(4), 279-297. doi: 
10.1007/s00395-007-0658-z 
Fishman, M. C., & Chien, K. R. (1997). Fashioning the vertebrate heart: earliest embryonic 
decisions. Development, 124(11), 2099-2117.  
Fong, S., Debs, R. J., & Desprez, P. Y. (2004). Id genes and proteins as promising targets in 
cancer therapy. Trends Mol Med, 10(8), 387-392. doi: 
10.1016/j.molmed.2004.06.008 
Foshay, K., Rodriguez, G., Hoel, B., Narayan, J., & Gallicano, G. I. (2005). JAK2/STAT3 
directs cardiomyogenesis within murine embryonic stem cells in vitro. Stem Cells, 
23(4), 530-543. doi: 10.1634/stemcells.2004-0293 
Frangogiannis, N. G., Smith, C. W., & Entman, M. L. (2002). The inflammatory response in 
myocardial infarction. Cardiovasc Res, 53(1), 31-47.  
Fu, X. Y., Kessler, D. S., Veals, S. A., Levy, D. E., & Darnell, J. E., Jr. (1990). ISGF3, the 
transcriptional activator induced by interferon alpha, consists of multiple 
interacting polypeptide chains. Proc Natl Acad Sci U S A, 87(21), 8555-8559.  
Fu, X. Y., Schindler, C., Improta, T., Aebersold, R., & Darnell, J. E., Jr. (1992). The proteins 
of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene 
family involved in signal transduction. Proc Natl Acad Sci U S A, 89(16), 7840-7843.  
 123 
 
Good, S. R., Thieu, V. T., Mathur, A. N., Yu, Q., Stritesky, G. L., Yeh, N., . . . Kaplan, M. H. 
(2009). Temporal induction pattern of STAT4 target genes defines potential for 
Th1 lineage-specific programming. J Immunol, 183(6), 3839-3847. doi: 
10.4049/jimmunol.0901411 
Gove, C., Walmsley, M., Nijjar, S., Bertwistle, D., Guille, M., Partington, G., . . . Patient, R. 
(1997). Over-expression of GATA-6 in Xenopus embryos blocks differentiation of 
heart precursors. EMBO J, 16(2), 355-368. doi: 10.1093/emboj/16.2.355 
Grepin, C., Dagnino, L., Robitaille, L., Haberstroh, L., Antakly, T., & Nemer, M. (1994). A 
hormone-encoding gene identifies a pathway for cardiac but not skeletal muscle 
gene transcription. Mol Cell Biol, 14(5), 3115-3129.  
Grepin, C., Nemer, G., & Nemer, M. (1997). Enhanced cardiogenesis in embryonic stem 
cells overexpressing the GATA-4 transcription factor. Development, 124(12), 
2387-2395.  
Grepin, C., Robitaille, L., Antakly, T., & Nemer, M. (1995). Inhibition of transcription factor 
GATA-4 expression blocks in vitro cardiac muscle differentiation. Mol Cell Biol, 
15(8), 4095-4102.  
Hamid, T., Gu, Y., Ortines, R. V., Bhattacharya, C., Wang, G., Xuan, Y. T., & Prabhu, S. D. 
(2009). Divergent tumor necrosis factor receptor-related remodeling responses 
in heart failure: role of nuclear factor-kappaB and inflammatory activation. 
Circulation, 119(10), 1386-1397. doi: 10.1161/circulationaha.108.802918 
Hao, A., Novotny-Diermayr, V., Bian, W., Lin, B., Lim, C. P., Jing, N., & Cao, X. (2005). The 
LIM/homeodomain protein Islet1 recruits Janus tyrosine kinases and signal 
transducer and activator of transcription 3 and stimulates their activities. Mol Biol 
Cell, 16(4), 1569-1583. doi: 10.1091/mbc.E04-08-0664 
Harvey, R. P., Lai, D., Elliott, D., Biben, C., Solloway, M., Prall, O., . . . Kirk, E. (2002). 
Homeodomain factor Nkx2-5 in heart development and disease. Cold Spring Harb 
Symp Quant Biol, 67, 107-114.  
Hattori, R., Maulik, N., Otani, H., Zhu, L., Cordis, G., Engelman, R. M., . . . Das, D. K. (2001). 
Role of STAT3 in ischemic preconditioning. J Mol Cell Cardiol, 33(11), 1929-1936. 
doi: 10.1006/jmcc.2001.1456 
Haudek, S. B., Taffet, G. E., Schneider, M. D., & Mann, D. L. (2007). TNF provokes 
cardiomyocyte apoptosis and cardiac remodeling through activation of multiple 
cell death pathways. J Clin Invest, 117(9), 2692-2701. doi: 10.1172/jci29134 
Heikinheimo, M., Scandrett, J. M., & Wilson, D. B. (1994). Localization of transcription 
factor GATA-4 to regions of the mouse embryo involved in cardiac development. 
Dev Biol, 164(2), 361-373. doi: 10.1006/dbio.1994.1206 
Heinrich, P. C., Behrmann, I., Muller-Newen, G., Schaper, F., & Graeve, L. (1998). 
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. 
Biochem J, 334 ( Pt 2), 297-314.  
Hescheler, J., Fleischmann, B. K., Wartenberg, M., Bloch, W., Kolossov, E., Ji, G., . . . Sauer, 
H. (1999). Establishment of ionic channels and signalling cascades in the 
embryonic stem cell-derived primitive endoderm and cardiovascular system. Cells 
Tissues Organs, 165(3-4), 153-164. doi: 16695 
Hilfiker-Kleiner, D., Hilfiker, A., & Drexler, H. (2005). Many good reasons to have STAT3 in 
the heart. Pharmacol Ther, 107(1), 131-137. doi: 
10.1016/j.pharmthera.2005.02.003 
Hilfiker-Kleiner, D., Hilfiker, A., Fuchs, M., Kaminski, K., Schaefer, A., Schieffer, B., . . . 
Drexler, H. (2004). Signal transducer and activator of transcription 3 is required 
 124 
 
for myocardial capillary growth, control of interstitial matrix deposition, and 
heart protection from ischemic injury. Circ Res, 95(2), 187-195. doi: 
10.1161/01.res.0000134921.50377.61 
Hilton, D. J. (1999). Negative regulators of cytokine signal transduction. Cell Mol Life Sci, 
55(12), 1568-1577.  
Ho, L., Miller, E. L., Ronan, J. L., Ho, W. Q., Jothi, R., & Crabtree, G. R. (2011). esBAF 
facilitates pluripotency by conditioning the genome for LIF/STAT3 signalling and 
by regulating polycomb function. Nat Cell Biol, 13(8), 903-913. doi: 
10.1038/ncb2285 
Holtzinger, A., & Evans, T. (2005). Gata4 regulates the formation of multiple organs. 
Development, 132(17), 4005-4014. doi: 10.1242/dev.01978 
Hutchins, A. P., Poulain, S., & Miranda-Saavedra, D. (2012). Genome-wide analysis of 
STAT3 binding in vivo predicts effectors of the anti-inflammatory response in 
macrophages. Blood, 119(13), e110-119. doi: 10.1182/blood-2011-09-381483 
Hwang, M. W., Matsumori, A., Furukawa, Y., Ono, K., Okada, M., Iwasaki, A., . . . Sasayama, 
S. (2001). Neutralization of interleukin-1beta in the acute phase of myocardial 
infarction promotes the progression of left ventricular remodeling. J Am Coll 
Cardiol, 38(5), 1546-1553.  
Ichijo, H., Nishida, E., Irie, K., ten Dijke, P., Saitoh, M., Moriguchi, T., . . . Gotoh, Y. (1997). 
Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK 
and p38 signaling pathways. Science, 275(5296), 90-94.  
Ionita, M. G., Arslan, F., de Kleijn, D. P., & Pasterkamp, G. (2010). Endogenous 
inflammatory molecules engage Toll-like receptors in cardiovascular disease. J 
Innate Immun, 2(4), 307-315. doi: 10.1159/000314270 
Ip, H. S., Wilson, D. B., Heikinheimo, M., Tang, Z., Ting, C. N., Simon, M. C., . . . Parmacek, 
M. S. (1994). The GATA-4 transcription factor transactivates the cardiac muscle-
specific troponin C promoter-enhancer in nonmuscle cells. Mol Cell Biol, 14(11), 
7517-7526.  
Jacoby, J. J., Kalinowski, A., Liu, M. G., Zhang, S. S., Gao, Q., Chai, G. X., . . . Fu, X. Y. (2003). 
Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to 
inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl 
Acad Sci U S A, 100(22), 12929-12934. doi: 10.1073/pnas.2134694100 
Jeon, J. H., Lee, K. N., Hwang, C. Y., Kwon, K. S., You, K. H., & Choi, I. (2005). Tumor 
suppressor VDUP1 increases p27(kip1) stability by inhibiting JAB1. Cancer Res, 
65(11), 4485-4489. doi: 10.1158/0008-5472.can-04-2271 
Ji, R. P., Phoon, C. K., Aristizabal, O., McGrath, K. E., Palis, J., & Turnbull, D. H. (2003). Onset 
of cardiac function during early mouse embryogenesis coincides with entry of 
primitive erythroblasts into the embryo proper. Circ Res, 92(2), 133-135.  
Jiang, Y., & Evans, T. (1996). The Xenopus GATA-4/5/6 genes are associated with cardiac 
specification and can regulate cardiac-specific transcription during 
embryogenesis. Dev Biol, 174(2), 258-270. doi: 10.1006/dbio.1996.0071 
Kaimul, A. M., Nakamura, H., Masutani, H., & Yodoi, J. (2007). Thioredoxin and 
thioredoxin-binding protein-2 in cancer and metabolic syndrome. Free Radic Biol 
Med, 43(6), 861-868. doi: 10.1016/j.freeradbiomed.2007.05.032 
Kami, K., & Senba, E. (2002). In vivo activation of STAT3 signaling in satellite cells and 




Kaplan, M. H., Schindler, U., Smiley, S. T., & Grusby, M. J. (1996). Stat6 is required for 
mediating responses to IL-4 and for development of Th2 cells. Immunity, 4(3), 
313-319.  
Kaplan, M. H., Sun, Y. L., Hoey, T., & Grusby, M. J. (1996). Impaired IL-12 responses and 
enhanced development of Th2 cells in Stat4-deficient mice. Nature, 382(6587), 
174-177. doi: 10.1038/382174a0 
Kattman, S. J., Huber, T. L., & Keller, G. M. (2006). Multipotent flk-1+ cardiovascular 
progenitor cells give rise to the cardiomyocyte, endothelial, and vascular smooth 
muscle lineages. Dev Cell, 11(5), 723-732. doi: 10.1016/j.devcel.2006.10.002 
Kawaguchi, M., Takahashi, M., Hata, T., Kashima, Y., Usui, F., Morimoto, H., . . . Ikeda, U. 
(2011). Inflammasome activation of cardiac fibroblasts is essential for myocardial 
ischemia/reperfusion injury. Circulation, 123(6), 594-604. doi: 
10.1161/circulationaha.110.982777 
Kelley, C., Blumberg, H., Zon, L. I., & Evans, T. (1993). GATA-4 is a novel transcription factor 
expressed in endocardium of the developing heart. Development, 118(3), 817-
827.  
Kelly, B. B., Narula, J., & Fuster, V. (2012). Recognizing global burden of cardiovascular 
disease and related chronic diseases. Mt Sinai J Med, 79(6), 632-640. doi: 
10.1002/msj.21345 
Kelly, R. G., Brown, N. A., & Buckingham, M. E. (2001). The arterial pole of the mouse heart 
forms from Fgf10-expressing cells in pharyngeal mesoderm. Dev Cell, 1(3), 435-
440.  
Kelly, R. G., & Buckingham, M. E. (2002). The anterior heart-forming field: voyage to the 
arterial pole of the heart. Trends Genet, 18(4), 210-216.  
Kidder, B. L., Yang, J., & Palmer, S. (2008). Stat3 and c-Myc genome-wide promoter 
occupancy in embryonic stem cells. PLoS One, 3(12), e3932. doi: 
10.1371/journal.pone.0003932 
Kirby, M. L., Gale, T. F., & Stewart, D. E. (1983). Neural crest cells contribute to normal 
aorticopulmonary septation. Science, 220(4601), 1059-1061.  
Kotenko, S. V., Izotova, L. S., Pollack, B. P., Muthukumaran, G., Paukku, K., Silvennoinen, 
O., . . . Pestka, S. (1996). Other kinases can substitute for Jak2 in signal 
transduction by interferon-gamma. J Biol Chem, 271(29), 17174-17182.  
Koutsourakis, M., Langeveld, A., Patient, R., Beddington, R., & Grosveld, F. (1999). The 
transcription factor GATA6 is essential for early extraembryonic development. 
Development, 126(9), 723-732.  
Kuo, C. T., Morrisey, E. E., Anandappa, R., Sigrist, K., Lu, M. M., Parmacek, M. S., . . . Leiden, 
J. M. (1997). GATA4 transcription factor is required for ventral morphogenesis 
and heart tube formation. Genes Dev, 11(8), 1048-1060.  
Lachtermacher, S., Esporcatte, B. L., Montalvao, F., Costa, P. C., Rodrigues, D. C., Belem, 
L., . . . Campos-de-Carvalho, A. C. (2010). Cardiac gene expression and systemic 
cytokine profile are complementary in a murine model of post-ischemic heart 
failure. Braz J Med Biol Res, 43(4), 377-389.  
Lan, Y., Kingsley, P. D., Cho, E. S., & Jiang, R. (2001). Osr2, a new mouse gene related to 
Drosophila odd-skipped, exhibits dynamic expression patterns during craniofacial, 
limb, and kidney development. Mech Dev, 107(1-2), 175-179.  
Laugwitz, K. L., Moretti, A., Caron, L., Nakano, A., & Chien, K. R. (2008). Islet1 
cardiovascular progenitors: a single source for heart lineages? Development, 
135(2), 193-205. doi: 10.1242/dev.001883 
 126 
 
Laverriere, A. C., MacNeill, C., Mueller, C., Poelmann, R. E., Burch, J. B., & Evans, T. (1994). 
GATA-4/5/6, a subfamily of three transcription factors transcribed in developing 
heart and gut. J Biol Chem, 269(37), 23177-23184.  
Lee, T. I., Johnstone, S. E., & Young, R. A. (2006). Chromatin immunoprecipitation and 
microarray-based analysis of protein location. Nat Protoc, 1(2), 729-748. doi: 
10.1038/nprot.2006.98 
Lee, Y., Shioi, T., Kasahara, H., Jobe, S. M., Wiese, R. J., Markham, B. E., & Izumo, S. (1998). 
The cardiac tissue-restricted homeobox protein Csx/Nkx2.5 physically associates 
with the zinc finger protein GATA4 and cooperatively activates atrial natriuretic 
factor gene expression. Mol Cell Biol, 18(6), 3120-3129.  
Leonard, M., Brice, M., Engel, J. D., & Papayannopoulou, T. (1993). Dynamics of GATA 
transcription factor expression during erythroid differentiation. Blood, 82(4), 
1071-1079.  
Leonard, W. J., & O'Shea, J. J. (1998). Jaks and STATs: biological implications. Annu Rev 
Immunol, 16, 293-322. doi: 10.1146/annurev.immunol.16.1.293 
Levy, D. E., & Darnell, J. E., Jr. (2002). Stats: transcriptional control and biological impact. 
Nat Rev Mol Cell Biol, 3(9), 651-662. doi: 10.1038/nrm909 
Li, P., Spolski, R., Liao, W., Wang, L., Murphy, T. L., Murphy, K. M., & Leonard, W. J. (2012). 
BATF-JUN is critical for IRF4-mediated transcription in T cells. Nature, 490(7421), 
543-546. doi: 10.1038/nature11530 
Lien, C. L., Wu, C., Mercer, B., Webb, R., Richardson, J. A., & Olson, E. N. (1999). Control 
of early cardiac-specific transcription of Nkx2-5 by a GATA-dependent enhancer. 
Development, 126(1), 75-84.  
Lim, C. P., & Cao, X. (2006). Structure, function, and regulation of STAT proteins. Mol 
Biosyst, 2(11), 536-550. doi: 10.1039/b606246f 
Lin, Q., Schwarz, J., Bucana, C., & Olson, E. N. (1997). Control of mouse cardiac 
morphogenesis and myogenesis by transcription factor MEF2C. Science, 
276(5317), 1404-1407.  
Lints, T. J., Parsons, L. M., Hartley, L., Lyons, I., & Harvey, R. P. (1993). Nkx-2.5: a novel 
murine homeobox gene expressed in early heart progenitor cells and their 
myogenic descendants. Development, 119(3), 969.  
Liu, Y., Lian, K., Zhang, L., Wang, R., Yi, F., Gao, C., . . . Tao, L. (2014). TXNIP mediates NLRP3 
inflammasome activation in cardiac microvascular endothelial cells as a novel 
mechanism in myocardial ischemia/reperfusion injury. Basic Res Cardiol, 109(5), 
415. doi: 10.1007/s00395-014-0415-z 
Loh, Y. H., Wu, Q., Chew, J. L., Vega, V. B., Zhang, W., Chen, X., . . . Ng, H. H. (2006). The 
Oct4 and Nanog transcription network regulates pluripotency in mouse 
embryonic stem cells. Nat Genet, 38(4), 431-440. doi: 10.1038/ng1760 
Lyons, I., Parsons, L. M., Hartley, L., Li, R., Andrews, J. E., Robb, L., & Harvey, R. P. (1995). 
Myogenic and morphogenetic defects in the heart tubes of murine embryos 
lacking the homeo box gene Nkx2-5. Genes Dev, 9(13), 1654-1666.  
Malinda, K. M., Nomizu, M., Chung, M., Delgado, M., Kuratomi, Y., Yamada, Y., . . . Ponce, 
M. L. (1999). Identification of laminin alpha1 and beta1 chain peptides active for 
endothelial cell adhesion, tube formation, and aortic sprouting. FASEB J, 13(1), 
53-62.  
Maltsev, V. A., Wobus, A. M., Rohwedel, J., Bader, M., & Hescheler, J. (1994). 
Cardiomyocytes differentiated in vitro from embryonic stem cells 
 127 
 
developmentally express cardiac-specific genes and ionic currents. Circ Res, 75(2), 
233-244.  
Mandal, M., Powers, S. E., Maienschein-Cline, M., Bartom, E. T., Hamel, K. M., Kee, B. L., . . . 
Clark, M. R. (2011). Epigenetic repression of the Igk locus by STAT5-mediated 
recruitment of the histone methyltransferase Ezh2. Nature immunology, 12(12), 
1212-1220. doi: 10.1038/ni.2136 
Mariathasan, S., Weiss, D. S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., . . . 
Dixit, V. M. (2006). Cryopyrin activates the inflammasome in response to toxins 
and ATP. Nature, 440(7081), 228-232. doi: 10.1038/nature04515 
Martin, G. R. (1981). Isolation of a pluripotent cell line from early mouse embryos cultured 
in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci U S A, 
78(12), 7634-7638.  
Martinon, F., Burns, K., & Tschopp, J. (2002). The inflammasome: a molecular platform 
triggering activation of inflammatory caspases and processing of proIL-beta. Mol 
Cell, 10(2), 417-426.  
Martinon, F., Mayor, A., & Tschopp, J. (2009). The inflammasomes: guardians of the body. 
Annu Rev Immunol, 27, 229-265. doi: 10.1146/annurev.immunol.021908.132715 
Masters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., . . . 
O'Neill, L. A. (2010). Activation of the NLRP3 inflammasome by islet amyloid 
polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat 
Immunol, 11(10), 897-904. doi: 10.1038/ni.1935 
Matsuda, T., Nakamura, T., Nakao, K., Arai, T., Katsuki, M., Heike, T., & Yokota, T. (1999). 
STAT3 activation is sufficient to maintain an undifferentiated state of mouse 
embryonic stem cells. EMBO J, 18(15), 4261-4269. doi: 
10.1093/emboj/18.15.4261 
Matsui, T., Kinoshita, T., Hirano, T., Yokota, T., & Miyajima, A. (2002). STAT3 down-
regulates the expression of cyclin D during liver development. J Biol Chem, 
277(39), 36167-36173. doi: 10.1074/jbc.M203184200 
Matsuzaki, Y., Xu, Y., Ikegami, M., Besnard, V., Park, K. S., Hull, W. M., . . . Whitsett, J. A. 
(2006). Stat3 is required for cytoprotection of the respiratory epithelium during 
adenoviral infection. J Immunol, 177(1), 527-537.  
McMurray, J. J., & Pfeffer, M. A. (2005). Heart failure. Lancet, 365(9474), 1877-1889. doi: 
10.1016/s0140-6736(05)66621-4 
Meraz, M. A., White, J. M., Sheehan, K. C., Bach, E. A., Rodig, S. J., Dighe, A. S., . . . Schreiber, 
R. D. (1996). Targeted disruption of the Stat1 gene in mice reveals unexpected 
physiologic specificity in the JAK-STAT signaling pathway. Cell, 84(3), 431-442.  
Mezzaroma, E., Toldo, S., Farkas, D., Seropian, I. M., Van Tassell, B. W., Salloum, F. N., . . . 
Abbate, A. (2011). The inflammasome promotes adverse cardiac remodeling 
following acute myocardial infarction in the mouse. Proc Natl Acad Sci U S A, 
108(49), 19725-19730. doi: 10.1073/pnas.1108586108 
Mjaatvedt, C. H., Nakaoka, T., Moreno-Rodriguez, R., Norris, R. A., Kern, M. J., Eisenberg, 
C. A., . . . Markwald, R. R. (2001). The outflow tract of the heart is recruited from 
a novel heart-forming field. Dev Biol, 238(1), 97-109. doi: 
10.1006/dbio.2001.0409 
Molkentin, J. D. (2000). The zinc finger-containing transcription factors GATA-4, -5, and -
6. Ubiquitously expressed regulators of tissue-specific gene expression. J Biol 
Chem, 275(50), 38949-38952. doi: 10.1074/jbc.R000029200 
 128 
 
Molkentin, J. D., Antos, C., Mercer, B., Taigen, T., Miano, J. M., & Olson, E. N. (2000). Direct 
activation of a GATA6 cardiac enhancer by Nkx2.5: evidence for a reinforcing 
regulatory network of Nkx2.5 and GATA transcription factors in the developing 
heart. Dev Biol, 217(2), 301-309. doi: 10.1006/dbio.1999.9544 
Molkentin, J. D., Lin, Q., Duncan, S. A., & Olson, E. N. (1997). Requirement of the 
transcription factor GATA4 for heart tube formation and ventral morphogenesis. 
Genes Dev, 11(8), 1061-1072.  
Morrisey, E. E., Ip, H. S., Lu, M. M., & Parmacek, M. S. (1996). GATA-6: a zinc finger 
transcription factor that is expressed in multiple cell lineages derived from lateral 
mesoderm. Dev Biol, 177(1), 309-322. doi: 10.1006/dbio.1996.0165 
Morrisey, E. E., Ip, H. S., Tang, Z., Lu, M. M., & Parmacek, M. S. (1997). GATA-5: a 
transcriptional activator expressed in a novel temporally and spatially-restricted 
pattern during embryonic development. Dev Biol, 183(1), 21-36. doi: 
10.1006/dbio.1996.8485 
Morrisey, E. E., Tang, Z., Sigrist, K., Lu, M. M., Jiang, F., Ip, H. S., & Parmacek, M. S. (1998). 
GATA6 regulates HNF4 and is required for differentiation of visceral endoderm in 
the mouse embryo. Genes Dev, 12(22), 3579-3590.  
Murase, S., Kim, E., Lin, L., Hoffman, D. A., & McKay, R. D. (2012). Loss of signal transducer 
and activator of transcription 3 (STAT3) signaling during elevated activity causes 
vulnerability in hippocampal neurons. J Neurosci, 32(44), 15511-15520. doi: 
10.1523/jneurosci.2940-12.2012 
Murphy, A. M., Thompson, W. R., Peng, L. F., & Jones, L., 2nd. (1997). Regulation of the 
rat cardiac troponin I gene by the transcription factor GATA-4. Biochem J, 322 ( Pt 
2), 393-401.  
Muruve, D. A., Petrilli, V., Zaiss, A. K., White, L. R., Clark, S. A., Ross, P. J., . . . Tschopp, J. 
(2008). The inflammasome recognizes cytosolic microbial and host DNA and 
triggers an innate immune response. Nature, 452(7183), 103-107. doi: 
10.1038/nature06664 
Narita, N., Bielinska, M., & Wilson, D. B. (1997a). Cardiomyocyte differentiation by GATA-
4-deficient embryonic stem cells. Development, 124(19), 3755-3764.  
Narita, N., Bielinska, M., & Wilson, D. B. (1997b). Wild-type endoderm abrogates the 
ventral developmental defects associated with GATA-4 deficiency in the mouse. 
Dev Biol, 189(2), 270-274. doi: 10.1006/dbio.1997.8684 
Negoro, S., Kunisada, K., Tone, E., Funamoto, M., Oh, H., Kishimoto, T., & Yamauchi-
Takihara, K. (2000). Activation of JAK/STAT pathway transduces cytoprotective 
signal in rat acute myocardial infarction. Cardiovasc Res, 47(4), 797-805.  
Nemer, G., & Nemer, M. (2003). Transcriptional activation of BMP-4 and regulation of 
mammalian organogenesis by GATA-4 and -6. Dev Biol, 254(1), 131-148.  
Nemer, G., Qureshi, S. T., Malo, D., & Nemer, M. (1999). Functional analysis and 
chromosomal mapping of Gata5, a gene encoding a zinc finger DNA-binding 
protein. Mamm Genome, 10(10), 993-999.  
Neumann, D. A., Lane, J. R., Allen, G. S., Herskowitz, A., & Rose, N. R. (1993). Viral 
myocarditis leading to cardiomyopathy: do cytokines contribute to pathogenesis? 
Clin Immunol Immunopathol, 68(2), 181-190.  
Nishiyama, A., Matsui, M., Iwata, S., Hirota, K., Masutani, H., Nakamura, H., . . . Yodoi, J. 
(1999). Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated 
protein 1 as a negative regulator of thioredoxin function and expression. J Biol 
Chem, 274(31), 21645-21650.  
 129 
 
Niwa, H., Burdon, T., Chambers, I., & Smith, A. (1998). Self-renewal of pluripotent 
embryonic stem cells is mediated via activation of STAT3. Genes Dev, 12(13), 
2048-2060.  
Okada, I., Hamanoue, H., Terada, K., Tohma, T., Megarbane, A., Chouery, E., . . . Saitsu, H. 
(2011). SMOC1 is essential for ocular and limb development in humans and mice. 
Am J Hum Genet, 88(1), 30-41. doi: 10.1016/j.ajhg.2010.11.012 
Olson, E. N., & Srivastava, D. (1996). Molecular pathways controlling heart development. 
Science, 272(5262), 671-676.  
Omichinski, J. G., Clore, G. M., Schaad, O., Felsenfeld, G., Trainor, C., Appella, E., . . . 
Gronenborn, A. M. (1993). NMR structure of a specific DNA complex of Zn-
containing DNA binding domain of GATA-1. Science, 261(5120), 438-446.  
Omichinski, J. G., Trainor, C., Evans, T., Gronenborn, A. M., Clore, G. M., & Felsenfeld, G. 
(1993). A small single-"finger" peptide from the erythroid transcription factor 
GATA-1 binds specifically to DNA as a zinc or iron complex. Proc Natl Acad Sci U S 
A, 90(5), 1676-1680.  
Ono, K., Matsumori, A., Shioi, T., Furukawa, Y., & Sasayama, S. (1998). Cytokine gene 
expression after myocardial infarction in rat hearts: possible implication in left 
ventricular remodeling. Circulation, 98(2), 149-156.  
Oshima, Y., Fujio, Y., Nakanishi, T., Itoh, N., Yamamoto, Y., Negoro, S., . . . Azuma, J. (2005). 
STAT3 mediates cardioprotection against ischemia/reperfusion injury through 
metallothionein induction in the heart. Cardiovasc Res, 65(2), 428-435. doi: 
10.1016/j.cardiores.2004.10.021 
Osugi, T., Oshima, Y., Fujio, Y., Funamoto, M., Yamashita, A., Negoro, S., . . . Kishimoto, T. 
(2002). Cardiac-specific activation of signal transducer and activator of 
transcription 3 promotes vascular formation in the heart. J Biol Chem, 277(8), 
6676-6681. doi: 10.1074/jbc.M108246200 
Pandolfi, P. P., Roth, M. E., Karis, A., Leonard, M. W., Dzierzak, E., Grosveld, F. G., . . . 
Lindenbaum, M. H. (1995). Targeted disruption of the GATA3 gene causes severe 
abnormalities in the nervous system and in fetal liver haematopoiesis. Nat Genet, 
11(1), 40-44. doi: 10.1038/ng0995-40 
Passier, R., Denning, C., & Mummery, C. (2006). Cardiomyocytes from Human Embryonic 
Stem Cells. In A. Wobus & K. Boheler (Eds.), Stem Cells (Vol. 174, pp. 101-122): 
Springer Berlin Heidelberg. 
Passier, R., Oostwaard, D. W., Snapper, J., Kloots, J., Hassink, R. J., Kuijk, E., . . . Mummery, 
C. (2005). Increased cardiomyocyte differentiation from human embryonic stem 
cells in serum-free cultures. Stem Cells, 23(6), 772-780. doi: 
10.1634/stemcells.2004-0184 
Patwari, P., Chutkow, W. A., Cummings, K., Verstraeten, V. L., Lammerding, J., Schreiter, 
E. R., & Lee, R. T. (2009). Thioredoxin-independent regulation of metabolism by 
the alpha-arrestin proteins. J Biol Chem, 284(37), 24996-25003. doi: 
10.1074/jbc.M109.018093 
Perrone, L., Devi, T. S., Hosoya, K., Terasaki, T., & Singh, L. P. (2009). Thioredoxin 
interacting protein (TXNIP) induces inflammation through chromatin 
modification in retinal capillary endothelial cells under diabetic conditions. J Cell 
Physiol, 221(1), 262-272. doi: 10.1002/jcp.21852 
Peterkin, T., Gibson, A., & Patient, R. (2003). GATA-6 maintains BMP-4 and Nkx2 
expression during cardiomyocyte precursor maturation. EMBO J, 22(16), 4260-
4273. doi: 10.1093/emboj/cdg400 
 130 
 
Pevny, L., Simon, M. C., Robertson, E., Klein, W. H., Tsai, S. F., D'Agati, V., . . . Costantini, 
F. (1991). Erythroid differentiation in chimaeric mice blocked by a targeted 
mutation in the gene for transcription factor GATA-1. Nature, 349(6306), 257-260. 
doi: 10.1038/349257a0 
Pomerantz, B. J., Reznikov, L. L., Harken, A. H., & Dinarello, C. A. (2001). Inhibition of 
caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 
and IL-1beta. Proc Natl Acad Sci U S A, 98(5), 2871-2876. doi: 
10.1073/pnas.041611398 
Rajan, P., & McKay, R. D. (1998). Multiple routes to astrocytic differentiation in the CNS. 
J Neurosci, 18(10), 3620-3629.  
Rajasingh, J., Bord, E., Hamada, H., Lambers, E., Qin, G., Losordo, D. W., & Kishore, R. 
(2007). STAT3-dependent mouse embryonic stem cell differentiation into 
cardiomyocytes: analysis of molecular signaling and therapeutic efficacy of 
cardiomyocyte precommitted mES transplantation in a mouse model of 
myocardial infarction. Circ Res, 101(9), 910-918. doi: 
10.1161/circresaha.107.156786 
Rauchhaus, M., Doehner, W., Francis, D. P., Davos, C., Kemp, M., Liebenthal, C., . . . Anker, 
S. D. (2000). Plasma cytokine parameters and mortality in patients with chronic 
heart failure. Circulation, 102(25), 3060-3067.  
Rawles, M. E. (1943). The Heart-Forming Areas of the Early Chick Blastoderm. 
Physiological Zoology, 16(1), 22-43. doi: 10.2307/30151667 
Raz, R., Lee, C. K., Cannizzaro, L. A., d'Eustachio, P., & Levy, D. E. (1999). Essential role of 
STAT3 for embryonic stem cell pluripotency. Proc Natl Acad Sci U S A, 96(6), 2846-
2851.  
Reecy, J. M., Li, X., Yamada, M., DeMayo, F. J., Newman, C. S., Harvey, R. P., & Schwartz, 
R. J. (1999). Identification of upstream regulatory regions in the heart-expressed 
homeobox gene Nkx2-5. Development, 126(4), 839-849.  
Reiter, J. F., Alexander, J., Rodaway, A., Yelon, D., Patient, R., Holder, N., & Stainier, D. Y. 
(1999). Gata5 is required for the development of the heart and endoderm in 
zebrafish. Genes Dev, 13(22), 2983-2995.  
Romero-Lanman, E. E., Pavlovic, S., Amlani, B., Chin, Y., & Benezra, R. (2012). Id1 
maintains embryonic stem cell self-renewal by up-regulation of Nanog and 
repression of Brachyury expression. Stem Cells Dev, 21(3), 384-393. doi: 
10.1089/scd.2011.0428 
Rosenquist, G. C. (1970). Location and movements of cardiogenic cells in the chick embryo: 
the heart-forming portion of the primitive streak. Dev Biol, 22(3), 461-475.  
Samavati, L., Rastogi, R., Du, W., Huttemann, M., Fite, A., & Franchi, L. (2009). STAT3 
tyrosine phosphorylation is critical for interleukin 1 beta and interleukin-6 
production in response to lipopolysaccharide and live bacteria. Mol Immunol, 
46(8-9), 1867-1877. doi: 10.1016/j.molimm.2009.02.018 
Sandanger, O., Ranheim, T., Vinge, L. E., Bliksoen, M., Alfsnes, K., Finsen, A. V., . . . 
Yndestad, A. (2013). The NLRP3 inflammasome is up-regulated in cardiac 
fibroblasts and mediates myocardial ischaemia-reperfusion injury. Cardiovasc Res, 
99(1), 164-174. doi: 10.1093/cvr/cvt091 
Sano, S., Itami, S., Takeda, K., Tarutani, M., Yamaguchi, Y., Miura, H., . . . Takeda, J. (1999). 
Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but 




Sato, H., Takahashi, M., Ise, H., Yamada, A., Hirose, S., Tagawa, Y., . . . Ikeda, U. (2006). 
Collagen synthesis is required for ascorbic acid-enhanced differentiation of 
mouse embryonic stem cells into cardiomyocytes. Biochem Biophys Res Commun, 
342(1), 107-112. doi: 10.1016/j.bbrc.2006.01.116 
Schindler, C., Shuai, K., Prezioso, V. R., & Darnell, J. E., Jr. (1992). Interferon-dependent 
tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science, 
257(5071), 809-813.  
Schulze, P. C., De Keulenaer, G. W., Yoshioka, J., Kassik, K. A., & Lee, R. T. (2002). Vitamin 
D3-upregulated protein-1 (VDUP-1) regulates redox-dependent vascular smooth 
muscle cell proliferation through interaction with thioredoxin. Circ Res, 91(8), 
689-695.  
Searcy, R. D., Vincent, E. B., Liberatore, C. M., & Yutzey, K. E. (1998). A GATA-dependent 
nkx-2.5 regulatory element activates early cardiac gene expression in transgenic 
mice. Development, 125(22), 4461-4470.  
Sepulveda, J. L., Belaguli, N., Nigam, V., Chen, C. Y., Nemer, M., & Schwartz, R. J. (1998). 
GATA-4 and Nkx-2.5 coactivate Nkx-2 DNA binding targets: role for regulating 
early cardiac gene expression. Mol Cell Biol, 18(6), 3405-3415.  
Sharma, R., Bolger, A. P., Li, W., Davlouros, P. A., Volk, H. D., Poole-Wilson, P. A., . . . Anker, 
S. D. (2003). Elevated circulating levels of inflammatory cytokines and bacterial 
endotoxin in adults with congenital heart disease. Am J Cardiol, 92(2), 188-193.  
Shim, W. S., Jiang, S., Wong, P., Tan, J., Chua, Y. L., Tan, Y. S., . . . Sim, E. (2004). Ex vivo 
differentiation of human adult bone marrow stem cells into cardiomyocyte-like 
cells. Biochem Biophys Res Commun, 324(2), 481-488. doi: 
10.1016/j.bbrc.2004.09.087 
Shimoda, K., van Deursen, J., Sangster, M. Y., Sarawar, S. R., Carson, R. T., Tripp, R. A., . . . 
Ihle, J. N. (1996). Lack of IL-4-induced Th2 response and IgE class switching in mice 
with disrupted Stat6 gene. Nature, 380(6575), 630-633. doi: 10.1038/380630a0 
Simon, M. C. (1995). Gotta have GATA. Nat Genet, 11(1), 9-11. doi: 10.1038/ng0995-9 
Smith, A. G. (2001). Embryo-derived stem cells: of mice and men. Annu Rev Cell Dev Biol, 
17, 435-462. doi: 10.1146/annurev.cellbio.17.1.435 
Smith, A. G., Heath, J. K., Donaldson, D. D., Wong, G. G., Moreau, J., Stahl, M., & Rogers, 
D. (1988). Inhibition of pluripotential embryonic stem cell differentiation by 
purified polypeptides. Nature, 336(6200), 688-690. doi: 10.1038/336688a0 
Smith, R. M., Suleman, N., Lacerda, L., Opie, L. H., Akira, S., Chien, K. R., & Sack, M. N. 
(2004). Genetic depletion of cardiac myocyte STAT-3 abolishes classical 
preconditioning. Cardiovasc Res, 63(4), 611-616. doi: 
10.1016/j.cardiores.2004.06.019 
Solloway, M. J., & Harvey, R. P. (2003). Molecular pathways in myocardial development: 
a stem cell perspective. Cardiovasc Res, 58(2), 264-277.  
Soudais, C., Bielinska, M., Heikinheimo, M., MacArthur, C. A., Narita, N., Saffitz, J. E., . . . 
Wilson, D. B. (1995). Targeted mutagenesis of the transcription factor GATA-4 
gene in mouse embryonic stem cells disrupts visceral endoderm differentiation 
in vitro. Development, 121(11), 3877-3888.  
Spangenburg, E. E., & Booth, F. W. (2002). Multiple signaling pathways mediate LIF-
induced skeletal muscle satellite cell proliferation. Am J Physiol Cell Physiol, 
283(1), C204-211. doi: 10.1152/ajpcell.00574.2001 
Stutz, A., Golenbock, D. T., & Latz, E. (2009). Inflammasomes: too big to miss. J Clin Invest, 
119(12), 3502-3511. doi: 10.1172/jci40599 
 132 
 
Suffredini, A. F., Reda, D., Banks, S. M., Tropea, M., Agosti, J. M., & Miller, R. (1995). Effects 
of recombinant dimeric TNF receptor on human inflammatory responses 
following intravenous endotoxin administration. J Immunol, 155(10), 5038-5045.  
Sun, L., Ma, K., Wang, H., Xiao, F., Gao, Y., Zhang, W., . . . Wu, Z. (2007). JAK1-STAT1-STAT3, 
a key pathway promoting proliferation and preventing premature differentiation 
of myoblasts. J Cell Biol, 179(1), 129-138. doi: 10.1083/jcb.200703184 
Takahashi, A., Takahashi, Y., Matsumoto, K., & Miyata, K. (1995). Synergistic effects of 
insulin-like growth factor II (IGF-II) with leukemia inhibiting factor (LIF) on 
establishment of rat pluripotential cell lines. J Vet Med Sci, 57(3), 553-556.  
Takahashi, T., Lord, B., Schulze, P. C., Fryer, R. M., Sarang, S. S., Gullans, S. R., & Lee, R. T. 
(2003). Ascorbic acid enhances differentiation of embryonic stem cells into 
cardiac myocytes. Circulation, 107(14), 1912-1916. doi: 
10.1161/01.cir.0000064899.53876.a3 
Takeda, K., Kaisho, T., Yoshida, N., Takeda, J., Kishimoto, T., & Akira, S. (1998). Stat3 
activation is responsible for IL-6-dependent T cell proliferation through 
preventing apoptosis: generation and characterization of T cell-specific Stat3-
deficient mice. J Immunol, 161(9), 4652-4660.  
Takeda, K., Noguchi, K., Shi, W., Tanaka, T., Matsumoto, M., Yoshida, N., . . . Akira, S. 
(1997). Targeted disruption of the mouse Stat3 gene leads to early embryonic 
lethality. Proc Natl Acad Sci U S A, 94(8), 3801-3804.  
Takeda, K., Tanaka, T., Shi, W., Matsumoto, M., Minami, M., Kashiwamura, S., . . . Akira, 
S. (1996). Essential role of Stat6 in IL-4 signalling. Nature, 380(6575), 627-630. doi: 
10.1038/380627a0 
Takeuchi, O., & Akira, S. (2010). Pattern recognition receptors and inflammation. Cell, 
140(6), 805-820. doi: 10.1016/j.cell.2010.01.022 
Thierfelder, W. E., van Deursen, J. M., Yamamoto, K., Tripp, R. A., Sarawar, S. R., Carson, 
R. T., . . . Ihle, J. N. (1996). Requirement for Stat4 in interleukin-12-mediated 
responses of natural killer and T cells. Nature, 382(6587), 171-174. doi: 
10.1038/382171a0 
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, 
V. S., & Jones, J. M. (1998). Embryonic stem cell lines derived from human 
blastocysts. Science, 282(5391), 1145-1147.  
Thuerauf, D. J., Hanford, D. S., & Glembotski, C. C. (1994). Regulation of rat brain 
natriuretic peptide transcription. A potential role for GATA-related transcription 
factors in myocardial cell gene expression. J Biol Chem, 269(27), 17772-17775.  
Tsai, F. Y., Keller, G., Kuo, F. C., Weiss, M., Chen, J., Rosenblatt, M., . . . Orkin, S. H. (1994). 
An early haematopoietic defect in mice lacking the transcription factor GATA-2. 
Nature, 371(6494), 221-226. doi: 10.1038/371221a0 
Ulevitch, R. J., & Tobias, P. S. (1995). Receptor-dependent mechanisms of cell stimulation 
by bacterial endotoxin. Annu Rev Immunol, 13, 437-457. doi: 
10.1146/annurev.iy.13.040195.002253 
Uozumi, H., Hiroi, Y., Zou, Y., Takimoto, E., Toko, H., Niu, P., . . . Komuro, I. (2001). gp130 
plays a critical role in pressure overload-induced cardiac hypertrophy. J Biol Chem, 
276(25), 23115-23119. doi: 10.1074/jbc.M100814200 
Valdembri, D., Serini, G., Vacca, A., Ribatti, D., & Bussolino, F. (2002). In vivo activation of 
JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF. FASEB J, 16(2), 
225-227. doi: 10.1096/fj.01-0633fje 
 133 
 
van Lunteren, E., & Moyer, M. (2007). Oxidoreductase, morphogenesis, extracellular 
matrix, and calcium ion-binding gene expression in streptozotocin-induced 
diabetic rat heart. Am J Physiol Endocrinol Metab, 293(3), E759-768. doi: 
10.1152/ajpendo.00191.2007 
Waldo, K. L., Kumiski, D. H., Wallis, K. T., Stadt, H. A., Hutson, M. R., Platt, D. H., & Kirby, 
M. L. (2001). Conotruncal myocardium arises from a secondary heart field. 
Development, 128(16), 3179-3188.  
Wang, J., Ohmuraya, M., Hirota, M., Baba, H., Zhao, G., Takeya, M., . . . Yamamura, K. 
(2008). Expression pattern of serine protease inhibitor kazal type 3 (Spink3) 
during mouse embryonic development. Histochem Cell Biol, 130(2), 387-397. doi: 
10.1007/s00418-008-0425-8 
Wang, K., Wang, C., Xiao, F., Wang, H., & Wu, Z. (2008). JAK2/STAT2/STAT3 are required 
for myogenic differentiation. J Biol Chem, 283(49), 34029-34036. doi: 
10.1074/jbc.M803012200 
Wang, Y., De Keulenaer, G. W., & Lee, R. T. (2002). Vitamin D(3)-up-regulated protein-1 is 
a stress-responsive gene that regulates cardiomyocyte viability through 
interaction with thioredoxin. J Biol Chem, 277(29), 26496-26500. doi: 
10.1074/jbc.M202133200 
Wang, Z., Rong, Y. P., Malone, M. H., Davis, M. C., Zhong, F., & Distelhorst, C. W. (2006). 
Thioredoxin-interacting protein (txnip) is a glucocorticoid-regulated primary 
response gene involved in mediating glucocorticoid-induced apoptosis. 
Oncogene, 25(13), 1903-1913. doi: 10.1038/sj.onc.1209218 
Wei, L., Vahedi, G., Sun, H. W., Watford, W. T., Takatori, H., Ramos, H. L., . . . Kanno, Y. 
(2010). Discrete roles of STAT4 and STAT6 transcription factors in tuning 
epigenetic modifications and transcription during T helper cell differentiation. 
Immunity, 32(6), 840-851. doi: 10.1016/j.immuni.2010.06.003 
Westberg, J. A., Serlachius, M., Lankila, P., Penkowa, M., Hidalgo, J., & Andersson, L. C. 
(2007). Hypoxic preconditioning induces neuroprotective stanniocalcin-1 in brain 
via IL-6 signaling. Stroke, 38(3), 1025-1030. doi: 
10.1161/01.STR.0000258113.67252.fa 
Williams, R. L., Hilton, D. J., Pease, S., Willson, T. A., Stewart, C. L., Gearing, D. P., . . . Gough, 
N. M. (1988). Myeloid leukaemia inhibitory factor maintains the developmental 
potential of embryonic stem cells. Nature, 336(6200), 684-687. doi: 
10.1038/336684a0 
Wobus, A. M., Rohwedel, J., Maltsev, V., & Hescheler, J. (1995). Development of 
cardiomyocytes expressing cardiac-specific genes, action potentials, and ionic 
channels during embryonic stem cell-derived cardiogenesis. Ann N Y Acad Sci, 752, 
460-469.  
Wobus, A. M., Wallukat, G., & Hescheler, J. (1991). Pluripotent mouse embryonic stem 
cells are able to differentiate into cardiomyocytes expressing chronotropic 
responses to adrenergic and cholinergic agents and Ca2+ channel blockers. 
Differentiation, 48(3), 173-182.  
World, C. J., Yamawaki, H., & Berk, B. C. (2006). Thioredoxin in the cardiovascular system. 
J Mol Med (Berl), 84(12), 997-1003. doi: 10.1007/s00109-006-0109-6 
Xiang, G., Seki, T., Schuster, M. D., Witkowski, P., Boyle, A. J., See, F., . . . Itescu, S. (2005). 
Catalytic degradation of vitamin D up-regulated protein 1 mRNA enhances 
cardiomyocyte survival and prevents left ventricular remodeling after myocardial 
ischemia. J Biol Chem, 280(47), 39394-39402. doi: 10.1074/jbc.M502966200 
 134 
 
Yajima, T., Yasukawa, H., Jeon, E. S., Xiong, D., Dorner, A., Iwatate, M., . . . Knowlton, K. U. 
(2006). Innate defense mechanism against virus infection within the cardiac 
myocyte requiring gp130-STAT3 signaling. Circulation, 114(22), 2364-2373. doi: 
10.1161/circulationaha.106.642454 
Yamamoto, M., Ko, L. J., Leonard, M. W., Beug, H., Orkin, S. H., & Engel, J. D. (1990). 
Activity and tissue-specific expression of the transcription factor NF-E1 multigene 
family. Genes Dev, 4(10), 1650-1662.  
Yamanaka, H., Maehira, F., Oshiro, M., Asato, T., Yanagawa, Y., Takei, H., & Nakashima, Y. 
(2000). A possible interaction of thioredoxin with VDUP1 in HeLa cells detected 
in a yeast two-hybrid system. Biochem Biophys Res Commun, 271(3), 796-800. doi: 
10.1006/bbrc.2000.2699 
Yamawaki, H., Pan, S., Lee, R. T., & Berk, B. C. (2005). Fluid shear stress inhibits vascular 
inflammation by decreasing thioredoxin-interacting protein in endothelial cells. J 
Clin Invest, 115(3), 733-738. doi: 10.1172/jci23001 
Yang, R. B., Mark, M. R., Gray, A., Huang, A., Xie, M. H., Zhang, M., . . . Godowski, P. J. 
(1998). Toll-like receptor-2 mediates lipopolysaccharide-induced cellular 
signalling. Nature, 395(6699), 284-288. doi: 10.1038/26239 
Yang, X. O., Panopoulos, A. D., Nurieva, R., Chang, S. H., Wang, D., Watowich, S. S., & Dong, 
C. (2007). STAT3 regulates cytokine-mediated generation of inflammatory helper 
T cells. J Biol Chem, 282(13), 9358-9363. doi: 10.1074/jbc.C600321200 
Yang, X. P., Ghoreschi, K., Steward-Tharp, S. M., Rodriguez-Canales, J., Zhu, J., Grainger, J. 
R., . . . Laurence, A. (2011). Opposing regulation of the locus encoding IL-17 
through direct, reciprocal actions of STAT3 and STAT5. Nature immunology, 12(3), 
247-254. doi: 10.1038/ni.1995 
Ying, Q. L., Nichols, J., Chambers, I., & Smith, A. (2003). BMP induction of Id proteins 
suppresses differentiation and sustains embryonic stem cell self-renewal in 
collaboration with STAT3. Cell, 115(3), 281-292.  
Yoshioka, J., Chutkow, W. A., Lee, S., Kim, J. B., Yan, J., Tian, R., . . . Lee, R. T. (2012). 
Deletion of thioredoxin-interacting protein in mice impairs mitochondrial 
function but protects the myocardium from ischemia-reperfusion injury. J Clin 
Invest, 122(1), 267-279. doi: 10.1172/jci44927 
Yoshioka, J., Imahashi, K., Gabel, S. A., Chutkow, W. A., Burds, A. A., Gannon, J., . . . Lee, 
R. T. (2007). Targeted deletion of thioredoxin-interacting protein regulates 
cardiac dysfunction in response to pressure overload. Circ Res, 101(12), 1328-
1338. doi: 10.1161/circresaha.106.160515 
Yu, H., Pardoll, D., & Jove, R. (2009). STATs in cancer inflammation and immunity: a 
leading role for STAT3. Nat Rev Cancer, 9(11), 798-809. doi: 10.1038/nrc2734 
Yu, H., Yue, X., Zhao, Y., Li, X., Wu, L., Zhang, C., . . . Hu, W. (2014). LIF negatively regulates 
tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. Nat 
Commun, 5, 5218. doi: 10.1038/ncomms6218 
Yue, P., Massie, B. M., Simpson, P. C., & Long, C. S. (1998). Cytokine expression increases 
in nonmyocytes from rats with postinfarction heart failure. Am J Physiol, 275(1 Pt 
2), H250-258.  
Yutzey, K. E., & Kirby, M. L. (2002). Wherefore heart thou? Embryonic origins of 
cardiogenic mesoderm. Dev Dyn, 223(3), 307-320. doi: 10.1002/dvdy.10068 
Zheng, W., & Flavell, R. A. (1997). The transcription factor GATA-3 is necessary and 
sufficient for Th2 cytokine gene expression in CD4 T cells. Cell, 89(4), 587-596.  
 135 
 
Zhou, R., Tardivel, A., Thorens, B., Choi, I., & Tschopp, J. (2010). Thioredoxin-interacting 
protein links oxidative stress to inflammasome activation. Nature immunology, 
11(2), 136-140. doi: 10.1038/ni.1831 
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011). A role for mitochondria in NLRP3 
inflammasome activation. Nature, 469(7329), 221-225. doi: 
10.1038/nature09663 
 
